CINXE.COM

<!doctype html> <html data-n-head-ssr lang="en" data-n-head="%7B%22lang%22:%7B%22ssr%22:%22en%22%7D%7D"> <head > <link data-n-head="ssr" rel="icon" type="image/png" sizes="16x16" href="https://brand.frontiersin.org/m/ed3f9ce840a03d7/favicon_16-tenantFavicon-Frontiers.png"> <link data-n-head="ssr" rel="icon" type="image/png" sizes="32x32" href="https://brand.frontiersin.org/m/ed3f9ce840a03d7/favicon_32-tenantFavicon-Frontiers.png"> <link data-n-head="ssr" rel="apple-touch-icon" type="image/png" sizes="180x180" href="https://brand.frontiersin.org/m/ed3f9ce840a03d7/favicon_180-tenantFavicon-Frontiers.png"> <title>Frontiers | Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report</title><meta data-n-head="ssr" charset="utf-8"><meta data-n-head="ssr" name="viewport" content="width=device-width, initial-scale=1"><meta data-n-head="ssr" data-hid="charset" charset="utf-8"><meta data-n-head="ssr" data-hid="mobile-web-app-capable" name="mobile-web-app-capable" content="yes"><meta data-n-head="ssr" data-hid="apple-mobile-web-app-title" name="apple-mobile-web-app-title" content="Frontiers | Articles"><meta data-n-head="ssr" data-hid="theme-color" name="theme-color" content="#0C4DED"><meta data-n-head="ssr" data-hid="description" property="description" name="description" content="BackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tole..."><meta data-n-head="ssr" data-hid="og:title" property="og:title" name="title" content="Frontiers | Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report"><meta data-n-head="ssr" data-hid="og:description" property="og:description" name="description" content="BackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tole..."><meta data-n-head="ssr" data-hid="keywords" name="keywords" content="Non-small cell lung cancer,Anti-angiogenesis therapy,front-line treatment,elderly patients,case report"><meta data-n-head="ssr" data-hid="og:site_name" property="og:site_name" name="site_name" content="Frontiers"><meta data-n-head="ssr" data-hid="og:image" property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g001.jpg"><meta data-n-head="ssr" data-hid="og:type" property="og:type" name="type" content="article"><meta data-n-head="ssr" data-hid="og:url" property="og:url" name="url" content="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1043244/full"><meta data-n-head="ssr" data-hid="twitter:card" name="twitter:card" content="summary_large_image"><meta data-n-head="ssr" data-hid="citation_volume" name="citation_volume" content="13"><meta data-n-head="ssr" data-hid="citation_journal_title" name="citation_journal_title" content="Frontiers in Oncology"><meta data-n-head="ssr" data-hid="citation_publisher" name="citation_publisher" content="Frontiers"><meta data-n-head="ssr" data-hid="citation_journal_abbrev" name="citation_journal_abbrev" content="Front. Oncol."><meta data-n-head="ssr" data-hid="citation_issn" name="citation_issn" content="2234-943X"><meta data-n-head="ssr" data-hid="citation_doi" name="citation_doi" content="10.3389/fonc.2023.1043244"><meta data-n-head="ssr" data-hid="citation_firstpage" name="citation_firstpage" content="1043244"><meta data-n-head="ssr" data-hid="citation_language" name="citation_language" content="English"><meta data-n-head="ssr" data-hid="citation_title" name="citation_title" content="Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report"><meta data-n-head="ssr" data-hid="citation_keywords" name="citation_keywords" content="Non-small cell lung cancer; Anti-angiogenesis therapy; front-line treatment; elderly patients; case report"><meta data-n-head="ssr" data-hid="citation_abstract" name="citation_abstract" content="<sec><title>Background</title><p>Half of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approved for the standard third-line treatment for NSCLC in China. Herein we report an elderly NSCLC patient without any driver gene mutations who was undergoing anlotinib as a front-line treatment and who achieved long-term survival.</p></sec><sec><title>Case summary</title><p>The 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1).</p></sec><sec><title>Conclusion</title><p>This patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy.</p></sec>"><meta data-n-head="ssr" data-hid="citation_pdf_url" name="citation_pdf_url" content="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1043244/pdf"><meta data-n-head="ssr" data-hid="citation_online_date" name="citation_online_date" content="2023/03/13"><meta data-n-head="ssr" data-hid="citation_publication_date" name="citation_publication_date" content="2023/04/06"><meta data-n-head="ssr" data-hid="citation_author_0" name="citation_author" content="Wang, Jingyi"><meta data-n-head="ssr" data-hid="citation_author_institution_0" name="citation_author_institution" content="Department of Oncology, Bishan Hospital of Chongqing Medical University, China"><meta data-n-head="ssr" data-hid="citation_author_1" name="citation_author" content="Li, Xiaoqing"><meta data-n-head="ssr" data-hid="citation_author_institution_1" name="citation_author_institution" content="Department of Oncology, Bishan Hospital of Chongqing Medical University, China"><meta data-n-head="ssr" data-hid="citation_author_2" name="citation_author" content="Zhou, Juan"><meta data-n-head="ssr" data-hid="citation_author_institution_2" name="citation_author_institution" content="Department of Oncology, Bishan Hospital of Chongqing Medical University, China"><meta data-n-head="ssr" data-hid="citation_author_3" name="citation_author" content="Qiu, Dan"><meta data-n-head="ssr" data-hid="citation_author_institution_3" name="citation_author_institution" content="Department of Oncology, Bishan Hospital of Chongqing Medical University, China"><meta data-n-head="ssr" data-hid="citation_author_4" name="citation_author" content="Zhang, Mengyao"><meta data-n-head="ssr" data-hid="citation_author_institution_4" name="citation_author_institution" content="Department of Oncology, Bishan Hospital of Chongqing Medical University, China"><meta data-n-head="ssr" data-hid="citation_author_5" name="citation_author" content="Sun, Lan"><meta data-n-head="ssr" data-hid="citation_author_institution_5" name="citation_author_institution" content="Department of Oncology, Bishan Hospital of Chongqing Medical University, China"><meta data-n-head="ssr" data-hid="citation_author_6" name="citation_author" content="Li, Shengwen Calvin"><meta data-n-head="ssr" data-hid="citation_author_institution_6" name="citation_author_institution" content="Neuro-Oncology and Stem Cell Research Laboratory, Center for Neuroscience Research, CHOC Children鈥檚 Research Institute, Children鈥檚 Hospital of Orange County (CHOC), United States"><meta data-n-head="ssr" data-hid="dc.identifier" name="dc.identifier" content="doi:10.3389/fonc.2023.1043244"><link data-n-head="ssr" rel="manifest" href="/article-pages/_nuxt/manifest.c499fc0a.json" data-hid="manifest"><link data-n-head="ssr" rel="canonical" href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1043244/full"><script data-n-head="ssr" data-hid="newrelic-browser-script" type="text/javascript">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"588603994","agentToken":null,"applicationTime":1.943983,"transactionName":"MQcDMkECCkNSW0YMWghNIgldDQFTRxd1IGFJTQ==","queueTime":0,"ttGuid":"596c3ead3cc8bdb4"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594400880",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIXFdSBAgOUg==",licenseKey:"598a124f17",applicationID:"588603994"};;/*! For license information please see nr-loader-spa-1.274.0.min.js.LICENSE.txt */ (()=>{var e,t,r={8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{if(null===e[a]){r[a]=null;continue}Array.isArray(e[a])&&Array.isArray(t[a])?r[a]=Array.from(new Set([...e[a],...t[a]])):"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},2555:(e,t,r)=>{"use strict";r.d(t,{Vp:()=>c,fn:()=>s,x1:()=>u});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){try{const t=c(e);return!!t.licenseKey&&!!t.errorBeacon&&!!t.applicationID}catch(e){return!1}}function c(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function u(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.info=a[e])}},9417:(e,t,r)=>{"use strict";r.d(t,{D0:()=>h,gD:()=>g,xN:()=>p});var n=r(993);const i=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var o=r(2614),a=r(944),s=r(384),c=r(8122);const u="[data-nr-mask]",d=()=>{const e={mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,harvestTimeSeconds:10,autoStart:!0},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},feature_flags:[],generic_events:{enabled:!0,harvestTimeSeconds:30,autoStart:!0},harvest:{tooManyRequestsDelay:60},jserrors:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},logging:{enabled:!0,harvestTimeSeconds:10,autoStart:!0,level:n.p_.INFO},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:o.wk,inactiveMs:o.BB},session_replay:{autoStart:!0,enabled:!1,harvestTimeSeconds:60,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){i(t)?e.mask_selector="".concat(t,",").concat(u):""===t||null===t?e.mask_selector=u:(0,a.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){i(t)?e.block_selector+=",".concat(t):""!==t&&(0,a.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,a.R)(7,t)}},session_trace:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},soft_navigations:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},spa:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},ssl:void 0,user_actions:{enabled:!0}}},l={},f="All configuration objects require an agent identifier!";function h(e){if(!e)throw new Error(f);if(!l[e])throw new Error("Configuration for ".concat(e," was never set"));return l[e]}function p(e,t){if(!e)throw new Error(f);l[e]=(0,c.a)(t,d());const r=(0,s.nY)(e);r&&(r.init=l[e])}function g(e,t){if(!e)throw new Error(f);var r=h(e);if(r){for(var n=t.split("."),i=0;i<n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}},5603:(e,t,r)=>{"use strict";r.d(t,{a:()=>c,o:()=>s});var n=r(384),i=r(8122);const o={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},a={};function s(e){if(!e)throw new Error("All loader-config objects require an agent identifier!");if(!a[e])throw new Error("LoaderConfig for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");a[e]=(0,i.a)(t,o);const r=(0,n.nY)(e);r&&(r.loader_config=a[e])}},3371:(e,t,r)=>{"use strict";r.d(t,{V:()=>f,f:()=>l});var n=r(8122),i=r(384),o=r(6154),a=r(9324);let s=0;const c={buildEnv:a.F3,distMethod:a.Xs,version:a.xv,originTime:o.WN},u={customTransaction:void 0,disabled:!1,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,onerror:void 0,ptid:void 0,releaseIds:{},appMetadata:{},session:void 0,denyList:void 0,timeKeeper:void 0,obfuscator:void 0},d={};function l(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!d[e])throw new Error("Runtime for ".concat(e," was never set"));return d[e]}function f(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");d[e]={...(0,n.a)(t,u),...c},Object.hasOwnProperty.call(d[e],"harvestCount")||Object.defineProperty(d[e],"harvestCount",{get:()=>++s});const r=(0,i.nY)(e);r&&(r.runtime=d[e])}},9324:(e,t,r)=>{"use strict";r.d(t,{F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.274.0",i="PROD",o="CDN",a="^2.0.0-alpha.17"},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>s,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>a,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),a=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),s="complete"===a?.document?.readyState,c=Boolean("hidden"===a?.document?.visibilityState),u=""+a?.location,d=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>a,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(s(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function a(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,a;i>0?(o=r.substring(0,i),a=r.substring(i)):(o=r,a="");let[s]=o.split(":");n.push({hostname:s,pathname:a})}}function s(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>c,Ze:()=>l,x3:()=>u});var n=r(7836),i=r(3606),o=r(860),a=r(2646);const s={};function c(e,t){const r={staged:!1,priority:o.P3[t]||0};d(e),s[e].get(t)||s[e].set(t,r)}function u(e,t){e&&s[e]&&(s[e].get(t)&&s[e].delete(t),h(e,t,!1),s[e].size&&f(e))}function d(e){if(!e)throw new Error("agentIdentifier required");s[e]||(s[e]=new Map)}function l(e="",t="feature",r=!1){if(d(e),!e||!s[e].get(t)||r)return h(e,t);s[e].get(t).staged=!0,f(e)}function f(e){const t=Array.from(s[e]);t.every((([e,t])=>t.staged))&&(t.sort(((e,t)=>e[1].priority-t[1].priority)),t.forEach((([t])=>{s[e].delete(t),h(e,t)})))}function h(e,t,r=!0){const o=e?n.ee.get(e):n.ee,s=i.i.handlers;if(!o.aborted&&o.backlog&&s){if(r){const e=o.backlog[t],r=s[t];if(r){for(let t=0;e&&t<e.length;++t)p(e[t],r);Object.entries(r).forEach((([e,t])=>{Object.values(t||{}).forEach((t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])}))}))}}o.isolatedBacklog||delete s[t],o.backlog[t]=null,o.emit("drain-"+t,[])}}function p(e,t){var r=e[1];Object.values(t[r]||{}).forEach((t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}}))}},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>c,ee:()=>u});var n=r(384),i=r(8990),o=r(3371),a=r(2646),s=r(5607);const c="nr@context:".concat(s.W),u=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&(0,o.f)(r).isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(u.aborted&&!i)return;t&&o&&t.emit(e,r,n);for(var a=h(n),c=g(e),d=c.length,l=0;l<d;l++)c[l].apply(a,r);var p=v()[s[e]];p&&p.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach((([e,n])=>{s[n]=t,t in r||(r[t]=[])}))},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach((e=>{delete f.backlog[e]}))},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof a.y?e:e?(0,i.I)(e,c,(()=>new a.y(c))):new a.y(c)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),d=(0,n.Zm)();d.ee||(d.ee=u)},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.d,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>s,ZF:()=>c,bz:()=>a,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map((e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const a=[];for(var s=0;s<e;s++)a.push(o(r,i++).toString(16));return a.join("")}function c(){return s(16)}function u(){return s(32)}},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>a,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>s,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,a=18e5,s={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},944:(e,t,r)=>{"use strict";function n(e,t){"function"==typeof console.debug&&console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t)}r.d(t,{R:()=>n})},5284:(e,t,r)=>{"use strict";r.d(t,{t:()=>c,B:()=>s});var n=r(7836),i=r(6154);const o="newrelic";const a=new Set,s={};function c(e,t){const r=n.ee.get(t);s[t]??={},e&&"object"==typeof e&&(a.has(t)||(r.emit("rumresp",[e]),s[t]=e,a.add(t),function(e={}){try{i.gm.dispatchEvent(new CustomEvent(o,{detail:e}))}catch(e){}}({loaded:!0})))}},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout((()=>{i=clearTimeout(i)}),t)),n||(clearTimeout(i),i=setTimeout((()=>{e.apply(this,r)}),t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,sB:()=>a});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function a(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}},384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>o,US:()=>d,Zm:()=>a,bQ:()=>c,dV:()=>s,nY:()=>u,pV:()=>l});var n=r(6154),i=r(1863);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function s(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket}),e}function c(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function u(e){let t=a();return t.initializedAgents?.[e]}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)}),r,i)}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),a=r(6154);const s={},c=a.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(s[t.debugId]++)return t;s[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(a.RI&&h(document,f),h(a.gm,f),h(c.prototype,f)),t.on(u+"-start",(function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)){var i=(0,o.I)(n,l,(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(d+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>c});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W);var a=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const a="-"===n.charAt(0);for(let s=0;s<t.length;s++){const c=t[s],u=e[c];d(u)||(e[c]=r(u,a?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,s,c){return d(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){u([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,d,l;try{a=this,o=[...arguments],d="function"==typeof n?n(o,a):n||{}}catch(t){u([t,"",[o,a,s],d],e)}i(r+"start",[o,a,s],d,c);try{return l=t.apply(a,o)}catch(e){throw i(r+"err",[o,a,e],d,c),e}finally{i(r+"end",[o,a,l],d,c)}}}function i(r,n,i,o){if(!s||t){var a=s;s=!0;try{e.emit(r,n,i,t,o)}catch(t){u([t,r,n,i],e)}s=a}}}function u(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function d(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},3333:(e,t,r)=>{"use strict";r.d(t,{TZ:()=>n,Zp:()=>i,mq:()=>s,nf:()=>a,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],a=4,s=1e3},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},993:(e,t,r)=>{"use strict";r.d(t,{ET:()=>o,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o="log",a=n.K7.logging},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),a=r(3969),s=r(993);function c(e,t,r={},c=s.p_.INFO){(0,n.p)(a.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(s.ET,[(0,i.t)(),t,r,c],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(s.p_).some((t=>t===e.toUpperCase().trim()))}},3969:(e,t,r)=>{"use strict";r.d(t,{TZ:()=>n,XG:()=>s,rs:()=>i,xV:()=>a,z_:()=>o});const n=r(860).K7.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,G4:()=>o,Qb:()=>l,TZ:()=>i,Ug:()=>a,_s:()=>s,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o={RECORD:"recordReplay",PAUSE:"pauseReplay",REPLAY_RUNNING:"replayRunning",ERROR_DURING_REPLAY:"errorDuringReplay"},a=.12,s={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api"}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>c,CT:()=>u,SR:()=>s});var n=r(384),i=r(9417),o=r(7767),a=r(6154);function s(e){return!!(0,n.dV)().o.MO&&(0,o.V)(e)&&!0===(0,i.gD)(e,"session_trace.enabled")}function c(e){return!0===(0,i.gD)(e,"session_replay.preload")&&s(e)}function u(e,t){const r=t.correctAbsoluteTimestamp(e);return{originalTimestamp:e,correctedTimestamp:r,timestampDiff:e-r,originTime:a.WN,correctedOriginTime:t.correctedOriginTime,originTimeDiff:Math.floor(a.WN-t.correctedOriginTime)}}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>s,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>a,jx:()=>l,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState",l=1e3},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>o,O2:()=>s,Qu:()=>c,TZ:()=>a,ih:()=>u,tC:()=>i});var n=r(860);const i=["click","keydown","submit"],o="api",a=n.K7.softNav,s={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},c={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},u={IP:"in progress",FIN:"finished",CAN:"cancelled"}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>A,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>E,uP:()=>s,wW:()=>T,xq:()=>a});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,A="jsTime",E="fetch"},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>o});var n=r(9417),i=r(6154);const o=e=>i.RI&&!0===(0,n.gD)(e,"privacy.cookies_enabled")},425:(e,t,r)=>{"use strict";r.d(t,{j:()=>j});var n=r(860),i=r(2555),o=r(3371),a=r(9908),s=r(7836),c=r(1687),u=r(5289),d=r(6154),l=r(944),f=r(3969),h=r(384),p=r(6344);const g=["setErrorHandler","finished","addToTrace","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId","setApplicationVersion","start",p.G4.RECORD,p.G4.PAUSE,"log","wrapLogger"],m=["setErrorHandler","finished","addToTrace","addRelease"];var v=r(1863),b=r(2614),y=r(993),w=r(3785),R=r(2646),x=r(3434);function T(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||s.ee).get("logger")}(e),o=(0,x.YM)(i),a=new R.y(s.P);return a.level=n.level,a.customAttributes=n.customAttributes,o.inPlace(t,[r],"wrap-logger-",a),i}function A(){const e=(0,h.pV)();g.forEach((t=>{e[t]=(...r)=>function(t,...r){let n=[];return Object.values(e.initializedAgents).forEach((e=>{e&&e.api?e.exposed&&e.api[t]&&n.push(e.api[t](...r)):(0,l.R)(38,t)})),n.length>1?n:n[0]}(t,...r)}))}const E={};var S=r(9417),N=r(5603),O=r(5284);const _=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};let I=!1;function j(e,t={},g,R){let{init:x,info:j,loader_config:P,runtime:C={},exposed:k=!0}=t;C.loaderType=g;const L=(0,h.pV)();j||(x=L.init,j=L.info,P=L.loader_config),(0,S.xN)(e.agentIdentifier,x||{}),(0,N.a)(e.agentIdentifier,P||{}),j.jsAttributes??={},d.bv&&(j.jsAttributes.isWorker=!0),(0,i.x1)(e.agentIdentifier,j);const H=(0,S.D0)(e.agentIdentifier),D=[j.beacon,j.errorBeacon];I||(H.proxy.assets&&(_(H.proxy.assets),D.push(H.proxy.assets)),H.proxy.beacon&&D.push(H.proxy.beacon),A(),(0,h.US)("activatedFeatures",O.B),e.runSoftNavOverSpa&&=!0===H.soft_navigations.enabled&&H.feature_flags.includes("soft_nav")),C.denyList=[...H.ajax.deny_list||[],...H.ajax.block_internal?D:[]],C.ptid=e.agentIdentifier,(0,o.V)(e.agentIdentifier,C),e.ee=s.ee.get(e.agentIdentifier),void 0===e.api&&(e.api=function(e,t,h=!1){t||(0,c.Ak)(e,"api");const g={};var R=s.ee.get(e),x=R.get("tracer");E[e]=b.g.OFF,R.on(p.G4.REPLAY_RUNNING,(t=>{E[e]=t}));var A="api-",S=A+"ixn-";function N(t,r,n,o){const a=(0,i.Vp)(e);return null===r?delete a.jsAttributes[t]:(0,i.x1)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),I(A,n,!0,o||null===r?"session":void 0)(t,r)}function O(){}g.log=function(e,{customAttributes:t={},level:r=y.p_.INFO}={}){(0,a.p)(f.xV,["API/log/called"],void 0,n.K7.metrics,R),(0,w.R)(R,e,t,r)},g.wrapLogger=(e,t,{customAttributes:r={},level:i=y.p_.INFO}={})=>{(0,a.p)(f.xV,["API/wrapLogger/called"],void 0,n.K7.metrics,R),T(R,e,t,{customAttributes:r,level:i})},m.forEach((e=>{g[e]=I(A,e,!0,"api")})),g.addPageAction=I(A,"addPageAction",!0,n.K7.genericEvents),g.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,o.f)(e).customTransaction=(r||"http://custom.transaction")+t,I(A,"setPageViewName",!0)()},g.setCustomAttribute=function(e,t,r=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof t)||null===t)return N(e,t,"setCustomAttribute",r);(0,l.R)(40,typeof t)}else(0,l.R)(39,typeof e)},g.setUserId=function(e){if("string"==typeof e||null===e)return N("enduser.id",e,"setUserId",!0);(0,l.R)(41,typeof e)},g.setApplicationVersion=function(e){if("string"==typeof e||null===e)return N("application.version",e,"setApplicationVersion",!1);(0,l.R)(42,typeof e)},g.start=()=>{try{(0,a.p)(f.xV,["API/start/called"],void 0,n.K7.metrics,R),R.emit("manual-start-all")}catch(e){(0,l.R)(23,e)}},g[p.G4.RECORD]=function(){(0,a.p)(f.xV,["API/recordReplay/called"],void 0,n.K7.metrics,R),(0,a.p)(p.G4.RECORD,[],void 0,n.K7.sessionReplay,R)},g[p.G4.PAUSE]=function(){(0,a.p)(f.xV,["API/pauseReplay/called"],void 0,n.K7.metrics,R),(0,a.p)(p.G4.PAUSE,[],void 0,n.K7.sessionReplay,R)},g.interaction=function(e){return(new O).get("object"==typeof e?e:{})};const _=O.prototype={createTracer:function(e,t){var r={},i=this,o="function"==typeof t;return(0,a.p)(f.xV,["API/createTracer/called"],void 0,n.K7.metrics,R),h||(0,a.p)(S+"tracer",[(0,v.t)(),e,r],i,n.K7.spa,R),function(){if(x.emit((o?"":"no-")+"fn-start",[(0,v.t)(),i,o],r),o)try{return t.apply(this,arguments)}catch(e){const t="string"==typeof e?new Error(e):e;throw x.emit("fn-err",[arguments,this,t],r),t}finally{x.emit("fn-end",[(0,v.t)()],r)}}}};function I(e,t,r,i){return function(){return(0,a.p)(f.xV,["API/"+t+"/called"],void 0,n.K7.metrics,R),i&&(0,a.p)(e+t,[(0,v.t)(),...arguments],r?null:this,i,R),r?void 0:this}}function j(){r.e(478).then(r.bind(r,8778)).then((({setAPI:t})=>{t(e),(0,c.Ze)(e,"api")})).catch((e=>{(0,l.R)(27,e),R.abort()}))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{_[e]=I(S,e,void 0,h?n.K7.softNav:n.K7.spa)})),g.setCurrentRouteName=h?I(S,"routeName",void 0,n.K7.softNav):I(A,"routeName",!0,n.K7.spa),g.noticeError=function(t,r){"string"==typeof t&&(t=new Error(t)),(0,a.p)(f.xV,["API/noticeError/called"],void 0,n.K7.metrics,R),(0,a.p)("err",[t,(0,v.t)(),!1,r,!!E[e]],void 0,n.K7.jserrors,R)},d.RI?(0,u.GG)((()=>j()),!0):j(),g}(e.agentIdentifier,R,e.runSoftNavOverSpa)),void 0===e.exposed&&(e.exposed=k),I=!0}},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>o,K7:()=>n,P3:()=>i});const n={ajax:"ajax",genericEvents:"generic_events",jserrors:"jserrors",logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.spa]:5,[n.ajax]:6,[n.sessionTrace]:7,[n.softNav]:8,[n.sessionReplay]:9,[n.logging]:10,[n.genericEvents]:11},o={[n.pageViewTiming]:"events",[n.ajax]:"events",[n.spa]:"events",[n.softNav]:"events",[n.metrics]:"jserrors",[n.jserrors]:"jserrors",[n.sessionTrace]:"browser/blobs",[n.sessionReplay]:"browser/blobs",[n.logging]:"browser/logs",[n.genericEvents]:"ins"}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.274.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.274.0.PROD:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){s=l;break}}if(!s){c=!0;var f={478:"sha512-1vUqEfJPB8Pihje9mv5CfYgkitO1FWcS+UQb84DbXqP8oYctRv4/lzl/MzNLPlRhcY1WVDBGL20I8vm6s2VV7g==",249:"sha512-Y/BeZAh6VSTmUtUNmS5XdyKxL92s30Fyyj8xVW76HSPxcKItL4+x2+kGMZc8pMJnUpZDz1L4eftZQAJh3D8NnA==",212:"sha512-Gn2tQ3qog5Yhrx/gRutkSTYPp+7nkKFt4/mIXg99LxcNpMDAYJZDBYmAACdoHNM86+iq1F3cBcQotFNzjIX8bw=="};(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&&s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+o),s.src=r,0!==s.src.indexOf(window.location.origin+"/")&&(s.crossOrigin="anonymous"),f[a]&&(s.integrity=f[a])}e[r]=[n];var h=(t,n)=>{s.onerror=s.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=h.bind(null,s.onerror),s.onload=h.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u<a.length;u++)o=a[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.274.0.PROD"]=self["webpackChunk:NRBA-1.274.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(944),t=i(6344),r=i(9566);class n{agentIdentifier;constructor(e=(0,r.LA)(16)){this.agentIdentifier=e}#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}addPageAction(e,t){return this.#e("addPageAction",e,t)}setPageViewName(e,t){return this.#e("setPageViewName",e,t)}setCustomAttribute(e,t,r){return this.#e("setCustomAttribute",e,t,r)}noticeError(e,t){return this.#e("noticeError",e,t)}setUserId(e){return this.#e("setUserId",e)}setApplicationVersion(e){return this.#e("setApplicationVersion",e)}setErrorHandler(e){return this.#e("setErrorHandler",e)}addRelease(e,t){return this.#e("addRelease",e,t)}log(e,t){return this.#e("log",e,t)}}class o extends n{#e(t,...r){if("function"==typeof this.api?.[t])return this.api[t](...r);(0,e.R)(35,t)}start(){return this.#e("start")}finished(e){return this.#e("finished",e)}recordReplay(){return this.#e(t.G4.RECORD)}pauseReplay(){return this.#e(t.G4.PAUSE)}addToTrace(e){return this.#e("addToTrace",e)}setCurrentRouteName(e){return this.#e("setCurrentRouteName",e)}interaction(){return this.#e("interaction")}wrapLogger(e,t,r){return this.#e("wrapLogger",e,t,r)}}var a=i(860),s=i(9417);const c=Object.values(a.K7);function u(e){const t={};return c.forEach((r=>{t[r]=function(e,t){return!0===(0,s.gD)(t,"".concat(e,".enabled"))}(r,e)})),t}var d=i(425);var l=i(1687),f=i(4234),h=i(5289),p=i(6154),g=i(5270),m=i(7767),v=i(6389);class b extends f.W{constructor(e,t,r=!0){super(e.agentIdentifier,t),this.auto=r,this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,!1===e.init[this.featureName].autoStart&&(this.auto=!1),this.auto?(0,l.Ak)(e.agentIdentifier,t):this.ee.on("manual-start-all",(0,v.J)((()=>{(0,l.Ak)(e.agentIdentifier,this.featureName),this.auto=!0,this.importAggregator(e)})))}importAggregator(t,r={}){if(this.featAggregate||!this.auto)return;let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let o;try{if((0,m.V)(this.agentIdentifier)){const{setupAgentSession:e}=await i.e(478).then(i.bind(i,6526));o=e(t)}}catch(t){(0,e.R)(20,t),this.ee.emit("internal-error",[t]),this.featureName===a.K7.sessionReplay&&this.abortHandler?.()}try{if(t.sharedAggregator)await t.sharedAggregator;else{t.sharedAggregator=i.e(478).then(i.bind(i,9337));const{EventAggregator:e}=await t.sharedAggregator;t.sharedAggregator=new e}if(!this.#t(this.featureName,o))return(0,l.Ze)(this.agentIdentifier,this.featureName),void n(!1);const{lazyFeatureLoader:e}=await i.e(478).then(i.bind(i,6103)),{Aggregate:a}=await e(this.featureName,"aggregate");this.featAggregate=new a(t,r),n(!0)}catch(t){(0,e.R)(34,t),this.abortHandler?.(),(0,l.Ze)(this.agentIdentifier,this.featureName,!0),n(!1),this.ee&&this.ee.abort()}};p.RI?(0,h.GG)((()=>o()),!0):o()}#t(e,t){switch(e){case a.K7.sessionReplay:return(0,g.SR)(this.agentIdentifier)&&!!t;case a.K7.sessionTrace:return!!t;default:return!0}}}var y=i(6630);class w extends b{static featureName=y.T;constructor(e,t=!0){super(e,y.T,t),this.importAggregator(e)}}var R=i(384);var x=i(9908),T=i(2843),A=i(3878),E=i(782),S=i(1863);class N extends b{static featureName=E.T;constructor(e,t=!0){super(e,E.T,t),p.RI&&((0,T.u)((()=>(0,x.p)("docHidden",[(0,S.t)()],void 0,E.T,this.ee)),!0),(0,A.sp)("pagehide",(()=>(0,x.p)("winPagehide",[(0,S.t)()],void 0,E.T,this.ee))),this.importAggregator(e))}}var O=i(3969);class _ extends b{static featureName=O.TZ;constructor(e,t=!0){super(e,O.TZ,t),this.importAggregator(e)}}var I=i(6774),j=i(3304);class P{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,j.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function C(e){return H(e)?e:new P(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic)}function k(e){const t="Unhandled Promise Rejection";if(!e?.reason)return;if(H(e.reason))try{return e.reason.message=t+": "+e.reason.message,C(e.reason)}catch(t){return C(e.reason)}const r=C(e.reason);return r.message=t+": "+r?.message,r}function L(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new P(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic);return t.name=SyntaxError.name,t}return H(e.error)?e.error:C(e)}function H(e){return e instanceof Error&&!!e.stack}class D extends b{static featureName=I.T;#r=!1;constructor(e,r=!0){super(e,I.T,r);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(e=>{this.abortHandler&&(0,x.p)("ierr",[C(e),(0,S.t)(),!0,{},this.#r],void 0,this.featureName,this.ee)})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.#r=e})),p.gm.addEventListener("unhandledrejection",(e=>{this.abortHandler&&(0,x.p)("err",[k(e),(0,S.t)(),!1,{unhandledPromiseRejection:1},this.#r],void 0,this.featureName,this.ee)}),(0,A.jT)(!1,this.removeOnAbort?.signal)),p.gm.addEventListener("error",(e=>{this.abortHandler&&(0,x.p)("err",[L(e),(0,S.t)(),!1,{},this.#r],void 0,this.featureName,this.ee)}),(0,A.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var M=i(8990);let K=1;const U="nr@id";function V(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===p.gm?0:(0,M.I)(e,U,(function(){return K++}))}function G(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,j.A)(e).length}catch(e){return}}}var F=i(8139),B=i(7836),W=i(3434);const z={},q=["open","send"];function Z(t){var r=t||B.ee;const n=function(e){return(e||B.ee).get("xhr")}(r);if(z[n.debugId]++)return n;z[n.debugId]=1,(0,F.u)(r);var i=(0,W.YM)(n),o=p.gm.XMLHttpRequest,a=p.gm.MutationObserver,s=p.gm.Promise,c=p.gm.setInterval,u="readystatechange",d=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],l=[],f=p.gm.XMLHttpRequest=function(t){const r=new o(t),a=n.context(r);try{n.emit("new-xhr",[r],a),r.addEventListener(u,(s=a,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,n.emit("xhr-resolved",[],e)),i.inPlace(e,d,"fn-",y)}),(0,A.jT)(!1))}catch(t){(0,e.R)(15,t);try{n.emit("internal-error",[t])}catch(e){}}var s;return r};function h(e,t){i.inPlace(t,["onreadystatechange"],"fn-",y)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,f),f.prototype=o.prototype,i.inPlace(f.prototype,q,"-xhr-",y),n.on("send-xhr-start",(function(e,t){h(e,t),function(e){l.push(e),a&&(g?g.then(b):c?c(b):(m=-m,v.data=m))}(t)})),n.on("open-xhr-start",h),a){var g=s&&s.resolve();if(!c&&!s){var m=1,v=document.createTextNode(m);new a(b).observe(v,{characterData:!0})}}else r.on("fn-end",(function(e){e[0]&&e[0].type===u||b()}));function b(){for(var e=0;e<l.length;e++)h(0,l[e]);l.length&&(l=[])}function y(e,t){return t}return n}var Y="fetch-",X=Y+"body-",J=["arrayBuffer","blob","json","text","formData"],Q=p.gm.Request,ee=p.gm.Response,te="prototype";const re={};function ne(e){const t=function(e){return(e||B.ee).get("fetch")}(e);if(!(Q&&ee&&p.gm.fetch))return t;if(re[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[B.P]&&o[B.P].dt&&(e=o[B.P].dt);var a=i.apply(this,r);return t.emit(n+"start",[r,e],a),a.then((function(e){return t.emit(n+"end",[null,e],a),e}),(function(e){throw t.emit(n+"end",[e],a),e}))})}return re[t.debugId]=1,J.forEach((e=>{r(Q[te],e,X),r(ee[te],e,X)})),r(p.gm,"fetch",Y),t.on(Y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(Y+"done",[null,r],n)}else t.emit(Y+"done",[e],n)})),t}var ie=i(7485),oe=i(5603);class ae{constructor(e){this.agentIdentifier=e}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var t=(0,oe.o)(this.agentIdentifier);if(!t)return null;var n=(t.accountID||"").toString()||null,i=(t.agentID||"").toString()||null,o=(t.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,r.ZF)(),s=(0,r.el)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof p.gm?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,j.A)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1,r={};if((0,s.gD)(this.agentIdentifier,"distributed_tracing")&&(r=(0,s.D0)(this.agentIdentifier).distributed_tracing),e.sameOrigin)t=!0;else if(r.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ie.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}isDtEnabled(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.enabled}excludeNewrelicHeader(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=(0,s.gD)(this.agentIdentifier,"distributed_tracing");return!!e&&!!e.cors_use_tracecontext_headers}}var se=i(9300),ce=i(7295),ue=["load","error","abort","timeout"],de=ue.length,le=(0,R.dV)().o.REQ,fe=(0,R.dV)().o.XHR;class he extends b{static featureName=se.T;constructor(e,t=!0){super(e,se.T,t),this.dt=new ae(e.agentIdentifier),this.handler=(e,t,r,n)=>(0,x.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};p.gm?.performance?.getEntriesByType("resource").forEach((t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},n={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};pe(r,t.name),this.handler("xhr",[r,n,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,a.K7.ajax)}}))}catch(e){}ne(this.ee),Z(this.ee),function(e,t,r,n){function i(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=R,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){T(t,e)}),(0,A.jT)(!1)),p.lR||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,A.jT)(!1))}function o(e){this.params={method:e[0]},pe(this,e[1]),this.metrics={}}function s(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var i=n.generateTracePayload(this.parsedOrigin);if(i){var o=!1;i.newrelicHeader&&(r.setRequestHeader("newrelic",i.newrelicHeader),o=!0),i.traceContextParentHeader&&(r.setRequestHeader("traceparent",i.traceContextParentHeader),i.traceContextStateHeader&&r.setRequestHeader("tracestate",i.traceContextStateHeader),o=!0),o&&(this.dt=i)}}function c(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var a=G(i);a&&(n.txSize=a)}this.startTime=(0,S.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var s=0;s<de;s++)r.addEventListener(ue[s],this.listener,(0,A.jT)(!1))}function u(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function d(e,t){var r=""+V(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function l(e,t){var r=""+V(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function f(){this.endTime=(0,S.t)()}function h(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function g(e,r){r instanceof fe&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function m(e,t,r){t instanceof fe&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,S.t)()))}function v(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,S.t)()-this.xhrCbStart,this.onload,r],r)}function b(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&p.RI&&(t=""+p.gm.location.href):e[0]&&e[0].url?t=e[0].url:p.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ie.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var i=n.generateTracePayload(this.parsedOrigin);if(i&&(i.newrelicHeader||i.traceContextParentHeader))if(e[0]&&e[0].headers)s(e[0].headers,i)&&(this.dt=i);else{var o={};for(var a in r)o[a]=r[a];o.headers=new Headers(r.headers||{}),s(o.headers,i)&&(this.dt=i),e.length>1?e[1]=o:e.push(o)}}function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function y(e,t){this.params={},this.metrics={},this.startTime=(0,S.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof le?r=i.url:p.gm?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),pe(this,r);var o=(""+(i&&i instanceof le&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.body=n.body,this.txSize=G(n.body)||0}function w(e,t){if(this.endTime=(0,S.t)(),this.params||(this.params={}),(0,ce.iW)(this.params))return;let n;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);const i={txSize:this.txSize,rxSize:n,duration:(0,S.t)()-this.startTime};r("xhr",[this.params,i,this.startTime,this.endTime,"fetch"],this,a.K7.ajax)}function R(e){const t=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<de;t++)e.removeEventListener(ue[t],this.listener,!1);t.aborted||(0,ce.iW)(t)||(n.duration=(0,S.t)()-this.startTime,this.loadCazptureCalled||4!==e.readyState?null==t.status&&(t.status=0):T(this,e),n.cbTime=this.cbTime,r("xhr",[t,n,this.startTime,this.endTime,"xhr"],this,a.K7.ajax))}}function T(e,r){e.params.status=r.status;var n=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?G(e.response):"text"===r||""===r||void 0===r?G(e.responseText):void 0}(r,e.lastSize);if(n&&(e.metrics.rxSize=n),e.sameOrigin){var i=r.getResponseHeader("X-NewRelic-App-Data");i&&((0,x.p)(O.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,a.K7.metrics,t),e.params.cat=i.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",i),t.on("open-xhr-start",o),t.on("open-xhr-end",s),t.on("send-xhr-start",c),t.on("xhr-cb-time",u),t.on("xhr-load-added",d),t.on("xhr-load-removed",l),t.on("xhr-resolved",f),t.on("addEventListener-end",h),t.on("removeEventListener-end",g),t.on("fn-end",v),t.on("fetch-before-start",b),t.on("fetch-start",y),t.on("fn-start",m),t.on("fetch-done",w)}(e,this.ee,this.handler,this.dt),this.importAggregator(e)}}function pe(e,t){var r=(0,ie.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const ge={},me=["pushState","replaceState"];function ve(e){const t=function(e){return(e||B.ee).get("history")}(e);return!p.RI||ge[t.debugId]++||(ge[t.debugId]=1,(0,W.YM)(t).inPlace(window.history,me,"-")),t}var be=i(3738);const{He:ye,bD:we,d3:Re,Kp:xe,TZ:Te,Lc:Ae,uP:Ee,Rz:Se}=be;class Ne extends b{static featureName=Te;constructor(e,t=!0){super(e,Te,t);if(!(0,m.V)(this.agentIdentifier))return void this.deregisterDrain();const r=this.ee;let n;ve(r),this.eventsEE=(0,F.u)(r),this.eventsEE.on(Ee,(function(e,t){this.bstStart=(0,S.t)()})),this.eventsEE.on(Ae,(function(e,t){(0,x.p)("bst",[e[0],t,this.bstStart,(0,S.t)()],void 0,a.K7.sessionTrace,r)})),r.on(Se+Re,(function(e){this.time=(0,S.t)(),this.startPath=location.pathname+location.hash})),r.on(Se+xe,(function(e){(0,x.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,a.K7.sessionTrace,r)}));try{n=new PerformanceObserver((e=>{const t=e.getEntries();(0,x.p)(ye,[t],void 0,a.K7.sessionTrace,r)})),n.observe({type:we,buffered:!0})}catch(e){}this.importAggregator(e,{resourceObserver:n})}}var Oe=i(2614);class _e extends b{static featureName=t.TZ;#i;#o;constructor(e,r=!0){let n;super(e,t.TZ,r),this.replayRunning=!1,this.#o=e;try{n=JSON.parse(localStorage.getItem("".concat(Oe.H3,"_").concat(Oe.uh)))}catch(e){}(0,g.SR)(e.agentIdentifier)&&this.ee.on(t.G4.RECORD,(()=>this.#a())),this.#s(n)?(this.#i=n?.sessionReplayMode,this.#c()):this.importAggregator(e),this.ee.on("err",(e=>{this.replayRunning&&(this.errorNoticed=!0,(0,x.p)(t.G4.ERROR_DURING_REPLAY,[e],void 0,this.featureName,this.ee))})),this.ee.on(t.G4.REPLAY_RUNNING,(e=>{this.replayRunning=e}))}#s(e){return e&&(e.sessionReplayMode===Oe.g.FULL||e.sessionReplayMode===Oe.g.ERROR)||(0,g.Aw)(this.agentIdentifier)}#u=!1;async#c(e){if(!this.#u){this.#u=!0;try{const{Recorder:t}=await Promise.all([i.e(478),i.e(249)]).then(i.bind(i,8589));this.recorder??=new t({mode:this.#i,agentIdentifier:this.agentIdentifier,trigger:e,ee:this.ee}),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording}catch(e){}this.importAggregator(this.#o,{recorder:this.recorder,errorNoticed:this.errorNoticed})}}#a(){this.featAggregate?this.featAggregate.mode!==Oe.g.FULL&&this.featAggregate.initializeRecording(Oe.g.FULL,!0):(this.#i=Oe.g.FULL,this.#c(t.Qb.API),this.recorder&&this.recorder.parent.mode!==Oe.g.FULL&&(this.recorder.parent.mode=Oe.g.FULL,this.recorder.stopRecording(),this.recorder.startRecording(),this.abortHandler=this.recorder.stopRecording))}}var Ie=i(3962);class je extends b{static featureName=Ie.TZ;constructor(e,t=!0){if(super(e,Ie.TZ,t),!p.RI||!(0,R.dV)().o.MO)return;const r=ve(this.ee);Ie.tC.forEach((e=>{(0,A.sp)(e,(e=>{a(e)}),!0)}));const n=()=>(0,x.p)("newURL",[(0,S.t)(),""+window.location],void 0,this.featureName,this.ee);r.on("pushState-end",n),r.on("replaceState-end",n);try{this.removeOnAbort=new AbortController}catch(e){}(0,A.sp)("popstate",(e=>(0,x.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)),!0,this.removeOnAbort?.signal);let i=!1;const o=new((0,R.dV)().o.MO)(((e,t)=>{i||(i=!0,requestAnimationFrame((()=>{(0,x.p)("newDom",[(0,S.t)()],void 0,this.featureName,this.ee),i=!1})))})),a=(0,v.s)((e=>{(0,x.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})}),100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,{domObserver:o})}}var Pe=i(7378);const Ce={},ke=["appendChild","insertBefore","replaceChild"];function Le(e){const t=function(e){return(e||B.ee).get("jsonp")}(e);if(!p.RI||Ce[t.debugId])return t;Ce[t.debugId]=!0;var r=(0,W.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function a(e,t){if(!e)return t;const r=e.match(o),n=r[1];return a(r[3],t[n])}return r.inPlace(Node.prototype,ke,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(s=e.src,c=s.match(n),c?c[1]:null);var s,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:a(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,A.jT)(!1)),e.removeEventListener("error",f,(0,A.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,A.jT)(!1)),e.removeEventListener("error",f,(0,A.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,A.jT)(!1)),e.addEventListener("error",f,(0,A.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}const He={};function De(e){const t=function(e){return(e||B.ee).get("promise")}(e);if(He[t.debugId])return t;He[t.debugId]=!0;var r=t.context,n=(0,W.YM)(t),i=p.gm.Promise;return i&&function(){function e(r){var o=t.context(),a=n(r,"executor-",o,null,!1);const s=Reflect.construct(i,[a],e);return t.context(s).getCtx=function(){return o},s}p.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach((function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,a=r(i);a.promise=i,e[0]=n(e[0],"cb-",a,null,!1),e[1]=n(e[1],"cb-",a,null,!1);const s=o.apply(this,e);return a.nextPromise=s,t.emit("propagate",[i,!0],s,!1,!1),s},i.prototype.then[W.Jt]=o,t.on("executor-start",(function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)})),t.on("executor-err",(function(e,t,r){e[1](r)})),t.on("cb-end",(function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)})),t.on("propagate",(function(e,r,n){this.getCtx&&!r||(this.getCtx=function(){if(e instanceof Promise)var r=t.context(e);return r&&r.getCtx?r.getCtx():this})}))}(),t}const Me={},Ke="setTimeout",Ue="setInterval",Ve="clearTimeout",Ge="-start",Fe=[Ke,"setImmediate",Ue,Ve,"clearImmediate"];function Be(e){const t=function(e){return(e||B.ee).get("timer")}(e);if(Me[t.debugId]++)return t;Me[t.debugId]=1;var r=(0,W.YM)(t);return r.inPlace(p.gm,Fe.slice(0,2),Ke+"-"),r.inPlace(p.gm,Fe.slice(2,3),Ue+"-"),r.inPlace(p.gm,Fe.slice(3),Ve+"-"),t.on(Ue+Ge,(function(e,t,n){e[0]=r(e[0],"fn-",null,n)})),t.on(Ke+Ge,(function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)})),t}const We={};function ze(e){const t=function(e){return(e||B.ee).get("mutation")}(e);if(!p.RI||We[t.debugId])return t;We[t.debugId]=!0;var r=(0,W.YM)(t),n=p.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:qe,d3:Ze,Kp:Ye,$p:Xe,wW:Je,e5:Qe,tH:$e,uP:et,rw:tt,Lc:rt}=Pe;class nt extends b{static featureName=qe;constructor(e,t=!0){if(super(e,qe,t),!p.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let r,n=0;const i=this.ee.get("tracer"),o=Le(this.ee),a=De(this.ee),s=Be(this.ee),c=Z(this.ee),u=this.ee.get("events"),d=ne(this.ee),l=ve(this.ee),f=ze(this.ee);function h(e,t){l.emit("newURL",[""+window.location,t])}function g(){n++,r=window.location.hash,this[et]=(0,S.t)()}function m(){n--,window.location.hash!==r&&h(0,!0);var e=(0,S.t)();this[Qe]=~~this[Qe]+e-this[et],this[rt]=e}function v(e,t){e.on(t,(function(){this[t]=(0,S.t)()}))}this.ee.on(et,g),a.on(tt,g),o.on(tt,g),this.ee.on(rt,m),a.on(Je,m),o.on(Je,m),this.ee.on("fn-err",((...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,x.p)("function-err",[...t],void 0,this.featureName,this.ee)})),this.ee.buffer([et,rt,"xhr-resolved"],this.featureName),u.buffer([et],this.featureName),s.buffer(["setTimeout"+Ye,"clearTimeout"+Ze,et],this.featureName),c.buffer([et,"new-xhr","send-xhr"+Ze],this.featureName),d.buffer([$e+Ze,$e+"-done",$e+Xe+Ze,$e+Xe+Ye],this.featureName),l.buffer(["newURL"],this.featureName),f.buffer([et],this.featureName),a.buffer(["propagate",tt,Je,"executor-err","resolve"+Ze],this.featureName),i.buffer([et,"no-"+et],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),v(d,$e+Ze),v(d,$e+"-done"),v(o,"new-jsonp"),v(o,"jsonp-end"),v(o,"cb-start"),l.on("pushState-end",h),l.on("replaceState-end",h),window.addEventListener("hashchange",h,(0,A.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",h,(0,A.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){h(0,n>1)}),(0,A.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#n,this.importAggregator(e)}#n(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var it=i(3333);class ot extends b{static featureName=it.TZ;constructor(e,t=!0){super(e,it.TZ,t);const r=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled];p.RI&&e.init.user_actions.enabled&&(it.Zp.forEach((e=>(0,A.sp)(e,(e=>(0,x.p)("ua",[e],void 0,this.featureName,this.ee)),!0))),it.qN.forEach((e=>(0,A.sp)(e,(e=>(0,x.p)("ua",[e],void 0,this.featureName,this.ee)))))),r.some((e=>e))?this.importAggregator(e):this.deregisterDrain()}}var at=i(993),st=i(3785);class ct extends b{static featureName=at.TZ;constructor(e,t=!0){super(e,at.TZ,t);const r=this.ee;this.ee.on("wrap-logger-end",(function([e]){const{level:t,customAttributes:n}=this;(0,st.R)(r,e,n,t)})),this.importAggregator(e)}}new class extends o{constructor(t,r){super(r),p.gm?(this.features={},(0,R.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(t.features||[]),this.desiredFeatures.add(w),this.runSoftNavOverSpa=[...this.desiredFeatures].some((e=>e.featureName===a.K7.softNav)),(0,d.j)(this,t,t.loaderType||"agent"),this.run()):(0,e.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}run(){try{const t=u(this.agentIdentifier),r=[...this.desiredFeatures];r.sort(((e,t)=>a.P3[e.featureName]-a.P3[t.featureName])),r.forEach((r=>{if(!t[r.featureName]&&r.featureName!==a.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&r.featureName===a.K7.spa)return;if(!this.runSoftNavOverSpa&&r.featureName===a.K7.softNav)return;const n=function(e){switch(e){case a.K7.ajax:return[a.K7.jserrors];case a.K7.sessionTrace:return[a.K7.ajax,a.K7.pageViewEvent];case a.K7.sessionReplay:return[a.K7.sessionTrace];case a.K7.pageViewTiming:return[a.K7.pageViewEvent];default:return[]}}(r.featureName).filter((e=>!(e in this.features)));n.length>0&&(0,e.R)(36,{targetFeature:r.featureName,missingDependencies:n}),this.features[r.featureName]=new r(this)}))}catch(t){(0,e.R)(22,t);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,R.Zm)();delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return r.ee.get(this.agentIdentifier).abort(),!1}}}({features:[he,w,N,Ne,_e,_,D,ot,ct,je,nt],loaderType:"spa"})})()})();</script><link rel="preload" href="/article-pages/_nuxt/9cc2c68.js" as="script"><link rel="preload" href="/article-pages/_nuxt/ca2a6ed.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/2e4c4d9.css" as="style"><link rel="preload" href="/article-pages/_nuxt/9b8d23d.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/c424848.css" as="style"><link rel="preload" href="/article-pages/_nuxt/92bc9eb.js" as="script"><link rel="preload" href="/article-pages/_nuxt/51ff06b.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/e5cdfa1.css" as="style"><link rel="preload" href="/article-pages/_nuxt/e16d0bc.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/82a0061.css" as="style"><link rel="preload" href="/article-pages/_nuxt/5f5c456.js" as="script"><link rel="preload" href="/article-pages/_nuxt/css/d80c00c.css" as="style"><link rel="preload" href="/article-pages/_nuxt/e261291.js" as="script"><link rel="preload" href="/article-pages/_nuxt/8eb37ac.js" as="script"><link rel="stylesheet" href="/article-pages/_nuxt/css/2e4c4d9.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/c424848.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/e5cdfa1.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/82a0061.css"><link rel="stylesheet" href="/article-pages/_nuxt/css/d80c00c.css"> <meta property="fb:admins" content="1841006843"> </head> <body > <button class="BypassBlock__firstEl"></button> <a href="#main-content" class="BypassBlock__wrapper"> <span class="BypassBlock__button">Skip to main content</span> </a>  <noscript> <iframe src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x" height="0" width="0" style="display:none;visibility:hidden"></iframe> </noscript>  <div data-server-rendered="true" id="__nuxt"><div id="__layout"><div theme="purple" class="ArticleLayout"><nav class="Ibar"><h1 class="acc-hidden">Top bar navigation</h1> <div class="Ibar__main"><div class="Ibar__wrapper"><button aria-label="Open Menu" data-event="iBar-btn-openMenu" class="Ibar__burger"></button> <div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg" class="Ibar__logo__svg"><path d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF" class="Ibar__logo__text"></path> <path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path> <path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path> <path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path> <path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path> <path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path> <path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path> <path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path> <path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path> <path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div> <a aria-label="Frontiers in Oncology" href="//www.frontiersin.org/journals/oncology" data-event="iBar-a-journalHome" class="Ibar__journalName"><div logoClass="Ibar__logo--mixed" class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Oncology</span></div></div></a> <div parent-data-event="iBar" class="Ibar__dropdown Ibar__dropdown--aboutUs"><button class="Ibar__dropdown__trigger"> About us </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title"> About us </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers' impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://progressreport.frontiersin.org/?utm_source=fweb&utm_medium=frep&utm_campaign=pr20" target="_blank" data-event="iBar-aboutUs_1-a_impactAndProgress">Progress Report 2022</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/progress-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">All progress reports</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li> <li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li> <li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersplanetprize.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.orgabout/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li></ul></div></div></div> <a href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals" class="Ibar__link">All journals</a><a href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles" class="Ibar__link">All articles</a> <a href="https://www.frontiersin.org/submission/submit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451" data-event="iBar-a-submit" class="Ibar__button Ibar__submit">Submit your research</a> <div class="Ibar__spacer"></div> <a href="/search" aria-label="Search" data-event="iBar-a-search" class="Ibar__icon Ibar__icon--search"><span>Search</span></a>    <div class="Ibar__userArea"></div></div></div> <div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg" class="Ibar__logo__svg"><path d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF" class="Ibar__logo__text"></path> <path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path> <path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path> <path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path> <path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path> <path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path> <path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path> <path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path> <path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path> <path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div> <button aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu" class="Ibar__close"></button></div> <div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/oncology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Oncology</span></div></div></a> <div parent-data-event="iBarMenu" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"> Sections </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title"> Sections </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <ul class="Ibar__dropdown__sections"><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li></ul></div></div> <a href="//www.frontiersin.org/journals/oncology/articles" data-event="iBar-a-articles" class="Ibar__link">Articles</a><a href="//www.frontiersin.org/journals/oncology/research-topics" data-event="iBar-a-researchTopics" class="Ibar__link">Research Topics</a><a href="//www.frontiersin.org/journals/oncology/editors" data-event="iBar-a-editorialBoard" class="Ibar__link">Editorial board</a> <div parent-data-event="iBarMenu" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"> About journal </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title"> About journal </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Scope</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_scope">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_0-a_scope">Mission & scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_0-a_scope">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_0-a_scope">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_0-a_scope">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_0-a_scope">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_0-a_scope">Quality</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">For authors</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Contact editorial office</a></li></ul></div></div></div></div> <div parent-data-event="iBarMenu" class="Ibar__dropdown Ibar__dropdown--aboutUs"><button class="Ibar__dropdown__trigger"> About us </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title"> About us </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers' impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://progressreport.frontiersin.org/?utm_source=fweb&utm_medium=frep&utm_campaign=pr20" target="_blank" data-event="iBar-aboutUs_1-a_impactAndProgress">Progress Report 2022</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/progress-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">All progress reports</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li> <li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li> <li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersplanetprize.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.orgabout/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li></ul></div></div></div> <a href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals" class="Ibar__link">All journals</a><a href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles" class="Ibar__link">All articles</a>    <a href="https://www.frontiersin.org/submission/submit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451" data-event="iBarMenu-a-submit" class="Ibar__button Ibar__submit">Submit your research</a></div></div> <div class="Ibar__journal"><div class="Ibar__wrapper Ibar__wrapper--journal"><a aria-label="Frontiers in Oncology" href="//www.frontiersin.org/journals/oncology" data-event="iBarJournal-a-journalHome" class="Ibar__journalName"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Oncology</span></div></div></a> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"> Sections </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title"> Sections </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <ul class="Ibar__dropdown__sections"><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li></ul></div></div> <a href="//www.frontiersin.org/journals/oncology/articles" data-event="iBar-a-articles" class="Ibar__link">Articles</a><a href="//www.frontiersin.org/journals/oncology/research-topics" data-event="iBar-a-researchTopics" class="Ibar__link">Research Topics</a><a href="//www.frontiersin.org/journals/oncology/editors" data-event="iBar-a-editorialBoard" class="Ibar__link">Editorial board</a> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"> About journal </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title"> About journal </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Scope</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_scope">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_0-a_scope">Mission & scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_0-a_scope">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_0-a_scope">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_0-a_scope">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_0-a_scope">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_0-a_scope">Quality</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">For authors</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Contact editorial office</a></li></ul></div></div></div> <div class="Ibar__spacer"></div></div></div> <div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg" class="Ibar__logo__svg"><path d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF" class="Ibar__logo__text"></path> <path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path> <path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path> <path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path> <path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path> <path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path> <path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path> <path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path> <path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path> <path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div> <a aria-label="Frontiers in Oncology" href="//www.frontiersin.org/journals/oncology" data-event="iBarJournal-a-journalHome" class="Ibar__journalName"><div logoClass="Ibar__logo--mixed" class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img src="" class="Ibar__journal__logo"></div> <div class="Ibar__journalName"><span>Frontiers in</span> <span> Oncology</span></div></div></a> <div class="Ibar__spacer"></div> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"> Sections </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title"> Sections </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <ul class="Ibar__dropdown__sections"><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li></ul></div></div> <a href="//www.frontiersin.org/journals/oncology/articles" data-event="iBar-a-articles" class="Ibar__link">Articles</a><a href="//www.frontiersin.org/journals/oncology/research-topics" data-event="iBar-a-researchTopics" class="Ibar__link">Research Topics</a><a href="//www.frontiersin.org/journals/oncology/editors" data-event="iBar-a-editorialBoard" class="Ibar__link">Editorial board</a> <div parent-data-event="iBarJournal" class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"> About journal </button> <div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button aria-label="Close Dropdown" class="Ibar__dropdown__menu__header__title"> About journal </button> <button aria-label="Close Dropdown" class="Ibar__close"></button></div> <div class="Ibar__dropdown__about"><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Scope</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_scope">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_0-a_scope">Mission & scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_0-a_scope">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_0-a_scope">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_0-a_scope">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_0-a_scope">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_0-a_scope">Quality</a></li></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">For authors</li> <li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_1-a_forAuthors">Contact editorial office</a></li></ul></div></div></div> <div class="Ibar__spacer"></div> <a href="https://www.frontiersin.org/submission/submit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451" data-event="iBarJournal-a-submit" class="Ibar__button Ibar__submit"><span>Submit</span> <span>聽your research</span></a> <a href="/search" aria-label="Search" data-event="iBar-a-search" class="Ibar__icon Ibar__icon--search"><span>Search</span></a>    <div class="Ibar__userArea"></div></div></div></nav> <div class="ArticlePage"><div><div class="Layout Layout--withAside Layout--withIbarMix ArticleDetails"> <aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div id="FloatingButtonsEl" class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--type ActionsDropDown__button--icon"><span class="ActionsDropDown__button__label">Download article</span></button> <div class="ActionsDropDown__menuWrapper"> <ul class="ActionsDropDown__menu"><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/pdf" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-pdf" class="ActionsDropDown__option"> Download PDF </a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2023.1043244" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-readCube" class="ActionsDropDown__option"> ReadCube </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/epub" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-epub" class="ActionsDropDown__option"> EPUB </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/xml/nlm" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-nlmXml" class="ActionsDropDown__option"> XML (NLM) </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div> <div class="ArticleDetails__aside__responsiveButtons__items"> <div class="ArticleDetailsShare__responsive"><button aria-label="Open share options" class="ArticleDetailsShare__trigger"></button> <div class="ArticleDetailsShare"><h5 class="ArticleDetailsShare__title">Share on</h5> <ul class="ArticleDetailsShare__list"><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1043244/full" target="_blank" title="Share on X" aria-label="Share on X" class="ArticleDetailsShare__link ArticleDetailsShare__link--x"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1043244/full" target="_blank" title="Share on Linkedin" aria-label="Share on Linkedin" class="ArticleDetailsShare__link ArticleDetailsShare__link--linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1043244/full" target="_blank" title="Share on Facebook" aria-label="Share on Facebook" class="ArticleDetailsShare__link ArticleDetailsShare__link--facebook"></a></li></ul></div></div> <div class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote"></button> <div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle"> Export citation </div> <ul class="ActionsDropDown__menu"><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/endNote" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-endNote" class="ActionsDropDown__option"> EndNote </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/reference" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-referenceManager" class="ActionsDropDown__option"> Reference Manager </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/text" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-simpleTextFile" class="ActionsDropDown__option"> Simple Text file </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/bibTex" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-bibTex" class="ActionsDropDown__option"> BibTex </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div></div></div> <div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number"> 886 </div> <div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div> <div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number"> 552 </div> <div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div> <div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number"> 2 </div> <div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div> <div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button> <div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button> <div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div> <div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/1043244#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact" class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right"><span>View article impact</span></a></span></div> <div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fonc.2023.1043244" data-condensed="true" data-link-target="new" class="altmetric-embed"></div> <span class="Link__wrapper"><a aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fonc.2023.1043244" target="_blank" data-event="customLink-link-a_viewAltmetricScore" class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right"><span>View altmetric score</span></a></span></div></div> <div class="ArticleDetailsShare"><h5 class="ArticleDetailsShare__title">Share on</h5> <ul class="ArticleDetailsShare__list"><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1043244/full" target="_blank" title="Share on X" aria-label="Share on X" class="ArticleDetailsShare__link ArticleDetailsShare__link--x"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1043244/full" target="_blank" title="Share on Linkedin" aria-label="Share on Linkedin" class="ArticleDetailsShare__link ArticleDetailsShare__link--linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1043244/full" target="_blank" title="Share on Facebook" aria-label="Share on Facebook" class="ArticleDetailsShare__link ArticleDetailsShare__link--facebook"></a></li></ul></div> <div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div> <a href="https://loop.frontiersin.org/people/1003220/overview" data-event="editorInfo-a-koheiFujita" class="ArticleDetailsEditors__ediorInfo"><figure class="Avatar Avatar--size-32"><img src="https://loop.frontiersin.org/images/profile/1003220/32" alt="Kohei Fujita" class="Avatar__img is-inside-mask"></figure> <div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name"> Kohei Fujita </div> <div class="ArticleDetailsEditors__ediorInfo__affiliation"> Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Japan </div></div></a></div></div> <div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div> <a href="https://loop.frontiersin.org/people/970570/overview" data-event="editorInfo-a-xiaoboDu" class="ArticleDetailsEditors__ediorInfo"><figure class="Avatar Avatar--size-32"><img src="https://loop.frontiersin.org/images/profile/970570/32" alt="Xiaobo Du" class="Avatar__img is-inside-mask"></figure> <div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name"> Xiaobo Du </div> <div class="ArticleDetailsEditors__ediorInfo__affiliation"> Mianyang Central Hospital, China </div></div></a><a href="https://loop.frontiersin.org/people/1116571/overview" data-event="editorInfo-a-taoQin" class="ArticleDetailsEditors__ediorInfo"><figure class="Avatar Avatar--size-32"><img src="https://loop.frontiersin.org/images/profile/1116571/32" alt="TAO QIN" class="Avatar__img is-inside-mask"></figure> <div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name"> TAO QIN </div> <div class="ArticleDetailsEditors__ediorInfo__affiliation"> Sun Yat-sen Memorial Hospital, China </div></div></a></div></div> <div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div> <div class="ArticleDetailsGlossary__header__arrow"></div></button> <div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"><li><a href="#h1">Abstract</a></li><li><a href="#h2">Introduction</a></li><li><a href="#h3">Background</a></li><li><a href="#h4">Discussion</a></li><li><a href="#h5">Conclusion</a></li><li><a href="#h6">Data availability statement</a></li><li><a href="#h7">Ethics statement</a></li><li><a href="#h8">Author contributions</a></li><li><a href="#h9">Funding</a></li><li><a href="#h10">Acknowledgments</a></li><li><a href="#h11">Conflict of interest</a></li><li><a href="#h12">Publisher’s note</a></li><li><a href="#h13">References</a></li></ul></div></div>  <div class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote"><span class="ActionsDropDown__button__label">Export citation</span></button> <div class="ActionsDropDown__menuWrapper"> <ul class="ActionsDropDown__menu"><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/endNote" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-endNote" class="ActionsDropDown__option"> EndNote </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/reference" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-referenceManager" class="ActionsDropDown__option"> Reference Manager </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/text" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-simpleTextFile" class="ActionsDropDown__option"> Simple Text file </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/bibTex" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-bibTex" class="ActionsDropDown__option"> BibTex </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div> <div class="CheckForUpdates"><button data-target="crossmark" data-event="checkForUpdates-btn-openModal" class="CheckForUpdates__link"><img src="/article-pages/_nuxt/img/crossmark.5c8ec60.svg" alt="Crossmark icon" class="CheckForUpdates__link__img"> <div class="CheckForUpdates__link__text">Check for updates</div></button></div>  </div>  <div><div class="FloatingButtons"> <div class="ActionsDropDown"><button aria-label="Open dropdown" data-event="actionsDropDown-button-toggle" class="ActionsDropDown__button ActionsDropDown__button--type ActionsDropDown__button--iconDownload"><span class="ActionsDropDown__button__label">Download article</span></button> <div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle"> Download </div> <ul class="ActionsDropDown__menu"><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/pdf" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-pdf" class="ActionsDropDown__option"> Download PDF </a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2023.1043244" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-readCube" class="ActionsDropDown__option"> ReadCube </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/epub" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-epub" class="ActionsDropDown__option"> EPUB </a></li><li><a href="/journals/oncology/articles/10.3389/fonc.2023.1043244/xml/nlm" target="_blank" rel="noopener noreferrer" data-event="actionsDropDown-a-nlmXml" class="ActionsDropDown__option"> XML (NLM) </a></li></ul> <button aria-label="Close modal" data-event="actionsDropDown-button-close" class="ActionsDropDown__mobileClose"></button></div></div></div> </div></div></aside> <main class="Layout__main"> <section class="ArticleDetails__main"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><h2 class="ArticleLayoutHeader__info__title">CASE REPORT article</h2> <div class="ArticleLayoutHeader__info__journalDate"><span>Front. Oncol.</span><span>, 06 April 2023</span></div> <div class="ArticleLayoutHeader__info__journalDate"> Sec. Thoracic Oncology </div> <div class="ArticleLayoutHeader__info__doiVolume"><span> Volume 13 - 2023 | </span> <a href="https://doi.org/10.3389/fonc.2023.1043244" class="ArticleLayoutHeader__info__doi"> https://doi.org/10.3389/fonc.2023.1043244 </a></div> </div>  <div class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span> <span class="ArticleLayoutHeader__isPartOfRT__title">Case Reports in Thoracic Oncology: 2022</span> <span class="Link__wrapper"><a aria-label="View all 42 articles" href="https://www.frontiersin.org/research-topics/41000/case-reports-in-thoracic-oncology-2022/articles" target="_self" data-event="customLink-link-a_viewAll42Articles" class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right"><span>View all 42 articles</span></a></span></div></div> <div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report</h1> </div> </div> <div class="JournalFullText"><div class="JournalAbstract"><a id="h1" name="h1"></a><div class="authors"><span class="author-wrapper"><a href="https://loop.frontiersin.org/people/1995236" class="user-id-1995236"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1995236/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Jingyi Wang&#x;">Jingyi Wang</a><sup>1†</sup></span><span class="author-wrapper"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Xiaoqing Li&#x;" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Xiaoqing Li<sup>1†</sup></span><span class="author-wrapper"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Juan Zhou" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Juan Zhou<sup>1</sup></span><span class="author-wrapper"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Dan Qiu" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Dan Qiu<sup>1</sup></span><span class="author-wrapper"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Mengyao Zhang" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Mengyao Zhang<sup>1</sup></span><span class="author-wrapper"><a href="https://loop.frontiersin.org/people/2043266" class="user-id-2043266"><img class="pr5" src="https://loop.frontiersin.org/images/profile/2043266/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Lan Sun*">Lan Sun</a><sup>1*</sup></span><span class="author-wrapper"><a href="https://loop.frontiersin.org/people/993634" class="user-id-993634"><img class="pr5" src="https://loop.frontiersin.org/images/profile/993634/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Shengwen Calvin Li,*">Shengwen Calvin Li</a><sup>2,3*</sup></span></div><ul class="notes"><li><span><sup>1</sup></span>Department of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, China</li><li><span><sup>2</sup></span>Neuro-Oncology and Stem Cell Research Laboratory, Center for Neuroscience Research, CHOC Children’s Research Institute, Children’s Hospital of Orange County (CHOC), Orange, CA, United States</li><li><span><sup>3</sup></span>Department of Neurology, University of California-Irvine School of Medicine, Orange, CA, United States</li></ul><p><b>Background:</b> Half of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approved for the standard third-line treatment for NSCLC in China. Herein we report an elderly NSCLC patient without any driver gene mutations who was undergoing anlotinib as a front-line treatment and who achieved long-term survival.</p><p><b>Case summary:</b> The 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1).</p><p><b>Conclusion:</b> This patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy.</p><div class="clear"></div></div><div class="JournalFullText"><a id="h2" name="h2"></a><h2>Introduction</h2><p class="mb0">Lung cancer is one of the most common malignant tumors and the leading cause of global cancer mortality (<a href="#B1">1</a>). Angiogenesis is one of the characteristics of malignant tumors, which can provide nutrition for the growth of tumor cells and secrete growth factors to promote cancer cell proliferation, thus playing an essential role in tumor growth, invasion, and metastasis (<a href="#B2">2</a>, <a href="#B3">3</a>). A growing number of studies have shown that advanced non-small cell lung cancer (NSCLC) patients can benefit from anti-angiogenesis therapy with higher anti-cancer activity and fewer adverse effects than traditional chemoradiotherapy (<a href="#B4">4</a>, <a href="#B5">5</a>). Anlotinib is a novel oral multitarget tyrosine kinase inhibitor which strongly inhibits vascular endothelial growth factor (VEGF), platelet-derived growth factor receptor (PDGF), fibroblast growth factor receptor (FGFR), and stem cell factor receptor (c-Kit), resulting in the inhibition of the growth of tumor blood vessels (<a href="#B6">6</a>). On May 9, 2018, anlotinib was approved by China Food and Drug Administration as a standard third-line treatment regimen for advanced NSCLC based on the results of the ALTER-0303 study (<a href="#B7">7</a>). However, the evidence for anlotinib as a front-line treatment for NSCLC is limited. Herein we report an elderly NSCLC patient without any driver gene mutations undergoing anlotinib as a front-line treatment.</p><a id="h3" name="h3"></a><h2>Background</h2><h3>Chief complaints</h3><p class="mb0">A 77–year-old male patient developed chest tightness after an activity and precardiac pain in June 2018. He had an occasional cough with sputum.</p><h3>History of present illness</h3><p class="mb0">The patient had chest tightness after an activity, precardiac pain, and occasional cough with sputum.</p><h3>History of past illness</h3><p class="mb0">The patient had a history of chronic obstructive pulmonary disease (COPD) and diabetes mellitus type 2 (T2DM), with a smoking history of 55 years averaging 20 cigarettes per day. He had quit smoking for more than 2 years.</p><h3>Personal and family history</h3><p class="mb0">The patient had a cancer-relative family susceptibility. His one brother and two sisters suffered from lung cancer, and another brother had liver cancer.</p><h3>Physical examination</h3><p class="mb0">The results of the physical examination showed that the patient’s body temperature was 36.3°C, the pulse rate was 70 beats per minute (bpm), the blood pressure was 128/76 mmHg, respiratory rate was 19 breaths/min, and the performance status score was 1.</p><h3>Laboratory examinations</h3><p class="mb0">His blood count showed a WBC level of 5.75 × 10<sup>9</sup>/L, Hb level of 116 g/L, and platelet count of 201 × 10<sup>9</sup>/L. The serum level of carcinoembryonic antigen was 6.6 ng/ml.</p><h3>Pathology and genetic testing</h3><p class="mb0">The histopathological analysis of the tissue biopsy samples collected from the right lung revealed poorly differentiated squamous cell carcinoma (<a href="#f1">Figure 1</a>). The immunohistochemistry result showed the following details: CK5/6 (+), P63 (+), P40 (+), NapsinA (-), TTF1 (-), CK7(-), and CK14(+). A molecular analysis did not find any driver gene mutations of EGFR, ALK, and ROS1. Tissue samples were detected <i>via</i> next-generation sequencing with a panel consisting of 211 genes, which revealed TP53 (mutant abundance: 14.37%) and tumor mutation burden (TMB) of 21.15 Muts/Mb. The somatic mutations are shown in <a href="#T1">Table 1</a>.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g001.jpg" name="" target="_blank"> <picture> <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g001.jpg" alt="www.frontiersin.org" id="f1" loading="lazy"> </picture> </a><p><b>Figure 1</b> Hematoxylin and eosin staining photomicrographs of a right lung tumor tissue biopsy. <b>(A)</b> Magnification, ×200. <b>(B)</b> Magnification, ×400.</p></div><div class="DottedLine"></div><div class="Imageheaders">TABLE 1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t001.jpg" name="table 1" target="_blank"> <picture> <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy"> </picture> </a><p><b>Table 1</b> List of somatic mutations.</p></div><div class="DottedLine"></div><h3>Imaging examinations</h3><p class="mb0">The chest scan first computed tomography (CT) result showed a mass which was 52 mm × 50 mm in size (<a href="#f2">Figure 2A</a>). No metastasis was observed on enhanced CT of the skull and the abdomen. The lymph node ultrasound showed no metastasis. As per the solid tumor version 1.1 (RECIST 1.1) response evaluation criteria, the maximum lesion reduction reached 40.4% after four cycles of anlotinib with platinum-based chemotherapy (<a href="#f2">Figure 2B</a>). After six courses of anlotinib monotherapy maintenance, the MRI results showed bilateral clavicular lymph node metastasis, and the patient’s PFS<sub>1</sub> was 10 months. Then, after 12 cycles of anlotinib in combination with tegafur, the lesion reduction reached 13.8% compared with the previous best curative effect (<a href="#f2">Figure 2C</a>). The disease remained stable after this, and there were no significantly enlarged lymph nodes on bilateral neck ultrasound. On May 24, 2021, the lesion enlarged by 41.4%, and the efficacy was evaluated as disease progression (<a href="#f2">Figure 2D</a>), so the patient’s PFS<sub>2</sub> was 24 months.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g002.jpg" name="" target="_blank"> <picture> <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g002.jpg" alt="www.frontiersin.org" id="f2" loading="lazy"> </picture> </a><p><b>Figure 2</b> Conversion of chest computed tomography at different times. (<b>A</b> and <b>a</b>) Baseline findings on chest computed tomography (tumor size: 52 × 55 mm). (<b>B</b> and <b>b</b>) The mass shrank significantly (tumor size: 31 × 18 mm) after treatment with four cycles of anlotinib plus cisplatin. (<b>C</b> and <b>c</b>) Stable disease (tumor size: 25 × 21 mm) following 12 cycles of anlotinib + tegafur. (<b>D</b> and <b>d</b>) Progressive disease (tumor size: 41 × 34 mm) after 29 cycles of anlotinib + tegafur.</p></div><div class="DottedLine"></div><h3>Final diagnosis</h3><p class="mb0">Finally, the patient was diagnosed with stage IIIB poorly differentiated driver gene-negative squamous cell lung carcinoma (cT3N2M0 in accordance with version 8 of TNM staging).</p><h3>Treatment</h3><p class="mb0">Since July 24, 2018, the patient was treated with anlotinib (12 mg, d1–d14, q3w) and nedaplatin (85 mg/m<sup>2</sup>, q3w) for the first-line therapy. After six courses of anlotinib combined with platinum-based chemotherapy, we used anlotinib monotherapy for maintenance treatment (12 mg, d1–d14, q3w), but the patient reduced the drug dose on his own during the last two courses of maintenance therapy. The disease progressed after six cycles of maintenance treatment. Afterwards, the regimen was switched to anlotinib (12 mg, d1–d14, q3w) combined with tegafur (120 mg d1–d14, q3w) (<a href="#f3">Figure 3</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g003.jpg" name="" target="_blank"> <picture> <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-g003.jpg" alt="www.frontiersin.org" id="f3" loading="lazy"> </picture> </a><p><b>Figure 3</b> Timeline of events from diagnosis to progressive disease and summary of the administered treatments. Treatment work flow from [(anlotinib + NDP) à (anlotinib + DDP)] (6 cycles) to(anlotinib) (6 cycles) and to (anlotinib + tegafur) (29 cycles). After undergoing this treatment strategy, the patient has achieved a PFS of 34 months and an OS of 53 months. These results surpass those seen in the majority of real-world studies and clinical trials.</p></div><div class="DottedLine"></div><h3>Outcome and follow-up</h3><p class="mb0">As of May 24, 2021, the patient received 2 years and 10 months of anlotinib treatment, with a progression-free survival of 34 months. The degree of adverse event was assessed according to Common Terminology Criteria Adverse Events Version 5.0. During the period of the treatment of anlotinib combined with nedaplatin, the patient experienced thrombocytopenia in the second cycle (grade 4), which was controlled with thrombopoietin therapy. Fatigue (grade 2) developed during the 11th and 12<sup>th</sup> cycles, which gradually improved during the interval between cycles. After the disease progressed, we proposed to adjust the treatment option several times, but the patient and his family refused. The last follow-up was on December 12, 2022, and the CT result showed that the lesion size was 78 mm × 59 mm, which increased from the original diagnosis of 52 mm × 50 mm in size (<a href="#f2">Figure 2A</a>).</p><a id="h4" name="h4"></a><h2>Discussion</h2><p class="mb15">In this case, the patient was diagnosed in July 2018 (cT3N2M0), and he could first be considered for surgery. However, his family adamantly refused due to his advanced age and underlying diseases. We also considered immunotherapy in combination with platinum-based chemotherapy, but PD-1 inhibitors were expensive and not financially affordable the patient and his family. Shortly before his diagnosis, anlotinib was approved by China Food and Drug Administration as a third-line treatment for advanced squamous lung cancer (the peripheral type only) based on the results of two clinical trials of anlotinib as a third-line or further treatment for NSCLC. One clinical study (ALTER0302) showed that the median progression-free survival (PFS) of the anlotinib group was significantly better than that of placebo (4.8 vs. 1.2 months) (<a href="#B8">8</a>). The other clinical trial (ALTER0303) showed that anlotinib has extended median OS and PFS significantly, that is, 9.6 months vs. 6.3 months and 5.4 months vs. 1.4 months, respectively, compared with the placebo. Under the third-line or beyond treatment setting, the anlotinib combination therapy showed manageable toxicities and encouraging efficacy, indicating a good application prospect (<a href="#B9">9</a>), which is one of the reasons why we administrated anlotinib as a front-line treatment. The other reasons are as follows: first, according to the National Comprehensive Cancer Network guidelines (2018 edition), radical concurrent chemo-radiotherapy is preferred for inoperable stage IIIB NSCLC patients. However, clinical studies have shown that concurrent radiotherapy is poorly tolerated in elderly patients (<a href="#B10">10</a>), with a high possibility of discontinuing treatment. Sequential chemoradiotherapy may be considered for patients who cannot tolerate concurrent chemoradiotherapy. However, this patient had multiple underlying diseases such as COPD and T2DM; thus, the risk of uncontrollable side effects was high. Moreover, the target volume was too large to determine an appropriate radiotherapy plan ensuring antitumor efficacy and safety. Third, the toxicity of anti-angiogenesis drugs, including anlotinib, is much lower than chemotherapy, and adverse effects are controllable (<a href="#B9">9</a>, <a href="#B11">11</a>). Anlotinib is reported to have the advantage of low toxicity (<a href="#B12">12</a>). The most frequent toxicities include hypertension, hand–foot syndrome, fatigue, <i>etc.</i> Fourth, anti-angiogenesis treatment required attention to the side effect of hemoptysis. Fortunately, this patient had no symptoms of active hemorrhage, and the lesion was peripheral, so the risk of hemorrhage was evaluated as low. Fifth, the patient and his family refused to undergo radiation therapy, so we applied to the Ethics Committee for the inclusion of anlotinib as first-line treatment. The patient and his family eventually chose anlotinib as the first-line treatment and signed the informed patient’s consent as approved. He achieved a total progression-free survival of 34 months using anlotinib as the front-line regimen. From the time of the patient’s diagnosis to the time of the last follow-up (46 months), the maximum diameter of his tumor lesion increased by 12 mm. No uncontrollable toxic side effects were observed in this patient during the drug administration. We analyzed this patient’s long-term survival for several reasons. Firstly, this patient did not develop distant metastases, and the clinical studies associated with anlotinib have validated distant metastases as an important prognosis (<a href="#B13">13</a>). Secondly, it has been shown that inhibition of autophagy improves the efficacy of anlotinib (<a href="#B14">14</a>), and age is one of the important reasons for the effect of autophagy (<a href="#B15">15</a>). Given the advanced age of this patient, we consider that he may have a sustainable survival benefit due to his autophagy inhibition status. Thirdly, this patient has hypofractionated squamous carcinoma. Although hypofractionated tumor cells are conventionally more malignant, there is a complex relationship between cancer and inflammation. Hypofractionated cell proliferation may inhibit the growth of tumor cells through specialized pro-resolving mediators (<a href="#B16">16</a>), which may also be a factor in this patient’s long survival. Fourthly, the patient in this case had TP53 mutations (mutant abundance: 14.37%) with TMB: 21.15 Muts/Mb. TP53 mutations have been identified to be involved in the process of neovascularization associated with increased VEGF expression, which is one of the important targets of anlotinib. Fu et al. found that TP53 mutations are significantly associated with a favorable prognosis in patients with advanced solid malignancies (<a href="#B17">17</a>). It has also been shown that advanced NSCLC patients with high TMB mutations (>10 Muts/Mb) can benefit from anti-angiogenesis therapy (<a href="#B18">18</a>). Unfortunately, we could not ascertain PD-L1 expression because of the insufficient volume of tissue obtained in the first biopsy and the patient’s unwillingness to undergo a repeat biopsy.</p><p class="mb0">This patient had disease progression after six cycles of anlotinib monotherapy maintenance. We switched to anlotinib combined with tegafur because oral tegafur treatment was more convenient and economical. The EAST study demonstrated that tegafur is equally as efficacious as docetaxel (<a href="#B19">19</a>). In addition, anti-angiogenesis therapy can improve the local hypoxic condition of the tumor microenvironment, which is more conducive to the entry of chemotherapeutic drugs into the tumor tissue. There is a growing number of studies on anlotinib as a second-line treatment from 2018 onwards. One study showed that anlotinib combined with chemotherapy might be an effective and well-tolerated treatment for advanced NSCLC in patients who fail in first- or second-line therapy (<a href="#B20">20</a>). Anlotinib plus camrelizumab had shown promising efficacy and manageable toxicity as a second-line or later-line therapy for NSCLC, especially in the 12 mg cohorts (<a href="#B21">21</a>). However, another study showed that anlotinib was less effective than platinum-pemetrexed chemotherapy in T790M-negative lung adenocarcinoma, implicating that it may be more suitable for squamous cell lung carcinoma (<a href="#B22">22</a>). Hence, anlotinib has a synergistic antitumor effect and good safety for NSCLC and may be promising for front-line treatment for NSCLC (<a href="#B20">20</a>). There have also been more studies of anlotinib as a first-line treatment in the last 2 years, and most of these studies have adopted the combination therapy model. The latest clinical analysis of first-line therapy in elderly patients with advanced lung adenocarcinoma without driver gene mutations showed similar median PFS (3.0 m vs. 2.8 m) and OS (7.0 m <i>vs</i>. 7.0 m) in the anlotinib group and the chemotherapy group (P > 0.05), and there was no significant difference in ORR (17.5 vs. 15%) or DCR (67.5 vs. 65.5%) between both treatment groups (<a href="#B23">23</a>). The other studies have shown that, for driver gene-negative NSCLC patients, the median PFS in the anlotinib combined with chemotherapy group was 1.54 months longer than that in the chemotherapy group (9.38 months vs. 7.84 months, <i>P</i> < 0.05), and the median OS in the anlotinib combined with chemotherapy group was longer as well (11.52 months vs. 10.46 months), but the difference was not statistically significant (<i>P</i> > 0.05) (<a href="#B24">24</a>). A study on inoperable NSCLC patients indicated that the median PFS of sequential chemoradiotherapy patients was 10.8 months, but grade 3 acute esophagitis occurred in four of 78 patients (5%) (<a href="#B25">25</a>). As shown in <a href="#T2">Table 2</a> (<a href="#B18">18</a>, <a href="#B23">23</a>, <a href="#B26">26</a>), anlotinib is promising for the first-line treatment for NSCLC with its median PFS range of 3.0 to 15.0 months.</p><div class="DottedLine"></div><div class="Imageheaders">TABLE 2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t002.jpg" name="table 2" target="_blank"> <picture> <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/1043244/fonc-13-1043244-HTML-r1/image_m/fonc-13-1043244-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy"> </picture> </a><p><b>Table 2</b> Some clinical trials of anlotinib in non-small cell lung cancer (NSCLC) for the first line.</p></div><div class="DottedLine"></div><p class="mb0">Recently, more studies focused on the first-line usage for NSCLC but less for elderly patients. To the best of our knowledge, the NSCLC patients in most clinical trials were not allowed to be older than 75 years—for example, the median age of patients with lung cancer who were treated in pivotal trials involving immunotherapy ranged from 61 and 65 years, which are lower than the median age at diagnosis. Thus, such poor representation of older patients in clinical trials makes truly evidence-based decisions on the best regimen for geriatric patients difficult. This patient was 77 years old at diagnosis and achieved a total PFS of 34 months and OS of 53 months after anlotinib treatment, which exceeded most of the results of real-world studies and clinical trials. This case report suggests that combining anlotinib with chemotherapy shows promise as a front-line treatment for elderly patients with advanced NSCLC. Further prospective studies are necessary to validate these findings.</p><a id="h5" name="h5"></a><h2>Conclusion</h2><p class="mb0">As a front-line treatment, anlotinib significantly prolonged this elderly NSCLC patient’s survival time and improved his quality of life.</p><a id="h6" name="h6"></a><h2>Data availability statement</h2><p class="mb0">The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p><a id="h7" name="h7"></a><h2>Ethics statement</h2><p class="mb0">The studies involving human participants were reviewed and approved by The ethics committee of The People’s Hospital of Bishan District Chongqing. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p><a id="h8" name="h8"></a><h2>Author contributions</h2><p class="mb15">JW and JZ contributed significantly to analysis and manuscript preparation. JW performed the data analyses and wrote the manuscript. XL and DQ helped perform the analysis with constructive discussions. MZ assisted in joint evaluation of patients and figure design. LS contributed to the conception of the study. SCL revised the article and made important suggestions. All authors contributed to the article and approved the submitted version.</p><a id="h9" name="h9"></a><h2>Funding</h2><p class="mb15">This work was supported in part by the Natural Science Foundation of Chongqing, China (cstc2020jcyjmsxmX1063) and Beijing Science and Technology Innovation Medical Development Foundation, China (KC2021-JX-0186-28). This work was also supported in part by the UCI ICTS Award #16004004 (CHOC).</p><a id="h10" name="h10"></a><h2>Acknowledgments</h2><p class="mb0">We thank the patient and his family for giving permission for his inclusion in this study.</p><a id="h11" name="h11"></a><h2>Conflict of interest</h2><p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><a id="h12" name="h12"></a><h2>Publisher’s note</h2><p class="mb15">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p><a id="h13" name="h13"></a><h2>References</h2><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B1" id="B1"></a> 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. <i>CA: Cancer J Clin</i> (2019) 691:7–34. doi: 10.3322/caac.21551</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3322/caac.21551" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RL+Siegel&author=KD+Miller&author=A+Jemal&publication_year=2019&title=Cancer%20statistics%2C%202019&journal=CA:+Cancer+J+Clin&volume=691&pages=7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B2" id="B2"></a> 2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. <i>Cell</i> (2011) 1445:646–74. doi: 10.1016/j.cell.2011.02.013</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1016/j.cell.2011.02.013" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Hanahan&author=RA+Weinberg&publication_year=2011&title=Hallmarks%20of%20cancer%3A%20The%20next%20generation&journal=Cell&volume=1445&pages=646-74" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B3" id="B3"></a> 3. Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer. <i>Curr Oncol (Toronto Ont.)</i> (2018) 25Suppl 1:S45–s58. doi: 10.3747/co.25.3747</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.3747/co.25.3747" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Alshangiti&author=G+Chandhoke&author=PM+Ellis&publication_year=2018&title=Antiangiogenic%20therapies%20in%20non-small-cell%20lung%20cancer&journal=Curr+Oncol+(Toronto+Ont.)&volume=25Suppl 1&pages=S45" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B4" id="B4"></a> 4. Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: Updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. <i>Ann Oncol</i> (2014) 255:1044–52. doi: 10.1093/annonc/mdu098</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1093/annonc/mdu098" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Barlesi&author=A+Scherpereel&author=V+Gorbunova&author=R+Gervais&author=A+Vikstr%C3%B6m&author=C+Chouaid&publication_year=2014&title=Maintenance%20bevacizumab-pemetrexed%20after%20first-line%20cisplatin-pemetrexed-bevacizumab%20for%20advanced%20nonsquamous%20nonsmall-cell%20lung%20cancer%3A%20Updated%20survival%20analysis%20of%20the%20AVAPERL%20%28MO22089%29%20randomized%20phase%20III%20trial&journal=Ann+Oncol&volume=255&pages=1044-52" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B5" id="B5"></a> 5. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. <i>J Clin Oncol</i> (2001) 193:851–6. doi: 10.1200/JCO.2001.19.3.851</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1200/JCO.2001.19.3.851" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Margolin&author=MS+Gordon&author=E+Holmgren&author=J+Gaudreault&author=W+Novotny&author=G+Fyfe&publication_year=2001&title=Phase%20ib%20trial%20of%20intravenous%20recombinant%20humanized%20monoclonal%20antibody%20to%20vascular%20endothelial%20growth%20factor%20in%20combination%20with%20chemotherapy%20in%20patients%20with%20advanced%20cancer%3A%20Pharmacologic%20and%20long-term%20safety%20data&journal=J+Clin+Oncol&volume=193&pages=851-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B6" id="B6"></a> 6. Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. <i>J Hematol Oncol</i> (2018) 111:120. doi: 10.1186/s13045-018-0664-7</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1186/s13045-018-0664-7" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Shen&author=F+Zheng&author=D+Ren&author=F+Du&author=Q+Dong&author=Z+Wang&publication_year=2018&title=Anlotinib%3A%20A%20novel%20multi-targeting%20tyrosine%20kinase%20inhibitor%20in%20clinical%20development&journal=J+Hematol+Oncol&volume=111&pages=120" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B7" id="B7"></a> 7. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial. <i>JAMA Oncol</i> (2018) 411:1569–75. doi: 10.1001/jamaoncol.2018.3039</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1001/jamaoncol.2018.3039" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B+Han&author=K+Li&author=Q+Wang&author=L+Zhang&author=J+Shi&author=Z+Wang&publication_year=2018&title=Effect%20of%20anlotinib%20as%20a%20third-line%20or%20further%20treatment%20on%20overall%20survival%20of%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%3A%20The%20ALTER%200303%20phase%203%20randomized%20clinical%20trial&journal=JAMA+Oncol&volume=411&pages=1569-75" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B8" id="B8"></a> 8. Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: A multicentre, randomised phase II trial (ALTER0302). <i>Br J Cancer</i> (2018) 1185:654–61. doi: 10.1038/bjc.2017.478</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/bjc.2017.478" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=B+Han&author=K+Li&author=Y+Zhao&author=B+Li&author=Y+Cheng&author=J+Zhou&publication_year=2018&title=Anlotinib%20as%20a%20third-line%20therapy%20in%20patients%20with%20refractory%20advanced%20non-small-cell%20lung%20cancer%3A%20A%20multicentre%2C%20randomised%20phase%20II%20trial%20%28ALTER0302%29&journal=Br+J+Cancer&volume=1185&pages=654-61" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B9" id="B9"></a> 9. Wang F, Jin F, Cheng B, Zhang Y, Zhou Q, Wang S. The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. <i>J Cancer Res Clin Oncol</i> (2021) 148(7):1721–35. doi: 10.21203/rs.3.rs-282608/v1</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34357411/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.21203/rs.3.rs-282608/v1" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Wang&author=F+Jin&author=B+Cheng&author=Y+Zhang&author=Q+Zhou&author=S+Wang&publication_year=2021&title=The%20real-world%20efficacy%20and%20safety%20of%20anlotinib%20in%20advanced%20non-small%20cell%20lung%20cancer&journal=J+Cancer+Res+Clin+Oncol&volume=148&pages=1721-35" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B10" id="B10"></a> 10. Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: Analysis of a phase III trial from the Hoosier oncology group (HOG) and US oncology. <i>Ann Oncol</i> (2012) 237:1730–8. doi: 10.1093/annonc/mdr565</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1093/annonc/mdr565" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SI+Jalal&author=HD+Riggs&author=A+Melnyk&author=D+Richards&author=A+Agarwala&author=M+Neubauer&publication_year=2012&title=Updated%20survival%20and%20outcomes%20for%20older%20adults%20with%20inoperable%20stage%20III%20non-small-cell%20lung%20cancer%20treated%20with%20cisplatin%2C%20etoposide%2C%20and%20concurrent%20chest%20radiation%20with%20or%20without%20consolidation%20docetaxel%3A%20Analysis%20of%20a%20phase%20III%20trial%20from%20the%20Hoosier%20oncology%20group%20%28HOG%29%20and%20US%20oncology&journal=Ann+Oncol&volume=237&pages=1730-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B11" id="B11"></a> 11. Shao L, Wang W, Song Z, Zhang Y. The efficacy and safety of anlotinib treatment for advanced lung cancer. <i>OncoTargets Ther</i> (2019) 12:6549–54. doi: 10.2147/OTT.S205674</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.2147/OTT.S205674" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Shao&author=W+Wang&author=Z+Song&author=Y+Zhang&publication_year=2019&title=The%20efficacy%20and%20safety%20of%20anlotinib%20treatment%20for%20advanced%20lung%20cancer&journal=OncoTargets+Ther&volume=12&pages=6549-54" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B12" id="B12"></a> 12. Sun Y, Niu W, Du F, Du C, Li S, Wang J, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. <i>J Hematol Oncol</i> (2016) 91:105. doi: 10.1186/s13045-016-0332-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1186/s13045-016-0332-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Sun&author=W+Niu&author=F+Du&author=C+Du&author=S+Li&author=J+Wang&publication_year=2016&title=Safety%2C%20pharmacokinetics%2C%20and%20antitumor%20properties%20of%20anlotinib%2C%20an%20oral%20multi-target%20tyrosine%20kinase%20inhibitor%2C%20in%20patients%20with%20advanced%20refractory%20solid%20tumors&journal=J+Hematol+Oncol&volume=91&pages=105" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B13" id="B13"></a> 13. Zhang K, Ma X, Gao H, Wang H, Qin H, Yang S, et al. Efficacy and safety of anlotinib in advanced non-small cell lung cancer: A real-world study. <i>Cancer Manage Res</i> (2020) 12:3409–17. doi: 10.2147/CMAR.S246000</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.2147/CMAR.S246000" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=K+Zhang&author=X+Ma&author=H+Gao&author=H+Wang&author=H+Qin&author=S+Yang&publication_year=2020&title=Efficacy%20and%20safety%20of%20anlotinib%20in%20advanced%20non-small%20cell%20lung%20cancer%3A%20A%20real-world%20study&journal=Cancer+Manage+Res&volume=12&pages=3409-17" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B14" id="B14"></a> 14. Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells. <i>J Exp Clin Cancer Res</i> (2019) 381:71. doi: 10.1186/s13046-019-1093-3</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1186/s13046-019-1093-3" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Liang&author=K+Hui&author=C+Hu&author=Y+Wen&author=S+Yang&author=P+Zhu&publication_year=2019&title=Autophagy%20inhibition%20potentiates%20the%20anti-angiogenic%20property%20of%20multikinase%20inhibitor%20anlotinib%20through%20JAK2%2FSTAT3%2FVEGFA%20signaling%20in%20non-small%20cell%20lung%20cancer%20cells&journal=J+Exp+Clin+Cancer+Res&volume=381&pages=71" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B15" id="B15"></a> 15. Leidal AM, Levine B, Debnath J. Autophagy and the cell biology of age-related disease. <i>Nat Cell Biol</i> (2018) 2012:1338–48. doi: 10.1038/s41556-018-0235-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1038/s41556-018-0235-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=AM+Leidal&author=B+Levine&author=J+Debnath&publication_year=2018&title=Autophagy%20and%20the%20cell%20biology%20of%20age-related%20disease&journal=Nat+Cell+Biol&volume=2012&pages=1338-48" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B16" id="B16"></a> 16. Norling LV, Serhan CN. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. <i>J Internal Med</i> (2010) 2681:15–24. doi: 10.1111/j.1365-2796.2010.02235.x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1111/j.1365-2796.2010.02235.x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=LV+Norling&author=CN+Serhan&publication_year=2010&title=Profiling%20in%20resolving%20inflammatory%20exudates%20identifies%20novel%20anti-inflammatory%20and%20pro-resolving%20mediators%20and%20signals%20for%20termination&journal=J+Internal+Med&volume=2681&pages=15" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B17" id="B17"></a> 17. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, et al. Phase I study of pazopanib and vorinostat: A therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. <i>Ann Oncol</i> (2015) 265:1012–8. doi: 10.1093/annonc/mdv066</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1093/annonc/mdv066" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Fu&author=MM+Hou&author=A+Naing&author=F+Janku&author=K+Hess&author=R+Zinner&publication_year=2015&title=Phase%20I%20study%20of%20pazopanib%20and%20vorinostat%3A%20A%20therapeutic%20approach%20for%20inhibiting%20mutant%20p53-mediated%20angiogenesis%20and%20facilitating%20mutant%20p53%20degradation&journal=Ann+Oncol&volume=265&pages=1012-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B18" id="B18"></a> 18. Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. <i>J Thorac Oncol</i> (2021) 164:643–52. doi: 10.1016/j.jtho.2020.11.026</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1016/j.jtho.2020.11.026" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Chu&author=R+Zhong&author=H+Zhong&author=B+Zhang&author=W+Zhang&author=C+Shi&publication_year=2021&title=Phase%201b%20study%20of%20sintilimab%20plus%20anlotinib%20as%20first-line%20therapy%20in%20patients%20with%20advanced%20NSCLC&journal=J+Thorac+Oncol&volume=164&pages=643-52" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B19" id="B19"></a> 19. Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, et al. Randomized controlled trial of s-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia s-1 trial in lung cancer). <i>Ann Oncol</i> (2017) 2811:2698–706. doi: 10.1093/annonc/mdx419</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1093/annonc/mdx419" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Nokihara&author=S+Lu&author=TSK+Mok&author=K+Nakagawa&author=N+Yamamoto&author=YK+Shi&publication_year=2017&title=Randomized%20controlled%20trial%20of%20s-1%20versus%20docetaxel%20in%20patients%20with%20non-small-cell%20lung%20cancer%20previously%20treated%20with%20platinum-based%20chemotherapy%20%28East%20Asia%20s-1%20trial%20in%20lung%20cancer%29&journal=Ann+Oncol&volume=2811&pages=2698-706" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B20" id="B20"></a> 20. Wang HY, Chu JF, Zhao Y, Tang H, Wang LL, Zhou MQ, et al. A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer. <i>Cancer Manage Res</i> (2020) 12:3827–34. doi: 10.2147/CMAR.S249678</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.2147/CMAR.S249678" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=HY+Wang&author=JF+Chu&author=Y+Zhao&author=H+Tang&author=LL+Wang&author=MQ+Zhou&publication_year=2020&title=A%20trial%20of%20the%20safety%20and%20efficacy%20of%20chemotherapy%20plus%20anlotinib%20vs%20chemotherapy%20alone%20as%20second-%20or%20third-line%20salvage%20treatment%20for%20advanced%20non-small%20cell%20lung%20cancer&journal=Cancer+Manage+Res&volume=12&pages=3827-34" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B21" id="B21"></a> 21. Zhou N, Jiang M, Li T, Zhu J, Liu K, Hou H, et al. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. <i>Lung Cancer (Amsterdam Netherlands)</i> (2021) 160:111–7. doi: 10.1016/j.lungcan.2021.08.006</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/34482102/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.lungcan.2021.08.006" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Zhou&author=M+Jiang&author=T+Li&author=J+Zhu&author=K+Liu&author=H+Hou&publication_year=2021&title=Anlotinib%20combined%20with%20anti-PD-1%20antibody%2C%20camrelizumab%20for%20advanced%20NSCLCs%20after%20multiple%20lines%20treatment%3A%20An%20open-label%2C%20dose%20escalation%20and%20expansion%20study&journal=Lung+Cancer+(Amsterdam+Netherlands)&volume=160&pages=111-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B22" id="B22"></a> 22. Zhong RB, Xu JL, Lou YQ, Chu TQ, Zhong H, Han BH, et al. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer. <i>Ann palliative Med</i> (2020) 94:1681–7. doi: 10.21037/apm-20-105</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.21037/apm-20-105" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RB+Zhong&author=JL+Xu&author=YQ+Lou&author=TQ+Chu&author=H+Zhong&author=BH+Han&publication_year=2020&title=Anlotinib%20or%20platinum-pemetrexed%20as%20second-line%20therapy%20in%20EGFR%20T790M-negative%20lung%20cancer&journal=Ann+palliative+Med&volume=94&pages=1681-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B23" id="B23"></a> 23. Zhu J, Xie Q, Zhong A, Le Y. Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations. <i>Anti-cancer Drugs</i> (2022) 331:e584–9. doi: 10.1097/CAD.0000000000001186</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1097/CAD.0000000000001186" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Zhu&author=Q+Xie&author=A+Zhong&author=Y+Le&publication_year=2022&title=Clinical%20analysis%20of%20anlotinib%20as%20first-line%20treatment%20for%20elderly%20patients%20with%20advanced%20lung%20adenocarcinoma%20without%20driver%20gene%20mutations&journal=Anti-cancer+Drugs&volume=331&pages=e584-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B24" id="B24"></a> 24. Zhang L, Zhang Q, Jin J, Liu X, Zhao Y, Yu H, et al. Efficacy of anlotinib combined with AN regimen in first-line treatment of advanced EGFR, ALK and ROS1 wild-type lung adenocarcinoma. <i>Guangdong Med</i> (2021) 42:151–6. doi: 10.13820/j.cnki.gdyx.20200278</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.13820/j.cnki.gdyx.20200278" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Zhang&author=Q+Zhang&author=J+Jin&author=X+Liu&author=Y+Zhao&author=H+Yu&publication_year=2021&title=Efficacy%20of%20anlotinib%20combined%20with%20AN%20regimen%20in%20first-line%20treatment%20of%20advanced%20EGFR%2C%20ALK%20and%20ROS1%20wild-type%20lung%20adenocarcinoma&journal=Guangdong+Med&volume=42&pages=151-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B25" id="B25"></a> 25. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). <i>Eur J Cancer (Oxford Engl 1990)</i> (2007) 431:114–21. doi: 10.1016/j.ejca.2006.09.005</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1016/j.ejca.2006.09.005" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Belderbos&author=L+Uitterhoeve&author=N+van%20Zandwijk&author=H+Belderbos&author=P+Rodrigus&author=P+van%20de%20Vaart&publication_year=2007&title=Randomised%20trial%20of%20sequential%20versus%20concurrent%20chemo-radiotherapy%20in%20patients%20with%20inoperable%20non-small%20cell%20lung%20cancer%20%28EORTC%2008972-22973%29&journal=Eur+J+Cancer+(Oxford+Engl+1990)&volume=431&pages=114-21" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B26" id="B26"></a> 26. Huang D, Zhong D, Zhang C, Zhang Y, Shang Y, Wang L, et al. Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004.Ann. <i>Oncol</i> (2021) 32:S969–9. doi: 10.1016/j.annonc.2021.08.1824</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1016/j.annonc.2021.08.1824" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=D+Huang&author=D+Zhong&author=C+Zhang&author=Y+Zhang&author=Y+Shang&author=L+Wang&publication_year=2021&title=Study%20of%20anlotinib%20combined%20with%20icotinib%20as%20the%20first-line%20treatment%20in%20NSCLC%20patients%20harboring%20activating%20EGFR%20mutations%3A%20Updated%20results%20of%20ALTER-L004.Ann&journal=Oncol&volume=32&pages=S969-9" target="_blank">Google Scholar</a></p></div></div><div class="thinLineM20"></div><div class="AbstractSummary"><p><span>Keywords:</span> non-small cell lung cancer, anti-angiogenesis therapy, front-line treatment, elderly patients, case report, Anlotinib hydrochloride, tegafur-uracil, chemotherapy</p><p><span>Citation:</span> Wang J, Li X, Zhou J, Qiu D, Zhang M, Sun L and Li SC (2023) Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report. <i>Front. Oncol.</i> 13:1043244. doi: 10.3389/fonc.2023.1043244</p><p id="timestamps"><span>Received:</span> 13 September 2022; <span>Accepted:</span> 13 March 2023;<br><span>Published:</span> 06 April 2023.</p><div><p>Edited by:</p><a href="https://loop.frontiersin.org/people/1003220">Kohei Fujita</a>, National Hospital Organization Kyoto Medical Center, Japan</div><div><p>Reviewed by:</p><a href="https://loop.frontiersin.org/people/970570">Xiaobo Du</a>, Mianyang Central Hospital, China<br><a href="https://loop.frontiersin.org/people/1116571">Tao Qin</a>, Sun Yat-sen Memorial Hospital, China</div><p><span>Copyright</span> © 2023 Wang, Li, Zhou, Qiu, Zhang, Sun and Li. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p><p><span>*Correspondence:</span> Lan Sun, <a id="encmail">c3VubGFuNjIwM0AxNjMuY29t</a>; Shengwen Calvin Li, <a id="encmail">c2xpQGNob2Mub3Jn</a></p><p><span><sup>†</sup></span>These authors have contributed equally to this work</p><div class="clear"></div></div></div></div> <p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></section></main></div> <div></div></div></div>  <footer class="Footer"><h1 class="acc-hidden">Footer</h1> <div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><li class="Accordion__item"><button class="Accordion__headline"> <div class="Accordion__title">Guidelines</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li></ul></div></li><li class="Accordion__item"><button class="Accordion__headline"> <div class="Accordion__title">Explore</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li></ul></div></li><li class="Accordion__item"><button class="Accordion__headline"> <div class="Accordion__title">Outreach</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersplanetprize.org/" target="_blank" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li></ul></div></li><li class="Accordion__item"><button class="Accordion__headline"> <div class="Accordion__title">Connect</div> <div class="Accordion__space"></div> <div class="Accordion__arrow"></div></button> <div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><ul><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://loop.frontiersin.org/settings/email-preferences?a=publishers" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li></ul></div></li></ul> <div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div> <span class="Link__wrapper"><a aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right"><span></span></a></span><span class="Link__wrapper"><a aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right"><span></span></a></span><span class="Link__wrapper"><a aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right"><span></span></a></span><span class="Link__wrapper"><a aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_" class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right"><span></span></a></span></div></div> <div class="Footer__copyright"><div><span>漏 2024 Frontiers Media S.A. All rights reserved</span></div> <div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a> <span>|</span> <a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer> <div class="SnackbarWrapper"><ul class="SnackbarContainer"></ul></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax,ay,az,aA,aB,aC,aD,aE,aF,aG,aH,aI,aJ,aK,aL,aM,aN,aO,aP,aQ,aR,aS,aT,aU,aV,aW,aX,aY,aZ,a_,a$,ba,bb,bc,bd,be,bf,bg,bh,bi,bj,bk,bl,bm,bn,bo,bp,bq,br,bs,bt,bu,bv,bw,bx,by,bz,bA,bB,bC,bD,bE,bF,bG,bH,bI,bJ,bK,bL,bM,bN,bO,bP,bQ,bR,bS,bT,bU,bV,bW,bX,bY,bZ,b_,b$,ca,cb,cc,cd,ce,cf,cg,ch,ci,cj,ck,cl,cm,cn,co,cp,cq,cr,cs,ct,cu,cv,cw,cx,cy,cz,cA,cB,cC,cD,cE,cF,cG,cH){as.id=at;as.name=au;as.slug=av;as.specialtyId=1118;as.__typename="journal_section";return {layout:"ArticleLayout",data:[{}],fetch:{},error:e,state:{currentJournal:{identifier:w,name:r,slug:x,banner:[{id:"A08FCA58-05EE-4283-A13E51F93BB73C97",src:T,name:"FONC_Main Visual_Purple_Website",tags:["body part","dead","anatomy","defending","protection","skin","treatment","cell"],type:U,width:7200,height:4050,idHash:"7f2922f165e2e1ba",archive:m,brandId:"22C10171-81B3-4DA6-99342F272A32E8BB",limited:m,fileSize:9449881,isPublic:c,original:"https:\u002F\u002Fbrand.frontiersin.org\u002Fm\u002F7f2922f165e2e1ba\u002Foriginal\u002FFONC_Main-Visual_Purple_Website.jpeg",copyright:"Copyright (c) 2021 Design_Cells\u002FShutterstock. No use without permission.",extension:["jpeg"],thumbnails:{mini:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002FA08FCA58-05EE-4283-A13E51F93BB73C97\u002Fmini-5795EAF1-94A7-4623-B52EAC7FC8A5098F.jpg",thul:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002FA08FCA58-05EE-4283-A13E51F93BB73C97\u002Fthul-301BCB38-FCF6-4517-9359D5382707B640.jpg",webimage:T,Guidelines:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002FA08FCA58-05EE-4283-A13E51F93BB73C97\u002F352DFCCB-44FF-4821-962507007B815780\u002FGuidelines-FONC_Main Visual_Purple_Website.png",WebsiteJpg_XL:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002FA08FCA58-05EE-4283-A13E51F93BB73C97\u002F352DFCCB-44FF-4821-962507007B815780\u002FWebsiteJpg_XL-FONC_Main Visual_Purple_Website.jpg",WebsiteWebP_L:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002FA08FCA58-05EE-4283-A13E51F93BB73C97\u002F352DFCCB-44FF-4821-962507007B815780\u002FWebsiteWebP_L-FONC_Main Visual_Purple_Website.webp",WebsiteWebP_M:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002FA08FCA58-05EE-4283-A13E51F93BB73C97\u002F352DFCCB-44FF-4821-962507007B815780\u002FWebsiteWebP_M-FONC_Main Visual_Purple_Website.webp",WebsiteWebP_XL:"https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002FA08FCA58-05EE-4283-A13E51F93BB73C97\u002F352DFCCB-44FF-4821-962507007B815780\u002FWebsiteWebP_XL-FONC_Main Visual_Purple_Website.webp"},dateCreated:V,description:"Cancer cell, cell grow out of control and become invasive. 3d illustration",orientation:"landscape",userCreated:"Caroline Sutter",watermarked:m,dateModified:V,datePublished:"2022-06-27T09:27:09Z",ecsArchiveFiles:[],propertyOptions:["414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF"],property_Channel:["frontiersin_org"],"property_Sub-Type":["Main_Visual"],property_Asset_Type:["Photography"],activeOriginalFocusPoint:{x:3600,y:2025},property_Office_Department:["Publishing"]}],description:"Highlights research in carcinogenesis and tumor progression, bridging the gap between basic research and clinical applications to advance diagnosis, personalized therapeutics and management strategies.",mission:"\u003Cp\u003EFrontiers in Oncology is a broad-scope, multidisciplinary journal covering all areas of cancer research to advance our knowledge of cancer epidemiology to improve diagnosis, therapeutics, and management strategies.\u003C\u002Fp\u003E\n\n\u003Cp\u003EThe journal is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University and Amgen, USA), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA). Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, Frontiers in Oncology welcomes clinical and experimental research contributions in the various domains of cancer research, which bridge the gap between basic research and clinical applications. Topics include, but are not limited to:\u003C\u002Fp\u003E\n\u003Cul\u003E\n \u003Cli\u003Ebreast cancer\u003C\u002Fli\u003E\n \u003Cli\u003Ecancer cell signaling\u003C\u002Fli\u003E\n \u003Cli\u003Ecancer epidemiology and prevention\u003C\u002Fli\u003E\n \u003Cli\u003Ecancer genetics\u003C\u002Fli\u003E\n \u003Cli\u003Ecancer imaging and image-directed interventions\u003C\u002Fli\u003E\n \u003Cli\u003Ecancer immunity and immunotherapy\u003C\u002Fli\u003E\n \u003Cli\u003Ecancer metabolism\u003C\u002Fli\u003E\n \u003Cli\u003Ecancer molecular targets and therapeutics\u003C\u002Fli\u003E\n \u003Cli\u003Ecardio-oncology\u003C\u002Fli\u003E\n \u003Cli\u003Egastrointestinal cancers\u003C\u002Fli\u003E\n \u003Cli\u003Egenitourinary oncology\u003C\u002Fli\u003E\n \u003Cli\u003Egynecological oncology\u003C\u002Fli\u003E\n \u003Cli\u003Ehead and neck cancer\u003C\u002Fli\u003E\n \u003Cli\u003Ehematologic malignancies\u003C\u002Fli\u003E\n \u003Cli\u003Emolecular and cellular oncology\u003C\u002Fli\u003E\n \u003Cli\u003Eneuro-oncology and neurosurgical oncology\u003C\u002Fli\u003E\n \u003Cli\u003Epediatric oncology\u003C\u002Fli\u003E\n \u003Cli\u003Epharmacology of anti-cancer drugs\u003C\u002Fli\u003E\n \u003Cli\u003Eradiation oncology\u003C\u002Fli\u003E\n \u003Cli\u003Eskin cancer\u003C\u002Fli\u003E\n \u003Cli\u003Esurgical oncology\u003C\u002Fli\u003E\n \u003Cli\u003Ethoracic oncology.\u003C\u002Fli\u003E\n\u003C\u002Ful\u003E\n\n\u003Cp\u003EIn particular, the journal welcomes submissions which support and advance the UN鈥檚 Sustainable Development Goals (SDGs), notable SDG 3: ensure healthy lives and promote well-being for all at all ages.\u003C\u002Fp\u003E\n\n\u003Cp\u003EManuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation \u003Cem\u003Ein vitro\u003C\u002Fem\u003E or \u003Cem\u003Ein vivo\u003C\u002Fem\u003E, which are not based on public databases) are not suitable for publication in this journal.\u003C\u002Fp\u003E\n\n\u003Cp\u003EFrontiers in Oncology is committed to advancing developments in the field of cancer research by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C\u002Fp\u003E",palette:"purple",impactFactor:"4.7",citeScore:"5.2",citations:"313000",showTagline:e,twitter:"@FrontOncology",__typename:"Journal"},currentFrontiersJournal:{id:w,name:r,slug:x,printISSN:e,shortName:H,electronicISSN:I,abbreviation:W,specialtyId:e,publicationDate:e,isOnline:h,isOpenForSubmissions:h,spaceId:c,field:{id:X,domainId:n,__typename:Y},__typename:a},articleHubSlug:f,articleHubPage:J,currentArticle:{id:1043244,doi:Z,title:_,acceptanceDate:new Date(1678700228000),receptionDate:new Date(1663068611000),publicationDate:new Date(1680739200000),isPublished:h,abstract:$,researchTopic:{id:41000,title:"Case Reports in Thoracic Oncology: 2022",articlesCount:42,isMagazinePage:l,slug:"case-reports-in-thoracic-oncology-2022",isOpenForSubmission:l},articleType:{id:84,name:"Case Report"},stage:{id:K,name:f},keywords:["Non-small cell lung cancer","Anti-angiogenesis therapy","front-line treatment","elderly patients","case report"],authors:[{id:aa,firstName:ab,lastName:"Wang",givenNames:ab,isCorresponding:l,isProfilePublic:h,userId:aa,affiliations:[{organizationName:s,countryName:o,cityName:f,stateName:f,zipCode:f}]},{id:m,firstName:ac,lastName:ad,givenNames:ac,isCorresponding:l,isProfilePublic:l,userId:m,affiliations:[{organizationName:s,countryName:o,cityName:f,stateName:f,zipCode:f}]},{id:m,firstName:ae,lastName:"Zhou",givenNames:ae,isCorresponding:l,isProfilePublic:l,userId:m,affiliations:[{organizationName:s,countryName:o,cityName:f,stateName:f,zipCode:f}]},{id:m,firstName:af,lastName:"Qiu",givenNames:af,isCorresponding:l,isProfilePublic:l,userId:m,affiliations:[{organizationName:s,countryName:o,cityName:f,stateName:f,zipCode:f}]},{id:m,firstName:ag,lastName:"Zhang",givenNames:ag,isCorresponding:l,isProfilePublic:l,userId:m,affiliations:[{organizationName:s,countryName:o,cityName:f,stateName:f,zipCode:f}]},{id:ah,firstName:ai,lastName:"Sun",givenNames:ai,isCorresponding:h,isProfilePublic:h,userId:ah,affiliations:[{organizationName:s,countryName:o,cityName:f,stateName:f,zipCode:f}]},{id:aj,firstName:ak,lastName:ad,givenNames:ak,isCorresponding:h,isProfilePublic:h,userId:aj,affiliations:[{organizationName:"Neuro-Oncology and Stem Cell Research Laboratory, Center for Neuroscience Research, CHOC Children鈥檚 Research Institute, Children鈥檚 Hospital of Orange County (CHOC)",countryName:al,cityName:f,stateName:f,zipCode:f},{organizationName:"Department of Neurology, University of California-Irvine School of Medicine",countryName:al,cityName:f,stateName:f,zipCode:f}]}],editors:[{id:am,firstName:an,lastName:"Fujita",givenNames:an,isCorresponding:l,isProfilePublic:h,userId:am,affiliations:[{organizationName:"Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center",countryName:"Japan",cityName:f,stateName:f,zipCode:f}]}],reviewers:[{id:ao,firstName:ap,lastName:"Du",givenNames:ap,isCorresponding:l,isProfilePublic:h,userId:ao,affiliations:[{organizationName:"Mianyang Central Hospital",countryName:o,cityName:f,stateName:f,zipCode:f}]},{id:aq,firstName:ar,lastName:"QIN",givenNames:ar,isCorresponding:l,isProfilePublic:h,userId:aq,affiliations:[{organizationName:"Sun Yat-sen Memorial Hospital",countryName:o,cityName:f,stateName:f,zipCode:f}]}],journal:{id:w,slug:x,name:r,shortName:H,electronicISSN:I,field:{id:X,domainId:n,__typename:Y},specialtyId:e,journalSectionPaths:[{section:as,__typename:"journal_journalSectionPath"}],__typename:a},section:as,impactMetrics:{views:886,downloads:552,citations:n},volume:L,articleVolume:"Volume 13 - 2023",relatedArticles:[],isPublishedV2:l,contents:{fullTextHtml:"\u003Cdiv class=\"JournalAbstract\"\u003E\u003Ch1\u003ELong-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report\u003C\u002Fh1\u003E\u003Ca id=\"h1\" name=\"h1\"\u003E\u003C\u002Fa\u003E\u003Cdiv class=\"authors\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Fpeople\u002Fu\u002F1995236\" class=\"user-id-1995236\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F1995236\u002F24\" onerror=\"this.src='http:\u002F\u002F3b76aaf63d1816bb57bf-a34624e694c43cdf8b40aa048a644ca4.r96.cf2.rackcdn.com\u002FDesign\u002FImages\u002Fnewprofile_default_profileimage_new.jpg'\"\u003E\u003C\u002Fimg\u003EJingyi Wang\u003C\u002Fa\u003E\u003Csup\u003E1†\u003C\u002Fsup\u003E, \u003Cimg class=\"pr5\" src=\"http:\u002F\u002F3b76aaf63d1816bb57bf-a34624e694c43cdf8b40aa048a644ca4.r96.cf2.rackcdn.com\u002FDesign\u002FImages\u002Fnewprofile_default_profileimage_new.jpg\"\u003E\u003C\u002Fimg\u003EXiaoqing Li\u003Csup\u003E1†\u003C\u002Fsup\u003E, \u003Cimg class=\"pr5\" src=\"http:\u002F\u002F3b76aaf63d1816bb57bf-a34624e694c43cdf8b40aa048a644ca4.r96.cf2.rackcdn.com\u002FDesign\u002FImages\u002Fnewprofile_default_profileimage_new.jpg\"\u003E\u003C\u002Fimg\u003EJuan Zhou\u003Csup\u003E1\u003C\u002Fsup\u003E, \u003Cimg class=\"pr5\" src=\"http:\u002F\u002F3b76aaf63d1816bb57bf-a34624e694c43cdf8b40aa048a644ca4.r96.cf2.rackcdn.com\u002FDesign\u002FImages\u002Fnewprofile_default_profileimage_new.jpg\"\u003E\u003C\u002Fimg\u003EDan Qiu\u003Csup\u003E1\u003C\u002Fsup\u003E, \u003Cimg class=\"pr5\" src=\"http:\u002F\u002F3b76aaf63d1816bb57bf-a34624e694c43cdf8b40aa048a644ca4.r96.cf2.rackcdn.com\u002FDesign\u002FImages\u002Fnewprofile_default_profileimage_new.jpg\"\u003E\u003C\u002Fimg\u003EMengyao Zhang\u003Csup\u003E1\u003C\u002Fsup\u003E, \u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Fpeople\u002Fu\u002F2043266\" class=\"user-id-2043266\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F2043266\u002F24\" onerror=\"this.src='http:\u002F\u002F3b76aaf63d1816bb57bf-a34624e694c43cdf8b40aa048a644ca4.r96.cf2.rackcdn.com\u002FDesign\u002FImages\u002Fnewprofile_default_profileimage_new.jpg'\"\u003E\u003C\u002Fimg\u003ELan Sun\u003C\u002Fa\u003E\u003Csup\u003E1*\u003C\u002Fsup\u003E and \u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Fpeople\u002Fu\u002F993634\" class=\"user-id-993634\"\u003E\u003Cimg class=\"pr5\" src=\"https:\u002F\u002Floop.frontiersin.org\u002Fimages\u002Fprofile\u002F993634\u002F24\" onerror=\"this.src='http:\u002F\u002F3b76aaf63d1816bb57bf-a34624e694c43cdf8b40aa048a644ca4.r96.cf2.rackcdn.com\u002FDesign\u002FImages\u002Fnewprofile_default_profileimage_new.jpg'\"\u003E\u003C\u002Fimg\u003EShengwen Calvin Li\u003C\u002Fa\u003E\u003Csup\u003E2,3*\u003C\u002Fsup\u003E\u003C\u002Fdiv\u003E\u003Cul class=\"notes\"\u003E\u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E1\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EDepartment of Oncology, Bishan Hospital of Chongqing Medical University, Chongqing, China\u003C\u002Fli\u003E\u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E2\u003C\u002Fsup\u003E\u003C\u002Fspan\u003ENeuro-Oncology and Stem Cell Research Laboratory, Center for Neuroscience Research, CHOC Children’s Research Institute, Children’s Hospital of Orange County (CHOC), Orange, CA, United States\u003C\u002Fli\u003E\u003Cli\u003E\u003Cspan\u003E\u003Csup\u003E3\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EDepartment of Neurology, University of California-Irvine School of Medicine, Orange, CA, United States\u003C\u002Fli\u003E\u003C\u002Ful\u003E\u003Cp\u003E\u003Cb\u003EBackground:\u003C\u002Fb\u003E Half of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approved for the standard third-line treatment for NSCLC in China. Herein we report an elderly NSCLC patient without any driver gene mutations who was undergoing anlotinib as a front-line treatment and who achieved long-term survival.\u003C\u002Fp\u003E\u003Cp\u003E\u003Cb\u003ECase summary:\u003C\u002Fb\u003E The 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1).\u003C\u002Fp\u003E\u003Cp\u003E\u003Cb\u003EConclusion:\u003C\u002Fb\u003E This patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy.\u003C\u002Fp\u003E\u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"JournalFullText\"\u003E\u003Ca id=\"h2\" name=\"h2\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EIntroduction\u003C\u002Fh2\u003E\u003Cp class=\"mb0\"\u003ELung cancer is one of the most common malignant tumors and the leading cause of global cancer mortality (\u003Ca href=\"#B1\"\u003E1\u003C\u002Fa\u003E). Angiogenesis is one of the characteristics of malignant tumors, which can provide nutrition for the growth of tumor cells and secrete growth factors to promote cancer cell proliferation, thus playing an essential role in tumor growth, invasion, and metastasis (\u003Ca href=\"#B2\"\u003E2\u003C\u002Fa\u003E, \u003Ca href=\"#B3\"\u003E3\u003C\u002Fa\u003E). A growing number of studies have shown that advanced non-small cell lung cancer (NSCLC) patients can benefit from anti-angiogenesis therapy with higher anti-cancer activity and fewer adverse effects than traditional chemoradiotherapy (\u003Ca href=\"#B4\"\u003E4\u003C\u002Fa\u003E, \u003Ca href=\"#B5\"\u003E5\u003C\u002Fa\u003E). Anlotinib is a novel oral multitarget tyrosine kinase inhibitor which strongly inhibits vascular endothelial growth factor (VEGF), platelet-derived growth factor receptor (PDGF), fibroblast growth factor receptor (FGFR), and stem cell factor receptor (c-Kit), resulting in the inhibition of the growth of tumor blood vessels (\u003Ca href=\"#B6\"\u003E6\u003C\u002Fa\u003E). On May 9, 2018, anlotinib was approved by China Food and Drug Administration as a standard third-line treatment regimen for advanced NSCLC based on the results of the ALTER-0303 study (\u003Ca href=\"#B7\"\u003E7\u003C\u002Fa\u003E). However, the evidence for anlotinib as a front-line treatment for NSCLC is limited. Herein we report an elderly NSCLC patient without any driver gene mutations undergoing anlotinib as a front-line treatment.\u003C\u002Fp\u003E\u003Ca id=\"h3\" name=\"h3\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EBackground\u003C\u002Fh2\u003E\u003Ch3\u003EChief complaints\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EA 77–year-old male patient developed chest tightness after an activity and precardiac pain in June 2018. He had an occasional cough with sputum.\u003C\u002Fp\u003E\u003Ch3\u003EHistory of present illness\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EThe patient had chest tightness after an activity, precardiac pain, and occasional cough with sputum.\u003C\u002Fp\u003E\u003Ch3\u003EHistory of past illness\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EThe patient had a history of chronic obstructive pulmonary disease (COPD) and diabetes mellitus type 2 (T2DM), with a smoking history of 55 years averaging 20 cigarettes per day. He had quit smoking for more than 2 years.\u003C\u002Fp\u003E\u003Ch3\u003EPersonal and family history\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EThe patient had a cancer-relative family susceptibility. His one brother and two sisters suffered from lung cancer, and another brother had liver cancer.\u003C\u002Fp\u003E\u003Ch3\u003EPhysical examination\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EThe results of the physical examination showed that the patient’s body temperature was 36.3°C, the pulse rate was 70 beats per minute (bpm), the blood pressure was 128\u002F76 mmHg, respiratory rate was 19 breaths\u002Fmin, and the performance status score was 1.\u003C\u002Fp\u003E\u003Ch3\u003ELaboratory examinations\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EHis blood count showed a WBC level of 5.75 × 10\u003Csup\u003E9\u003C\u002Fsup\u003E\u002FL, Hb level of 116 g\u002FL, and platelet count of 201 × 10\u003Csup\u003E9\u003C\u002Fsup\u003E\u002FL. The serum level of carcinoembryonic antigen was 6.6 ng\u002Fml.\u003C\u002Fp\u003E\u003Ch3\u003EPathology and genetic testing\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EThe histopathological analysis of the tissue biopsy samples collected from the right lung revealed poorly differentiated squamous cell carcinoma (\u003Ca href=\"#f1\"\u003EFigure 1\u003C\u002Fa\u003E). The immunohistochemistry result showed the following details: CK5\u002F6 (+), P63 (+), P40 (+), NapsinA (-), TTF1 (-), CK7(-), and CK14(+). A molecular analysis did not find any driver gene mutations of EGFR, ALK, and ROS1. Tissue samples were detected \u003Ci\u003Evia\u003C\u002Fi\u003E next-generation sequencing with a panel consisting of 211 genes, which revealed TP53 (mutant abundance: 14.37%) and tumor mutation burden (TMB) of 21.15 Muts\u002FMb. The somatic mutations are shown in \u003Ca href=\"#T1\"\u003ETable 1\u003C\u002Fa\u003E.\u003C\u002Fp\u003E\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"Imageheaders\"\u003EFIGURE 1\u003C\u002Fdiv\u003E\u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_m\u002Ffonc-13-1043244-g001.jpg\" name=\"\" target=\"_blank\"\u003E\u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_t\u002Ffonc-13-1043244-g001.gif\" id=\"f1\" alt=\"www.frontiersin.org\"\u003E\u003C\u002Fimg\u003E\u003C\u002Fa\u003E\u003Cp\u003E\u003Cb\u003EFigure 1\u003C\u002Fb\u003E Hematoxylin and eosin staining photomicrographs of a right lung tumor tissue biopsy. \u003Cb\u003E(A)\u003C\u002Fb\u003E Magnification, ×200. \u003Cb\u003E(B)\u003C\u002Fb\u003E Magnification, ×400.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"Imageheaders\"\u003ETABLE 1\u003C\u002Fdiv\u003E\u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_m\u002Ffonc-13-1043244-t001.jpg\" name=\"table 1\" target=\"_blank\"\u003E\u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_t\u002Ffonc-13-1043244-t001.gif\" id=\"T1\" alt=\"www.frontiersin.org\"\u003E\u003C\u002Fimg\u003E\u003C\u002Fa\u003E\u003Cp\u003E\u003Cb\u003ETable 1\u003C\u002Fb\u003E List of somatic mutations.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\u003Ch3\u003EImaging examinations\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EThe chest scan first computed tomography (CT) result showed a mass which was 52 mm × 50 mm in size (\u003Ca href=\"#f2\"\u003EFigure 2A\u003C\u002Fa\u003E). No metastasis was observed on enhanced CT of the skull and the abdomen. The lymph node ultrasound showed no metastasis. As per the solid tumor version 1.1 (RECIST 1.1) response evaluation criteria, the maximum lesion reduction reached 40.4% after four cycles of anlotinib with platinum-based chemotherapy (\u003Ca href=\"#f2\"\u003EFigure 2B\u003C\u002Fa\u003E). After six courses of anlotinib monotherapy maintenance, the MRI results showed bilateral clavicular lymph node metastasis, and the patient’s PFS\u003Csub\u003E1\u003C\u002Fsub\u003E was 10 months. Then, after 12 cycles of anlotinib in combination with tegafur, the lesion reduction reached 13.8% compared with the previous best curative effect (\u003Ca href=\"#f2\"\u003EFigure 2C\u003C\u002Fa\u003E). The disease remained stable after this, and there were no significantly enlarged lymph nodes on bilateral neck ultrasound. On May 24, 2021, the lesion enlarged by 41.4%, and the efficacy was evaluated as disease progression (\u003Ca href=\"#f2\"\u003EFigure 2D\u003C\u002Fa\u003E), so the patient’s PFS\u003Csub\u003E2\u003C\u002Fsub\u003E was 24 months.\u003C\u002Fp\u003E\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"Imageheaders\"\u003EFIGURE 2\u003C\u002Fdiv\u003E\u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_m\u002Ffonc-13-1043244-g002.jpg\" name=\"\" target=\"_blank\"\u003E\u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_t\u002Ffonc-13-1043244-g002.gif\" id=\"f2\" alt=\"www.frontiersin.org\"\u003E\u003C\u002Fimg\u003E\u003C\u002Fa\u003E\u003Cp\u003E\u003Cb\u003EFigure 2\u003C\u002Fb\u003E Conversion of chest computed tomography at different times. (\u003Cb\u003EA\u003C\u002Fb\u003E and \u003Cb\u003Ea\u003C\u002Fb\u003E) Baseline findings on chest computed tomography (tumor size: 52 × 55 mm). (\u003Cb\u003EB\u003C\u002Fb\u003E and \u003Cb\u003Eb\u003C\u002Fb\u003E) The mass shrank significantly (tumor size: 31 × 18 mm) after treatment with four cycles of anlotinib plus cisplatin. (\u003Cb\u003EC\u003C\u002Fb\u003E and \u003Cb\u003Ec\u003C\u002Fb\u003E) Stable disease (tumor size: 25 × 21 mm) following 12 cycles of anlotinib + tegafur. (\u003Cb\u003ED\u003C\u002Fb\u003E and \u003Cb\u003Ed\u003C\u002Fb\u003E) Progressive disease (tumor size: 41 × 34 mm) after 29 cycles of anlotinib + tegafur.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\u003Ch3\u003EFinal diagnosis\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EFinally, the patient was diagnosed with stage IIIB poorly differentiated driver gene-negative squamous cell lung carcinoma (cT3N2M0 in accordance with version 8 of TNM staging).\u003C\u002Fp\u003E\u003Ch3\u003ETreatment\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003ESince July 24, 2018, the patient was treated with anlotinib (12 mg, d1–d14, q3w) and nedaplatin (85 mg\u002Fm\u003Csup\u003E2\u003C\u002Fsup\u003E, q3w) for the first-line therapy. After six courses of anlotinib combined with platinum-based chemotherapy, we used anlotinib monotherapy for maintenance treatment (12 mg, d1–d14, q3w), but the patient reduced the drug dose on his own during the last two courses of maintenance therapy. The disease progressed after six cycles of maintenance treatment. Afterwards, the regimen was switched to anlotinib (12 mg, d1–d14, q3w) combined with tegafur (120 mg d1–d14, q3w) (\u003Ca href=\"#f3\"\u003EFigure 3\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"Imageheaders\"\u003EFIGURE 3\u003C\u002Fdiv\u003E\u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_m\u002Ffonc-13-1043244-g003.jpg\" name=\"\" target=\"_blank\"\u003E\u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_t\u002Ffonc-13-1043244-g003.gif\" id=\"f3\" alt=\"www.frontiersin.org\"\u003E\u003C\u002Fimg\u003E\u003C\u002Fa\u003E\u003Cp\u003E\u003Cb\u003EFigure 3\u003C\u002Fb\u003E Timeline of events from diagnosis to progressive disease and summary of the administered treatments. Treatment work flow from [(anlotinib + NDP) à (anlotinib + DDP)] (6 cycles) to(anlotinib) (6 cycles) and to (anlotinib + tegafur) (29 cycles). After undergoing this treatment strategy, the patient has achieved a PFS of 34 months and an OS of 53 months. These results surpass those seen in the majority of real-world studies and clinical trials.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\u003Ch3\u003EOutcome and follow-up\u003C\u002Fh3\u003E\u003Cp class=\"mb0\"\u003EAs of May 24, 2021, the patient received 2 years and 10 months of anlotinib treatment, with a progression-free survival of 34 months. The degree of adverse event was assessed according to Common Terminology Criteria Adverse Events Version 5.0. During the period of the treatment of anlotinib combined with nedaplatin, the patient experienced thrombocytopenia in the second cycle (grade 4), which was controlled with thrombopoietin therapy. Fatigue (grade 2) developed during the 11th and 12\u003Csup\u003Eth\u003C\u002Fsup\u003E cycles, which gradually improved during the interval between cycles. After the disease progressed, we proposed to adjust the treatment option several times, but the patient and his family refused. The last follow-up was on December 12, 2022, and the CT result showed that the lesion size was 78 mm × 59 mm, which increased from the original diagnosis of 52 mm × 50 mm in size (\u003Ca href=\"#f2\"\u003EFigure 2A\u003C\u002Fa\u003E).\u003C\u002Fp\u003E\u003Ca id=\"h4\" name=\"h4\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EDiscussion\u003C\u002Fh2\u003E\u003Cp class=\"mb15\"\u003EIn this case, the patient was diagnosed in July 2018 (cT3N2M0), and he could first be considered for surgery. However, his family adamantly refused due to his advanced age and underlying diseases. We also considered immunotherapy in combination with platinum-based chemotherapy, but PD-1 inhibitors were expensive and not financially affordable the patient and his family. Shortly before his diagnosis, anlotinib was approved by China Food and Drug Administration as a third-line treatment for advanced squamous lung cancer (the peripheral type only) based on the results of two clinical trials of anlotinib as a third-line or further treatment for NSCLC. One clinical study (ALTER0302) showed that the median progression-free survival (PFS) of the anlotinib group was significantly better than that of placebo (4.8 vs. 1.2 months) (\u003Ca href=\"#B8\"\u003E8\u003C\u002Fa\u003E). The other clinical trial (ALTER0303) showed that anlotinib has extended median OS and PFS significantly, that is, 9.6 months vs. 6.3 months and 5.4 months vs. 1.4 months, respectively, compared with the placebo. Under the third-line or beyond treatment setting, the anlotinib combination therapy showed manageable toxicities and encouraging efficacy, indicating a good application prospect (\u003Ca href=\"#B9\"\u003E9\u003C\u002Fa\u003E), which is one of the reasons why we administrated anlotinib as a front-line treatment. The other reasons are as follows: first, according to the National Comprehensive Cancer Network guidelines (2018 edition), radical concurrent chemo-radiotherapy is preferred for inoperable stage IIIB NSCLC patients. However, clinical studies have shown that concurrent radiotherapy is poorly tolerated in elderly patients (\u003Ca href=\"#B10\"\u003E10\u003C\u002Fa\u003E), with a high possibility of discontinuing treatment. Sequential chemoradiotherapy may be considered for patients who cannot tolerate concurrent chemoradiotherapy. However, this patient had multiple underlying diseases such as COPD and T2DM; thus, the risk of uncontrollable side effects was high. Moreover, the target volume was too large to determine an appropriate radiotherapy plan ensuring antitumor efficacy and safety. Third, the toxicity of anti-angiogenesis drugs, including anlotinib, is much lower than chemotherapy, and adverse effects are controllable (\u003Ca href=\"#B9\"\u003E9\u003C\u002Fa\u003E, \u003Ca href=\"#B11\"\u003E11\u003C\u002Fa\u003E). Anlotinib is reported to have the advantage of low toxicity (\u003Ca href=\"#B12\"\u003E12\u003C\u002Fa\u003E). The most frequent toxicities include hypertension, hand–foot syndrome, fatigue, \u003Ci\u003Eetc.\u003C\u002Fi\u003E Fourth, anti-angiogenesis treatment required attention to the side effect of hemoptysis. Fortunately, this patient had no symptoms of active hemorrhage, and the lesion was peripheral, so the risk of hemorrhage was evaluated as low. Fifth, the patient and his family refused to undergo radiation therapy, so we applied to the Ethics Committee for the inclusion of anlotinib as first-line treatment. The patient and his family eventually chose anlotinib as the first-line treatment and signed the informed patient’s consent as approved. He achieved a total progression-free survival of 34 months using anlotinib as the front-line regimen. From the time of the patient’s diagnosis to the time of the last follow-up (46 months), the maximum diameter of his tumor lesion increased by 12 mm. No uncontrollable toxic side effects were observed in this patient during the drug administration. We analyzed this patient’s long-term survival for several reasons. Firstly, this patient did not develop distant metastases, and the clinical studies associated with anlotinib have validated distant metastases as an important prognosis (\u003Ca href=\"#B13\"\u003E13\u003C\u002Fa\u003E). Secondly, it has been shown that inhibition of autophagy improves the efficacy of anlotinib (\u003Ca href=\"#B14\"\u003E14\u003C\u002Fa\u003E), and age is one of the important reasons for the effect of autophagy (\u003Ca href=\"#B15\"\u003E15\u003C\u002Fa\u003E). Given the advanced age of this patient, we consider that he may have a sustainable survival benefit due to his autophagy inhibition status. Thirdly, this patient has hypofractionated squamous carcinoma. Although hypofractionated tumor cells are conventionally more malignant, there is a complex relationship between cancer and inflammation. Hypofractionated cell proliferation may inhibit the growth of tumor cells through specialized pro-resolving mediators (\u003Ca href=\"#B16\"\u003E16\u003C\u002Fa\u003E), which may also be a factor in this patient’s long survival. Fourthly, the patient in this case had TP53 mutations (mutant abundance: 14.37%) with TMB: 21.15 Muts\u002FMb. TP53 mutations have been identified to be involved in the process of neovascularization associated with increased VEGF expression, which is one of the important targets of anlotinib. Fu et al. found that TP53 mutations are significantly associated with a favorable prognosis in patients with advanced solid malignancies (\u003Ca href=\"#B17\"\u003E17\u003C\u002Fa\u003E). It has also been shown that advanced NSCLC patients with high TMB mutations (>10 Muts\u002FMb) can benefit from anti-angiogenesis therapy (\u003Ca href=\"#B18\"\u003E18\u003C\u002Fa\u003E). Unfortunately, we could not ascertain PD-L1 expression because of the insufficient volume of tissue obtained in the first biopsy and the patient’s unwillingness to undergo a repeat biopsy.\u003C\u002Fp\u003E\u003Cp class=\"mb0\"\u003EThis patient had disease progression after six cycles of anlotinib monotherapy maintenance. We switched to anlotinib combined with tegafur because oral tegafur treatment was more convenient and economical. The EAST study demonstrated that tegafur is equally as efficacious as docetaxel (\u003Ca href=\"#B19\"\u003E19\u003C\u002Fa\u003E). In addition, anti-angiogenesis therapy can improve the local hypoxic condition of the tumor microenvironment, which is more conducive to the entry of chemotherapeutic drugs into the tumor tissue. There is a growing number of studies on anlotinib as a second-line treatment from 2018 onwards. One study showed that anlotinib combined with chemotherapy might be an effective and well-tolerated treatment for advanced NSCLC in patients who fail in first- or second-line therapy (\u003Ca href=\"#B20\"\u003E20\u003C\u002Fa\u003E). Anlotinib plus camrelizumab had shown promising efficacy and manageable toxicity as a second-line or later-line therapy for NSCLC, especially in the 12 mg cohorts (\u003Ca href=\"#B21\"\u003E21\u003C\u002Fa\u003E). However, another study showed that anlotinib was less effective than platinum-pemetrexed chemotherapy in T790M-negative lung adenocarcinoma, implicating that it may be more suitable for squamous cell lung carcinoma (\u003Ca href=\"#B22\"\u003E22\u003C\u002Fa\u003E). Hence, anlotinib has a synergistic antitumor effect and good safety for NSCLC and may be promising for front-line treatment for NSCLC (\u003Ca href=\"#B20\"\u003E20\u003C\u002Fa\u003E). There have also been more studies of anlotinib as a first-line treatment in the last 2 years, and most of these studies have adopted the combination therapy model. The latest clinical analysis of first-line therapy in elderly patients with advanced lung adenocarcinoma without driver gene mutations showed similar median PFS (3.0 m vs. 2.8 m) and OS (7.0 m \u003Ci\u003Evs\u003C\u002Fi\u003E. 7.0 m) in the anlotinib group and the chemotherapy group (P > 0.05), and there was no significant difference in ORR (17.5 vs. 15%) or DCR (67.5 vs. 65.5%) between both treatment groups (\u003Ca href=\"#B23\"\u003E23\u003C\u002Fa\u003E). The other studies have shown that, for driver gene-negative NSCLC patients, the median PFS in the anlotinib combined with chemotherapy group was 1.54 months longer than that in the chemotherapy group (9.38 months vs. 7.84 months, \u003Ci\u003EP\u003C\u002Fi\u003E < 0.05), and the median OS in the anlotinib combined with chemotherapy group was longer as well (11.52 months vs. 10.46 months), but the difference was not statistically significant (\u003Ci\u003EP\u003C\u002Fi\u003E > 0.05) (\u003Ca href=\"#B24\"\u003E24\u003C\u002Fa\u003E). A study on inoperable NSCLC patients indicated that the median PFS of sequential chemoradiotherapy patients was 10.8 months, but grade 3 acute esophagitis occurred in four of 78 patients (5%) (\u003Ca href=\"#B25\"\u003E25\u003C\u002Fa\u003E). As shown in \u003Ca href=\"#T2\"\u003ETable 2\u003C\u002Fa\u003E (\u003Ca href=\"#B18\"\u003E18\u003C\u002Fa\u003E, \u003Ca href=\"#B23\"\u003E23\u003C\u002Fa\u003E, \u003Ca href=\"#B26\"\u003E26\u003C\u002Fa\u003E), anlotinib is promising for the first-line treatment for NSCLC with its median PFS range of 3.0 to 15.0 months.\u003C\u002Fp\u003E\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"Imageheaders\"\u003ETABLE 2\u003C\u002Fdiv\u003E\u003Cdiv class=\"FigureDesc\"\u003E\u003Ca href=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_m\u002Ffonc-13-1043244-t002.jpg\" name=\"table 2\" target=\"_blank\"\u003E\u003Cimg src=\"https:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_t\u002Ffonc-13-1043244-t002.gif\" id=\"T2\" alt=\"www.frontiersin.org\"\u003E\u003C\u002Fimg\u003E\u003C\u002Fa\u003E\u003Cp\u003E\u003Cb\u003ETable 2\u003C\u002Fb\u003E Some clinical trials of anlotinib in non-small cell lung cancer (NSCLC) for the first line.\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"DottedLine\"\u003E\u003C\u002Fdiv\u003E\u003Cp class=\"mb0\"\u003ERecently, more studies focused on the first-line usage for NSCLC but less for elderly patients. To the best of our knowledge, the NSCLC patients in most clinical trials were not allowed to be older than 75 years—for example, the median age of patients with lung cancer who were treated in pivotal trials involving immunotherapy ranged from 61 and 65 years, which are lower than the median age at diagnosis. Thus, such poor representation of older patients in clinical trials makes truly evidence-based decisions on the best regimen for geriatric patients difficult. This patient was 77 years old at diagnosis and achieved a total PFS of 34 months and OS of 53 months after anlotinib treatment, which exceeded most of the results of real-world studies and clinical trials. This case report suggests that combining anlotinib with chemotherapy shows promise as a front-line treatment for elderly patients with advanced NSCLC. Further prospective studies are necessary to validate these findings.\u003C\u002Fp\u003E\u003Ca id=\"h5\" name=\"h5\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EConclusion\u003C\u002Fh2\u003E\u003Cp class=\"mb0\"\u003EAs a front-line treatment, anlotinib significantly prolonged this elderly NSCLC patient’s survival time and improved his quality of life.\u003C\u002Fp\u003E\u003Ca id=\"h6\" name=\"h6\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EData availability statement\u003C\u002Fh2\u003E\u003Cp class=\"mb0\"\u003EThe original contributions presented in the study are included in the article\u002Fsupplementary material. Further inquiries can be directed to the corresponding author.\u003C\u002Fp\u003E\u003Ca id=\"h7\" name=\"h7\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EEthics statement\u003C\u002Fh2\u003E\u003Cp class=\"mb0\"\u003EThe studies involving human participants were reviewed and approved by The ethics committee of The People’s Hospital of Bishan District Chongqing. The patients\u002Fparticipants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.\u003C\u002Fp\u003E\u003Ca id=\"h8\" name=\"h8\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EAuthor contributions\u003C\u002Fh2\u003E\u003Cp class=\"mb15\"\u003EJW and JZ contributed significantly to analysis and manuscript preparation. JW performed the data analyses and wrote the manuscript. XL and DQ helped perform the analysis with constructive discussions. MZ assisted in joint evaluation of patients and figure design. LS contributed to the conception of the study. SCL revised the article and made important suggestions. All authors contributed to the article and approved the submitted version.\u003C\u002Fp\u003E\u003Ca id=\"h9\" name=\"h9\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EFunding\u003C\u002Fh2\u003E\u003Cp class=\"mb15\"\u003EThis work was supported in part by the Natural Science Foundation of Chongqing, China (cstc2020jcyjmsxmX1063) and Beijing Science and Technology Innovation Medical Development Foundation, China (KC2021-JX-0186-28). This work was also supported in part by the UCI ICTS Award #16004004 (CHOC).\u003C\u002Fp\u003E\u003Ca id=\"h10\" name=\"h10\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EAcknowledgments\u003C\u002Fh2\u003E\u003Cp class=\"mb0\"\u003EWe thank the patient and his family for giving permission for his inclusion in this study.\u003C\u002Fp\u003E\u003Ca id=\"h11\" name=\"h11\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EConflict of interest\u003C\u002Fh2\u003E\u003Cp class=\"mb0\"\u003EThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C\u002Fp\u003E\u003Ca id=\"h12\" name=\"h12\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EPublisher’s note\u003C\u002Fh2\u003E\u003Cp class=\"mb15\"\u003EAll claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C\u002Fp\u003E\u003Ca id=\"h13\" name=\"h13\"\u003E\u003C\u002Fa\u003E\u003Ch2\u003EReferences\u003C\u002Fh2\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B1\" id=\"B1\"\u003E\u003C\u002Fa\u003E 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. \u003Ci\u003ECA: Cancer J Clin\u003C\u002Fi\u003E (2019) 691:7–34. doi: 10.3322\u002Fcaac.21551\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.3322\u002Fcaac.21551\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=RL+Siegel&author=KD+Miller&author=A+Jemal&publication_year=2019&title=Cancer%20statistics%2C%202019&journal=CA:+Cancer+J+Clin&volume=691&pages=7\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B2\" id=\"B2\"\u003E\u003C\u002Fa\u003E 2. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. \u003Ci\u003ECell\u003C\u002Fi\u003E (2011) 1445:646–74. doi: 10.1016\u002Fj.cell.2011.02.013\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.cell.2011.02.013\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=D+Hanahan&author=RA+Weinberg&publication_year=2011&title=Hallmarks%20of%20cancer%3A%20The%20next%20generation&journal=Cell&volume=1445&pages=646-74\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B3\" id=\"B3\"\u003E\u003C\u002Fa\u003E 3. Alshangiti A, Chandhoke G, Ellis PM. Antiangiogenic therapies in non-small-cell lung cancer. \u003Ci\u003ECurr Oncol (Toronto Ont.)\u003C\u002Fi\u003E (2018) 25Suppl 1:S45–s58. doi: 10.3747\u002Fco.25.3747\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.3747\u002Fco.25.3747\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=A+Alshangiti&author=G+Chandhoke&author=PM+Ellis&publication_year=2018&title=Antiangiogenic%20therapies%20in%20non-small-cell%20lung%20cancer&journal=Curr+Oncol+(Toronto+Ont.)&volume=25Suppl 1&pages=S45\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B4\" id=\"B4\"\u003E\u003C\u002Fa\u003E 4. Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: Updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. \u003Ci\u003EAnn Oncol\u003C\u002Fi\u003E (2014) 255:1044–52. doi: 10.1093\u002Fannonc\u002Fmdu098\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1093\u002Fannonc\u002Fmdu098\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=F+Barlesi&author=A+Scherpereel&author=V+Gorbunova&author=R+Gervais&author=A+Vikstr%C3%B6m&author=C+Chouaid&publication_year=2014&title=Maintenance%20bevacizumab-pemetrexed%20after%20first-line%20cisplatin-pemetrexed-bevacizumab%20for%20advanced%20nonsquamous%20nonsmall-cell%20lung%20cancer%3A%20Updated%20survival%20analysis%20of%20the%20AVAPERL%20%28MO22089%29%20randomized%20phase%20III%20trial&journal=Ann+Oncol&volume=255&pages=1044-52\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B5\" id=\"B5\"\u003E\u003C\u002Fa\u003E 5. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. \u003Ci\u003EJ Clin Oncol\u003C\u002Fi\u003E (2001) 193:851–6. doi: 10.1200\u002FJCO.2001.19.3.851\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1200\u002FJCO.2001.19.3.851\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=K+Margolin&author=MS+Gordon&author=E+Holmgren&author=J+Gaudreault&author=W+Novotny&author=G+Fyfe&publication_year=2001&title=Phase%20ib%20trial%20of%20intravenous%20recombinant%20humanized%20monoclonal%20antibody%20to%20vascular%20endothelial%20growth%20factor%20in%20combination%20with%20chemotherapy%20in%20patients%20with%20advanced%20cancer%3A%20Pharmacologic%20and%20long-term%20safety%20data&journal=J+Clin+Oncol&volume=193&pages=851-6\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B6\" id=\"B6\"\u003E\u003C\u002Fa\u003E 6. Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, et al. Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. \u003Ci\u003EJ Hematol Oncol\u003C\u002Fi\u003E (2018) 111:120. doi: 10.1186\u002Fs13045-018-0664-7\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs13045-018-0664-7\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=G+Shen&author=F+Zheng&author=D+Ren&author=F+Du&author=Q+Dong&author=Z+Wang&publication_year=2018&title=Anlotinib%3A%20A%20novel%20multi-targeting%20tyrosine%20kinase%20inhibitor%20in%20clinical%20development&journal=J+Hematol+Oncol&volume=111&pages=120\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B7\" id=\"B7\"\u003E\u003C\u002Fa\u003E 7. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial. \u003Ci\u003EJAMA Oncol\u003C\u002Fi\u003E (2018) 411:1569–75. doi: 10.1001\u002Fjamaoncol.2018.3039\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1001\u002Fjamaoncol.2018.3039\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=B+Han&author=K+Li&author=Q+Wang&author=L+Zhang&author=J+Shi&author=Z+Wang&publication_year=2018&title=Effect%20of%20anlotinib%20as%20a%20third-line%20or%20further%20treatment%20on%20overall%20survival%20of%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%3A%20The%20ALTER%200303%20phase%203%20randomized%20clinical%20trial&journal=JAMA+Oncol&volume=411&pages=1569-75\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B8\" id=\"B8\"\u003E\u003C\u002Fa\u003E 8. Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: A multicentre, randomised phase II trial (ALTER0302). \u003Ci\u003EBr J Cancer\u003C\u002Fi\u003E (2018) 1185:654–61. doi: 10.1038\u002Fbjc.2017.478\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fbjc.2017.478\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=B+Han&author=K+Li&author=Y+Zhao&author=B+Li&author=Y+Cheng&author=J+Zhou&publication_year=2018&title=Anlotinib%20as%20a%20third-line%20therapy%20in%20patients%20with%20refractory%20advanced%20non-small-cell%20lung%20cancer%3A%20A%20multicentre%2C%20randomised%20phase%20II%20trial%20%28ALTER0302%29&journal=Br+J+Cancer&volume=1185&pages=654-61\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B9\" id=\"B9\"\u003E\u003C\u002Fa\u003E 9. Wang F, Jin F, Cheng B, Zhang Y, Zhou Q, Wang S. The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer. \u003Ci\u003EJ Cancer Res Clin Oncol\u003C\u002Fi\u003E (2021) 148(7):1721–35. doi: 10.21203\u002Frs.3.rs-282608\u002Fv1\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34357411\u002F\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.21203\u002Frs.3.rs-282608\u002Fv1\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=F+Wang&author=F+Jin&author=B+Cheng&author=Y+Zhang&author=Q+Zhou&author=S+Wang&publication_year=2021&title=The%20real-world%20efficacy%20and%20safety%20of%20anlotinib%20in%20advanced%20non-small%20cell%20lung%20cancer&journal=J+Cancer+Res+Clin+Oncol&volume=148&pages=1721-35\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B10\" id=\"B10\"\u003E\u003C\u002Fa\u003E 10. Jalal SI, Riggs HD, Melnyk A, Richards D, Agarwala A, Neubauer M, et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: Analysis of a phase III trial from the Hoosier oncology group (HOG) and US oncology. \u003Ci\u003EAnn Oncol\u003C\u002Fi\u003E (2012) 237:1730–8. doi: 10.1093\u002Fannonc\u002Fmdr565\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1093\u002Fannonc\u002Fmdr565\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=SI+Jalal&author=HD+Riggs&author=A+Melnyk&author=D+Richards&author=A+Agarwala&author=M+Neubauer&publication_year=2012&title=Updated%20survival%20and%20outcomes%20for%20older%20adults%20with%20inoperable%20stage%20III%20non-small-cell%20lung%20cancer%20treated%20with%20cisplatin%2C%20etoposide%2C%20and%20concurrent%20chest%20radiation%20with%20or%20without%20consolidation%20docetaxel%3A%20Analysis%20of%20a%20phase%20III%20trial%20from%20the%20Hoosier%20oncology%20group%20%28HOG%29%20and%20US%20oncology&journal=Ann+Oncol&volume=237&pages=1730-8\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B11\" id=\"B11\"\u003E\u003C\u002Fa\u003E 11. Shao L, Wang W, Song Z, Zhang Y. The efficacy and safety of anlotinib treatment for advanced lung cancer. \u003Ci\u003EOncoTargets Ther\u003C\u002Fi\u003E (2019) 12:6549–54. doi: 10.2147\u002FOTT.S205674\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.2147\u002FOTT.S205674\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=L+Shao&author=W+Wang&author=Z+Song&author=Y+Zhang&publication_year=2019&title=The%20efficacy%20and%20safety%20of%20anlotinib%20treatment%20for%20advanced%20lung%20cancer&journal=OncoTargets+Ther&volume=12&pages=6549-54\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B12\" id=\"B12\"\u003E\u003C\u002Fa\u003E 12. Sun Y, Niu W, Du F, Du C, Li S, Wang J, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. \u003Ci\u003EJ Hematol Oncol\u003C\u002Fi\u003E (2016) 91:105. doi: 10.1186\u002Fs13045-016-0332-8\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs13045-016-0332-8\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=Y+Sun&author=W+Niu&author=F+Du&author=C+Du&author=S+Li&author=J+Wang&publication_year=2016&title=Safety%2C%20pharmacokinetics%2C%20and%20antitumor%20properties%20of%20anlotinib%2C%20an%20oral%20multi-target%20tyrosine%20kinase%20inhibitor%2C%20in%20patients%20with%20advanced%20refractory%20solid%20tumors&journal=J+Hematol+Oncol&volume=91&pages=105\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B13\" id=\"B13\"\u003E\u003C\u002Fa\u003E 13. Zhang K, Ma X, Gao H, Wang H, Qin H, Yang S, et al. Efficacy and safety of anlotinib in advanced non-small cell lung cancer: A real-world study. \u003Ci\u003ECancer Manage Res\u003C\u002Fi\u003E (2020) 12:3409–17. doi: 10.2147\u002FCMAR.S246000\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.2147\u002FCMAR.S246000\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=K+Zhang&author=X+Ma&author=H+Gao&author=H+Wang&author=H+Qin&author=S+Yang&publication_year=2020&title=Efficacy%20and%20safety%20of%20anlotinib%20in%20advanced%20non-small%20cell%20lung%20cancer%3A%20A%20real-world%20study&journal=Cancer+Manage+Res&volume=12&pages=3409-17\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B14\" id=\"B14\"\u003E\u003C\u002Fa\u003E 14. Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, et al. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2\u002FSTAT3\u002FVEGFA signaling in non-small cell lung cancer cells. \u003Ci\u003EJ Exp Clin Cancer Res\u003C\u002Fi\u003E (2019) 381:71. doi: 10.1186\u002Fs13046-019-1093-3\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs13046-019-1093-3\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=L+Liang&author=K+Hui&author=C+Hu&author=Y+Wen&author=S+Yang&author=P+Zhu&publication_year=2019&title=Autophagy%20inhibition%20potentiates%20the%20anti-angiogenic%20property%20of%20multikinase%20inhibitor%20anlotinib%20through%20JAK2%2FSTAT3%2FVEGFA%20signaling%20in%20non-small%20cell%20lung%20cancer%20cells&journal=J+Exp+Clin+Cancer+Res&volume=381&pages=71\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B15\" id=\"B15\"\u003E\u003C\u002Fa\u003E 15. Leidal AM, Levine B, Debnath J. Autophagy and the cell biology of age-related disease. \u003Ci\u003ENat Cell Biol\u003C\u002Fi\u003E (2018) 2012:1338–48. doi: 10.1038\u002Fs41556-018-0235-8\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41556-018-0235-8\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=AM+Leidal&author=B+Levine&author=J+Debnath&publication_year=2018&title=Autophagy%20and%20the%20cell%20biology%20of%20age-related%20disease&journal=Nat+Cell+Biol&volume=2012&pages=1338-48\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B16\" id=\"B16\"\u003E\u003C\u002Fa\u003E 16. Norling LV, Serhan CN. Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination. \u003Ci\u003EJ Internal Med\u003C\u002Fi\u003E (2010) 2681:15–24. doi: 10.1111\u002Fj.1365-2796.2010.02235.x\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1365-2796.2010.02235.x\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=LV+Norling&author=CN+Serhan&publication_year=2010&title=Profiling%20in%20resolving%20inflammatory%20exudates%20identifies%20novel%20anti-inflammatory%20and%20pro-resolving%20mediators%20and%20signals%20for%20termination&journal=J+Internal+Med&volume=2681&pages=15\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B17\" id=\"B17\"\u003E\u003C\u002Fa\u003E 17. Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, et al. Phase I study of pazopanib and vorinostat: A therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. \u003Ci\u003EAnn Oncol\u003C\u002Fi\u003E (2015) 265:1012–8. doi: 10.1093\u002Fannonc\u002Fmdv066\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1093\u002Fannonc\u002Fmdv066\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=S+Fu&author=MM+Hou&author=A+Naing&author=F+Janku&author=K+Hess&author=R+Zinner&publication_year=2015&title=Phase%20I%20study%20of%20pazopanib%20and%20vorinostat%3A%20A%20therapeutic%20approach%20for%20inhibiting%20mutant%20p53-mediated%20angiogenesis%20and%20facilitating%20mutant%20p53%20degradation&journal=Ann+Oncol&volume=265&pages=1012-8\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B18\" id=\"B18\"\u003E\u003C\u002Fa\u003E 18. Chu T, Zhong R, Zhong H, Zhang B, Zhang W, Shi C, et al. Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC. \u003Ci\u003EJ Thorac Oncol\u003C\u002Fi\u003E (2021) 164:643–52. doi: 10.1016\u002Fj.jtho.2020.11.026\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jtho.2020.11.026\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=T+Chu&author=R+Zhong&author=H+Zhong&author=B+Zhang&author=W+Zhang&author=C+Shi&publication_year=2021&title=Phase%201b%20study%20of%20sintilimab%20plus%20anlotinib%20as%20first-line%20therapy%20in%20patients%20with%20advanced%20NSCLC&journal=J+Thorac+Oncol&volume=164&pages=643-52\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B19\" id=\"B19\"\u003E\u003C\u002Fa\u003E 19. Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, et al. Randomized controlled trial of s-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia s-1 trial in lung cancer). \u003Ci\u003EAnn Oncol\u003C\u002Fi\u003E (2017) 2811:2698–706. doi: 10.1093\u002Fannonc\u002Fmdx419\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1093\u002Fannonc\u002Fmdx419\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=H+Nokihara&author=S+Lu&author=TSK+Mok&author=K+Nakagawa&author=N+Yamamoto&author=YK+Shi&publication_year=2017&title=Randomized%20controlled%20trial%20of%20s-1%20versus%20docetaxel%20in%20patients%20with%20non-small-cell%20lung%20cancer%20previously%20treated%20with%20platinum-based%20chemotherapy%20%28East%20Asia%20s-1%20trial%20in%20lung%20cancer%29&journal=Ann+Oncol&volume=2811&pages=2698-706\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B20\" id=\"B20\"\u003E\u003C\u002Fa\u003E 20. Wang HY, Chu JF, Zhao Y, Tang H, Wang LL, Zhou MQ, et al. A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer. \u003Ci\u003ECancer Manage Res\u003C\u002Fi\u003E (2020) 12:3827–34. doi: 10.2147\u002FCMAR.S249678\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.2147\u002FCMAR.S249678\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=HY+Wang&author=JF+Chu&author=Y+Zhao&author=H+Tang&author=LL+Wang&author=MQ+Zhou&publication_year=2020&title=A%20trial%20of%20the%20safety%20and%20efficacy%20of%20chemotherapy%20plus%20anlotinib%20vs%20chemotherapy%20alone%20as%20second-%20or%20third-line%20salvage%20treatment%20for%20advanced%20non-small%20cell%20lung%20cancer&journal=Cancer+Manage+Res&volume=12&pages=3827-34\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B21\" id=\"B21\"\u003E\u003C\u002Fa\u003E 21. Zhou N, Jiang M, Li T, Zhu J, Liu K, Hou H, et al. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. \u003Ci\u003ELung Cancer (Amsterdam Netherlands)\u003C\u002Fi\u003E (2021) 160:111–7. doi: 10.1016\u002Fj.lungcan.2021.08.006\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F34482102\u002F\" target=\"_blank\"\u003EPubMed Abstract\u003C\u002Fa\u003E | \u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.lungcan.2021.08.006\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=N+Zhou&author=M+Jiang&author=T+Li&author=J+Zhu&author=K+Liu&author=H+Hou&publication_year=2021&title=Anlotinib%20combined%20with%20anti-PD-1%20antibody%2C%20camrelizumab%20for%20advanced%20NSCLCs%20after%20multiple%20lines%20treatment%3A%20An%20open-label%2C%20dose%20escalation%20and%20expansion%20study&journal=Lung+Cancer+(Amsterdam+Netherlands)&volume=160&pages=111-7\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B22\" id=\"B22\"\u003E\u003C\u002Fa\u003E 22. Zhong RB, Xu JL, Lou YQ, Chu TQ, Zhong H, Han BH, et al. Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer. \u003Ci\u003EAnn palliative Med\u003C\u002Fi\u003E (2020) 94:1681–7. doi: 10.21037\u002Fapm-20-105\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.21037\u002Fapm-20-105\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=RB+Zhong&author=JL+Xu&author=YQ+Lou&author=TQ+Chu&author=H+Zhong&author=BH+Han&publication_year=2020&title=Anlotinib%20or%20platinum-pemetrexed%20as%20second-line%20therapy%20in%20EGFR%20T790M-negative%20lung%20cancer&journal=Ann+palliative+Med&volume=94&pages=1681-7\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B23\" id=\"B23\"\u003E\u003C\u002Fa\u003E 23. Zhu J, Xie Q, Zhong A, Le Y. Clinical analysis of anlotinib as first-line treatment for elderly patients with advanced lung adenocarcinoma without driver gene mutations. \u003Ci\u003EAnti-cancer Drugs\u003C\u002Fi\u003E (2022) 331:e584–9. doi: 10.1097\u002FCAD.0000000000001186\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1097\u002FCAD.0000000000001186\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=J+Zhu&author=Q+Xie&author=A+Zhong&author=Y+Le&publication_year=2022&title=Clinical%20analysis%20of%20anlotinib%20as%20first-line%20treatment%20for%20elderly%20patients%20with%20advanced%20lung%20adenocarcinoma%20without%20driver%20gene%20mutations&journal=Anti-cancer+Drugs&volume=331&pages=e584-9\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B24\" id=\"B24\"\u003E\u003C\u002Fa\u003E 24. Zhang L, Zhang Q, Jin J, Liu X, Zhao Y, Yu H, et al. Efficacy of anlotinib combined with AN regimen in first-line treatment of advanced EGFR, ALK and ROS1 wild-type lung adenocarcinoma. \u003Ci\u003EGuangdong Med\u003C\u002Fi\u003E (2021) 42:151–6. doi: 10.13820\u002Fj.cnki.gdyx.20200278\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.13820\u002Fj.cnki.gdyx.20200278\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=L+Zhang&author=Q+Zhang&author=J+Jin&author=X+Liu&author=Y+Zhao&author=H+Yu&publication_year=2021&title=Efficacy%20of%20anlotinib%20combined%20with%20AN%20regimen%20in%20first-line%20treatment%20of%20advanced%20EGFR%2C%20ALK%20and%20ROS1%20wild-type%20lung%20adenocarcinoma&journal=Guangdong+Med&volume=42&pages=151-6\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B25\" id=\"B25\"\u003E\u003C\u002Fa\u003E 25. Belderbos J, Uitterhoeve L, van Zandwijk N, Belderbos H, Rodrigus P, van de Vaart P, et al. Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). \u003Ci\u003EEur J Cancer (Oxford Engl 1990)\u003C\u002Fi\u003E (2007) 431:114–21. doi: 10.1016\u002Fj.ejca.2006.09.005\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ejca.2006.09.005\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=J+Belderbos&author=L+Uitterhoeve&author=N+van%20Zandwijk&author=H+Belderbos&author=P+Rodrigus&author=P+van%20de%20Vaart&publication_year=2007&title=Randomised%20trial%20of%20sequential%20versus%20concurrent%20chemo-radiotherapy%20in%20patients%20with%20inoperable%20non-small%20cell%20lung%20cancer%20%28EORTC%2008972-22973%29&journal=Eur+J+Cancer+(Oxford+Engl+1990)&volume=431&pages=114-21\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\"\u003E\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\"\u003E\u003Ca name=\"B26\" id=\"B26\"\u003E\u003C\u002Fa\u003E 26. Huang D, Zhong D, Zhang C, Zhang Y, Shang Y, Wang L, et al. Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004.Ann. \u003Ci\u003EOncol\u003C\u002Fi\u003E (2021) 32:S969–9. doi: 10.1016\u002Fj.annonc.2021.08.1824\u003C\u002Fp\u003E\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\"\u003E\u003Ca href=\"https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.annonc.2021.08.1824\" target=\"_blank\"\u003ECrossRef Full Text\u003C\u002Fa\u003E | \u003Ca href=\"http:\u002F\u002Fscholar.google.com\u002Fscholar_lookup?author=D+Huang&author=D+Zhong&author=C+Zhang&author=Y+Zhang&author=Y+Shang&author=L+Wang&publication_year=2021&title=Study%20of%20anlotinib%20combined%20with%20icotinib%20as%20the%20first-line%20treatment%20in%20NSCLC%20patients%20harboring%20activating%20EGFR%20mutations%3A%20Updated%20results%20of%20ALTER-L004.Ann&journal=Oncol&volume=32&pages=S969-9\" target=\"_blank\"\u003EGoogle Scholar\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003C\u002Fdiv\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"thinLineM20\"\u003E\u003C\u002Fdiv\u003E\u003Cdiv class=\"AbstractSummary\"\u003E\u003Cp\u003E\u003Cspan\u003EKeywords:\u003C\u002Fspan\u003E non-small cell lung cancer, anti-angiogenesis therapy, front-line treatment, elderly patients, case report, Anlotinib hydrochloride, tegafur-uracil, chemotherapy\u003C\u002Fp\u003E\u003Cp\u003E\u003Cspan\u003ECitation:\u003C\u002Fspan\u003E Wang J, Li X, Zhou J, Qiu D, Zhang M, Sun L and Li SC (2023) Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report. \u003Ci\u003EFront. Oncol.\u003C\u002Fi\u003E 13:1043244. doi: 10.3389\u002Ffonc.2023.1043244\u003C\u002Fp\u003E\u003Cp id=\"timestamps\"\u003E\u003Cspan\u003EReceived:\u003C\u002Fspan\u003E 13 September 2022; \u003Cspan\u003EAccepted:\u003C\u002Fspan\u003E 13 March 2023;\u003Cbr\u002F\u003E\u003Cspan\u003EPublished:\u003C\u002Fspan\u003E 06 April 2023.\u003C\u002Fp\u003E\u003Cdiv\u003E\u003Cp\u003EEdited by:\u003C\u002Fp\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1003220\"\u003EKohei Fujita\u003C\u002Fa\u003E, National Hospital Organization Kyoto Medical Center, Japan\u003C\u002Fdiv\u003E\u003Cdiv\u003E\u003Cp\u003EReviewed by:\u003C\u002Fp\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F970570\"\u003EXiaobo Du\u003C\u002Fa\u003E, Mianyang Central Hospital, China\u003Cbr\u002F\u003E\u003Ca href=\"https:\u002F\u002Floop.frontiersin.org\u002Fpeople\u002F1116571\"\u003ETao Qin\u003C\u002Fa\u003E, Sun Yat-sen Memorial Hospital, China\u003C\u002Fdiv\u003E\u003Cp\u003E\u003Cspan\u003ECopyright\u003C\u002Fspan\u003E © 2023 Wang, Li, Zhou, Qiu, Zhang, Sun and Li. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http:\u002F\u002Fcreativecommons.org\u002Flicenses\u002Fby\u002F4.0\u002F\" target=\"_blank\"\u003ECreative Commons Attribution License (CC BY)\u003C\u002Fa\u003E. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C\u002Fp\u003E\u003Cp\u003E\u003Cspan\u003E*Correspondence:\u003C\u002Fspan\u003E Lan Sun, \u003Ca href=\"mailto:sunlan6203@163.com\"\u003Esunlan6203@163.com\u003C\u002Fa\u003E; Shengwen Calvin Li, \u003Ca href=\"mailto:sli@choc.org\"\u003Esli@choc.org\u003C\u002Fa\u003E\u003C\u002Fp\u003E\u003Cp\u003E\u003Cspan\u003E\u003Csup\u003E†\u003C\u002Fsup\u003E\u003C\u002Fspan\u003EThese authors have contributed equally to this work\u003C\u002Fp\u003E\u003Cdiv class=\"clear\"\u003E\u003C\u002Fdiv\u003E\u003C\u002Fdiv\u003E",menuHtml:"\u003Cul class=\"flyoutJournal\"\u003E\u003Cli\u003E\u003Ca href=\"#h1\"\u003EAbstract\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h2\"\u003EIntroduction\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h3\"\u003EBackground\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h4\"\u003EDiscussion\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h5\"\u003EConclusion\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h6\"\u003EData availability statement\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h7\"\u003EEthics statement\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h8\"\u003EAuthor contributions\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h9\"\u003EFunding\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h10\"\u003EAcknowledgments\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h11\"\u003EConflict of interest\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h12\"\u003EPublisher’s note\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003Cli\u003E\u003Ca href=\"#h13\"\u003EReferences\u003C\u002Fa\u003E\u003C\u002Fli\u003E\u003C\u002Ful\u003E"},files:[{name:"EPUB.epub",fileServerPackageEntryId:f,type:{code:aw,name:aw}},{name:M,fileServerPackageEntryId:M,type:{code:t,name:t}},{name:M,fileServerPackageEntryId:f,type:{code:t,name:t}},{name:ax,fileServerPackageEntryId:ax,type:{code:"NLM_XML",name:"XML"}},{name:"Provisional PDF.pdf",fileServerPackageEntryId:f,type:{code:t,name:t}}]},currentArticlePageMetaInfo:{title:ay,link:[{rel:"canonical",href:az}],meta:[{hid:z,property:z,name:z,content:aA},{hid:aB,property:aB,name:"title",content:ay},{hid:aC,property:aC,name:z,content:aA},{hid:aD,name:aD,content:"Non-small cell lung cancer,Anti-angiogenesis therapy,front-line treatment,elderly patients,case report"},{hid:aE,property:aE,name:"site_name",content:A},{hid:aF,property:aF,name:U,content:"https:\u002F\u002Fimages-provider.frontiersin.org\u002Fapi\u002Fipx\u002Fw=1200&f=png\u002Fhttps:\u002F\u002Fwww.frontiersin.org\u002Ffiles\u002FArticles\u002F1043244\u002Ffonc-13-1043244-HTML-r1\u002Fimage_m\u002Ffonc-13-1043244-g001.jpg"},{hid:aG,property:aG,name:"type",content:"article"},{hid:aH,property:aH,name:"url",content:az},{hid:aI,name:aI,content:"summary_large_image"},{hid:aJ,name:aJ,content:"13"},{hid:aK,name:aK,content:r},{hid:aL,name:aL,content:A},{hid:aM,name:aM,content:H},{hid:aN,name:aN,content:I},{hid:aO,name:aO,content:Z},{hid:aP,name:aP,content:"1043244"},{hid:aQ,name:aQ,content:"English"},{hid:aR,name:aR,content:_},{hid:aS,name:aS,content:"Non-small cell lung cancer; Anti-angiogenesis therapy; front-line treatment; elderly patients; case report"},{hid:aT,name:aT,content:$},{hid:aU,name:aU,content:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Farticles\u002F10.3389\u002Ffonc.2023.1043244\u002Fpdf"},{hid:aV,name:aV,content:"2023\u002F03\u002F13"},{hid:aW,name:aW,content:"2023\u002F04\u002F06"},{hid:"citation_author_0",name:p,content:"Wang, Jingyi"},{hid:"citation_author_institution_0",name:q,content:u},{hid:"citation_author_1",name:p,content:"Li, Xiaoqing"},{hid:"citation_author_institution_1",name:q,content:u},{hid:"citation_author_2",name:p,content:"Zhou, Juan"},{hid:"citation_author_institution_2",name:q,content:u},{hid:"citation_author_3",name:p,content:"Qiu, Dan"},{hid:"citation_author_institution_3",name:q,content:u},{hid:"citation_author_4",name:p,content:"Zhang, Mengyao"},{hid:"citation_author_institution_4",name:q,content:u},{hid:"citation_author_5",name:p,content:"Sun, Lan"},{hid:"citation_author_institution_5",name:q,content:u},{hid:"citation_author_6",name:p,content:"Li, Shengwen Calvin"},{hid:"citation_author_institution_6",name:q,content:"Neuro-Oncology and Stem Cell Research Laboratory, Center for Neuroscience Research, CHOC Children鈥檚 Research Institute, Children鈥檚 Hospital of Orange County (CHOC), United States"},{hid:aX,name:aX,content:"doi:10.3389\u002Ffonc.2023.1043244"}],script:[{src:"https:\u002F\u002Fcdnjs.cloudflare.com\u002Fpolyfill\u002Fv3\u002Fpolyfill.min.js?features=es6",body:h,async:h},{src:"https:\u002F\u002Fcdnjs.cloudflare.com\u002Fajax\u002Flibs\u002Fmathjax\u002F2.7.1\u002FMathJax.js?config=TeX-MML-AM_CHTML",body:h,async:h},{src:"https:\u002F\u002Fd1bxh8uas1mnw7.cloudfront.net\u002Fassets\u002Faltmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",body:h,async:h},{src:"https:\u002F\u002Fapi.altmetric.com\u002Fv1\u002Fdoi\u002F10.3389\u002Ffonc.2023.1043244?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",body:h,async:h},{src:"https:\u002F\u002Fwidgets.figshare.com\u002Fstatic\u002Ffigshare.js",body:h,async:h},{src:"https:\u002F\u002Fcrossmark-cdn.crossref.org\u002Fwidget\u002Fv2.0\u002Fwidget.js",body:h,async:h}]},articleHubArticlesList:[],showCrossmarkWidget:h,hasSupplementalData:l,isPreviewArticlePage:l,settingsFeaturesSwitchers:{displayTitlePillLabels:h,displayRelatedArticlesBox:h,showEditors:h,showReviewers:h,showLoopImpactLink:h},tenantConfig:{spaceId:c,name:A,availableJournalPages:[aY,aZ,a_,"volumes","about"]},components:{ibar:{tenantLogo:f,journalLogo:f,aboutUs:[{title:"Who we are",links:[{text:"Mission and values",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fmission",target:g,ariaLabel:e},{text:"History",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fhistory",target:g,ariaLabel:e},{text:"Leadership",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fleadership",target:g,ariaLabel:e},{text:"Awards",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fawards",target:g,ariaLabel:e}]},{title:"Impact and progress",links:[{text:"Frontiers' impact",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fimpact",target:g,ariaLabel:e},{text:"Progress Report 2022",url:"https:\u002F\u002Fprogressreport.frontiersin.org\u002F?utm_source=fweb&utm_medium=frep&utm_campaign=pr20",target:k,ariaLabel:e},{text:"All progress reports",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fprogress-reports",target:g,ariaLabel:e}]},{title:"Publishing model",links:[{text:a$,url:ba,target:g,ariaLabel:e},{text:"Open access",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fopen-access",target:g,ariaLabel:e},{text:bb,url:bc,target:g,ariaLabel:e},{text:"Peer review",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fpeer-review",target:g,ariaLabel:e},{text:"Research integrity",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fresearch-integrity",target:g,ariaLabel:e},{text:bd,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fresearch-topics",target:g,ariaLabel:e}]},{title:"Services",links:[{text:"Societies",url:"https:\u002F\u002Fpublishingpartnerships.frontiersin.org\u002F",target:k,ariaLabel:e},{text:"National consortia",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fopen-access-agreements\u002Fconsortia",target:g,ariaLabel:e},{text:"Institutional partnerships",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fopen-access-agreements",target:g,ariaLabel:e},{text:"Collaborators",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fcollaborators",target:g,ariaLabel:e}]},{title:"More from Frontiers",links:[{text:"Frontiers Forum",url:be,target:k,ariaLabel:"this link will take you to the Frontiers Forum website"},{text:bf,url:bg,target:k,ariaLabel:bh},{text:"Press office",url:"https:\u002F\u002Fpressoffice.frontiersin.org\u002F",target:k,ariaLabel:"this link will take you to the Frontiers press office website"},{text:"Sustainability",url:"https:\u002F\u002Fwww.frontiersin.orgabout\u002Fsustainability",target:g,ariaLabel:"link to information about Frontiers' sustainability"},{text:bi,url:bj,target:k,ariaLabel:"this link will take you to the Frontiers careers website"},{text:"Contact us",url:bk,target:g,ariaLabel:"this link will take you to the help pages to contact our support team"}]}],submitUrl:"https:\u002F\u002Fwww.frontiersin.org\u002Fsubmission\u002Fsubmit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451",showSubmitButton:h,journal:{id:w,name:r,slug:x,sections:[{id:500,name:"Breast Cancer",slug:"breast-cancer"},{id:2606,name:"Cancer Cell Signaling",slug:"cancer-cell-signaling"},{id:513,name:"Cancer Epidemiology and Prevention",slug:"cancer-epidemiology-and-prevention"},{id:506,name:"Cancer Genetics",slug:"cancer-genetics"},{id:515,name:"Cancer Imaging and Image-directed Interventions",slug:"cancer-imaging-and-image-directed-interventions"},{id:527,name:"Cancer Immunity and Immunotherapy",slug:"cancer-immunity-and-immunotherapy"},{id:1510,name:"Cancer Metabolism",slug:"cancer-metabolism"},{id:507,name:"Cancer Molecular Targets and Therapeutics",slug:"cancer-molecular-targets-and-therapeutics"},{id:1513,name:"Cardio-Oncology",slug:"cardio-oncology"},{id:2413,name:"Gastrointestinal Cancers: Colorectal Cancer",slug:"gastrointestinal-cancers-colorectal-cancer"},{id:2415,name:"Gastrointestinal Cancers: Gastric and Esophageal Cancers",slug:"gastrointestinal-cancers-gastric-and-esophageal-cancers"},{id:2414,name:"Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers",slug:"gastrointestinal-cancers-hepato-pancreatic-biliary-cancers"},{id:503,name:"Genitourinary Oncology",slug:"genitourinary-oncology"},{id:2079,name:"Gynecological Oncology",slug:"gynecological-oncology"},{id:517,name:"Head and Neck Cancer",slug:"head-and-neck-cancer"},{id:505,name:"Hematologic Malignancies",slug:"hematologic-malignancies"},{id:508,name:"Molecular and Cellular Oncology",slug:"molecular-and-cellular-oncology"},{id:150,name:"Neuro-Oncology and Neurosurgical Oncology",slug:"neuro-oncology-and-neurosurgical-oncology"},{id:509,name:"Pediatric Oncology",slug:"pediatric-oncology"},{id:192,name:"Pharmacology of Anti-Cancer Drugs",slug:"pharmacology-of-anti-cancer-drugs"},{id:511,name:"Radiation Oncology",slug:"radiation-oncology"},{id:1630,name:"Skin Cancer",slug:bl},{id:512,name:"Surgical Oncology",slug:"surgical-oncology"},{id:at,name:au,slug:av}]},sectionTerm:"Sections",aboutJournal:[{title:"Scope",links:[{text:"Field chief editors",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Fabout#about-editors",target:g,ariaLabel:e},{text:"Mission & scope",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Fabout#about-scope",target:g,ariaLabel:e},{text:"Facts",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Fabout#about-facts",target:g,ariaLabel:e},{text:"Journal sections",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Fabout#about-submission",target:g,ariaLabel:e},{text:"Open access statement",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Fabout#about-open",target:g,ariaLabel:e},{text:"Copyright statement",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Fabout#copyright-statement",target:g,ariaLabel:e},{text:"Quality",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Fabout#about-quality",target:g,ariaLabel:e}]},{title:"For authors",links:[{text:"Why submit?",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Ffor-authors\u002Fwhy-submit",target:g,ariaLabel:e},{text:"Article types",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Ffor-authors\u002Farticle-types",target:g,ariaLabel:e},{text:bm,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Ffor-authors\u002Fauthor-guidelines",target:g,ariaLabel:e},{text:bn,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Ffor-authors\u002Feditor-guidelines",target:g,ariaLabel:e},{text:"Publishing fees",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Ffor-authors\u002Fpublishing-fees",target:g,ariaLabel:e},{text:"Submission checklist",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Ffor-authors\u002Fsubmission-checklist",target:g,ariaLabel:e},{text:"Contact editorial office",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Ffor-authors\u002Fcontact-editorial-office",target:g,ariaLabel:e}]}],mainLinks:[{text:"All journals",url:bo,target:g,ariaLabel:e},{text:"All articles",url:bp,target:g,ariaLabel:e}],journalLinks:[{text:bq,url:aY,target:g,ariaLabel:e},{text:bd,url:a_,target:g,ariaLabel:e},{text:"Editorial board",url:aZ,target:g,ariaLabel:e}],helpCenterLink:{text:B,url:br,target:k,ariaLabel:B}},footer:{blocks:[{title:"Guidelines",links:[{text:bm,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fguidelines\u002Fauthor-guidelines",target:g,ariaLabel:e},{text:bn,url:"https:\u002F\u002Fwww.frontiersin.org\u002Fguidelines\u002Feditor-guidelines",target:g,ariaLabel:e},{text:"Policies and publication ethics",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fguidelines\u002Fpolicies-and-publication-ethics",target:g,ariaLabel:e},{text:bb,url:bc,target:g,ariaLabel:e}]},{title:"Explore",links:[{text:bq,url:bp,target:g,ariaLabel:e},{text:"Research Topics ",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fresearch-topics",target:g,ariaLabel:e},{text:"Journals",url:bo,target:g,ariaLabel:e},{text:a$,url:ba,target:g,ariaLabel:e}]},{title:"Outreach",links:[{text:"Frontiers Forum ",url:be,target:k,ariaLabel:"Frontiers Forum website"},{text:"Frontiers Policy Labs ",url:"https:\u002F\u002Fpolicylabs.frontiersin.org\u002F",target:k,ariaLabel:e},{text:bs,url:"https:\u002F\u002Fkids.frontiersin.org\u002F",target:k,ariaLabel:"Frontiers for Young Minds journal"},{text:bf,url:bg,target:k,ariaLabel:bh}]},{title:"Connect",links:[{text:B,url:br,target:k,ariaLabel:B},{text:"Emails and alerts ",url:"https:\u002F\u002Floop.frontiersin.org\u002Fsettings\u002Femail-preferences?a=publishers",target:k,ariaLabel:"Subscribe to Frontiers emails"},{text:"Contact us ",url:bk,target:g,ariaLabel:"Subscribe to newsletter"},{text:"Submit",url:"https:\u002F\u002Fwww.frontiersin.org\u002Fsubmission\u002Fsubmit",target:g,ariaLabel:e},{text:bi,url:bj,target:k,ariaLabel:e}]}],socialLinks:[{link:{text:bt,url:"https:\u002F\u002Fwww.facebook.com\u002FFrontiersin",target:k,ariaLabel:bt},type:C,color:D,icon:"Facebook",size:E,hiddenText:h},{link:{text:"Frontiers Twitter",url:"https:\u002F\u002Ftwitter.com\u002Ffrontiersin",target:k,ariaLabel:e},type:C,color:D,icon:"Twitter",size:E,hiddenText:h},{link:{text:"Frontiers LinkedIn",url:"https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Ffrontiers",target:k,ariaLabel:e},type:C,color:D,icon:"LinkedIn",size:E,hiddenText:h},{link:{text:"Frontiers Instagram",url:"https:\u002F\u002Fwww.instagram.com\u002Ffrontiersin_",target:k,ariaLabel:e},type:C,color:D,icon:"Instagram",size:E,hiddenText:h}],copyright:"Frontiers Media S.A. All rights reserved",termsAndConditionsUrl:"https:\u002F\u002Fwww.frontiersin.org\u002Flegal\u002Fterms-and-conditions",privacyPolicyUrl:"https:\u002F\u002Fwww.frontiersin.org\u002Flegal\u002Fprivacy-policy"},newsletterComponent:e,snackbarItems:[]},mainHeader:{title:f,image:J,breadcrumbs:[],linksCollection:{total:m,items:[]},metricsCollection:{total:m,items:[]}},user:{loggedUserInfo:J},journals:[{id:bu,name:bv,slug:bw,abbreviation:bx,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2445,name:bv,slug:bw,abbreviation:bx,space:{id:c,domainName:d,__typename:b},__typename:a},{id:N,name:"Test SSPH Journal",slug:"test-ssph-journal",abbreviation:"testjournal",space:{id:v,domainName:F,__typename:b},__typename:a},{id:by,name:"TEST ALF Journal",slug:"test-alf-journal",abbreviation:"talfj",space:{id:y,domainName:O,__typename:b},__typename:a},{id:i,name:bz,slug:bA,abbreviation:bB,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2360,name:bz,slug:bA,abbreviation:bB,space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Smoke Test Field",slug:"smoke-test-field",abbreviation:"FJST",space:{id:P,domainName:bC,__typename:b},__typename:a},{id:by,name:bD,slug:bE,abbreviation:bF,space:{id:v,domainName:F,__typename:b},__typename:a},{id:2077,name:bD,slug:bE,abbreviation:bF,space:{id:c,domainName:d,__typename:b},__typename:a},{id:N,name:bG,slug:bH,abbreviation:bI,space:{id:y,domainName:O,__typename:b},__typename:a},{id:N,name:bG,slug:bH,abbreviation:bI,space:{id:c,domainName:d,__typename:b},__typename:a},{id:bJ,name:bK,slug:bL,abbreviation:bM,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3776,name:bK,slug:bL,abbreviation:bM,space:{id:c,domainName:d,__typename:b},__typename:a},{id:bN,name:bO,slug:bP,abbreviation:bQ,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3765,name:bO,slug:bP,abbreviation:bQ,space:{id:c,domainName:d,__typename:b},__typename:a},{id:14,name:bR,slug:bS,abbreviation:bT,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3414,name:bR,slug:bS,abbreviation:bT,space:{id:c,domainName:d,__typename:b},__typename:a},{id:20,name:bU,slug:bV,abbreviation:bW,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3754,name:bU,slug:bV,abbreviation:bW,space:{id:c,domainName:d,__typename:b},__typename:a},{id:P,name:bX,slug:bY,abbreviation:bZ,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2444,name:bX,slug:bY,abbreviation:bZ,space:{id:c,domainName:d,__typename:b},__typename:a},{id:b_,name:b$,slug:ca,abbreviation:cb,space:{id:v,domainName:F,__typename:b},__typename:a},{id:b_,name:b$,slug:ca,abbreviation:cb,space:{id:c,domainName:d,__typename:b},__typename:a},{id:i,name:"GSL Test",slug:"gsl-test",abbreviation:"gslt",space:{id:n,domainName:Q,__typename:b},__typename:a},{id:2356,name:"Frontiers in the Internet of Things",slug:"the-internet-of-things",abbreviation:"friot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:656,name:"Frontiers in Zoological Science",slug:"zoological-science",abbreviation:"fzoos",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1720,name:"Frontiers in Zoological Research",slug:"zoological-research",abbreviation:"fzolr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3162,name:"Frontiers in Wound Care",slug:"wound-care",abbreviation:"fwoca",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3136,name:"Frontiers in Worm Science",slug:"worm-science",abbreviation:"fwors",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3583,name:"Frontiers in Wind Energy",slug:"wind-energy",abbreviation:"fwinde",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1451,name:"Frontiers in Water",slug:"water",abbreviation:"frwa",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1561,name:"Frontiers in Virtual Reality",slug:"virtual-reality",abbreviation:"frvir",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2000,name:"Frontiers in Virology",slug:"virology",abbreviation:"fviro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:649,name:"Frontiers in Veterinary Science",slug:"veterinary-science",abbreviation:"fvets",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2176,name:"Frontiers in Urology",slug:"urology",abbreviation:"fruro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3099,name:"Frontiers in Tuberculosis",slug:"tuberculosis",abbreviation:"ftubr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1843,name:"Frontiers in Tropical Diseases",slug:"tropical-diseases",abbreviation:"fitd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2417,name:"Frontiers in Transplantation",slug:"transplantation",abbreviation:"frtra",space:{id:c,domainName:d,__typename:b},__typename:a},{id:473,name:"Frontiers in Toxicology",slug:"toxicology",abbreviation:"ftox",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2105,name:"Frontiers in Thermal Engineering",slug:"thermal-engineering",abbreviation:"fther",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3190,name:"Frontiers in The Neurobiology of Pain",slug:"the-neurobiology-of-pain",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:1967,name:"Frontiers in Test_Field_Science_Archive",slug:"testfieldsciencearchive",abbreviation:"fntesc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1347,name:"Frontiers in Test_Field_Humanities_Archive",slug:"testfieldhumanitiesarchive",abbreviation:"fntes",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3573,name:"Frontiers in Taxonomy",slug:"taxonomy",abbreviation:"Front. Taxon.",space:{id:c,domainName:d,__typename:b},__typename:a},{id:v,name:"Frontiers in Systems Neuroscience",slug:"systems-neuroscience",abbreviation:"fnsys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1721,name:"Frontiers in Systems Biology",slug:"systems-biology",abbreviation:"fsysb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3381,name:"Frontiers in Synthetic Biology",slug:"synthetic-biology",abbreviation:"fsybi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:22,name:"Frontiers in Synaptic Neuroscience",slug:"synaptic-neuroscience",abbreviation:"fnsyn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2299,name:"Frontiers in Sustainable Tourism",slug:"sustainable-tourism",abbreviation:"frsut",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2483,name:"Frontiers in Sustainable Resource Management",slug:"sustainable-resource-management",abbreviation:"fsrma",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1335,name:"Frontiers in Sustainable Food Systems",slug:"sustainable-food-systems",abbreviation:"fsufs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2726,name:"Frontiers in Sustainable Energy Policy",slug:"sustainable-energy-policy",abbreviation:"fsuep",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1468,name:"Frontiers in Sustainable Cities",slug:"sustainable-cities",abbreviation:"frsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1397,name:"Frontiers in Sustainable Business",slug:"sustainable-business",abbreviation:"fisb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1547,name:"Frontiers in Sustainability",slug:"sustainability",abbreviation:"frsus",space:{id:c,domainName:d,__typename:b},__typename:a},{id:604,name:"Frontiers in Surgery",slug:"surgery",abbreviation:"fsurg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2504,name:"Frontiers in Structural Biology",slug:"structural-biology",abbreviation:"frsbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2497,name:"Frontiers in Stroke",slug:"stroke",abbreviation:"fstro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3434,name:"Frontiers in Stem Cells",slug:"stem-cells",abbreviation:"fstce",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1482,name:"Frontiers in Sports and Active Living",slug:"sports-and-active-living",abbreviation:"fspor",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1695,name:"Frontiers in Space Technologies",slug:"space-technologies",abbreviation:"frspt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3519,name:"Frontiers in Solar Energy",slug:"solar-energy",abbreviation:"fsoln",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1718,name:"Frontiers in Soil Science",slug:"soil-science",abbreviation:"fsoil",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2346,name:"Frontiers in Soft Matter",slug:"soft-matter",abbreviation:"frsfm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1213,name:"Frontiers in Sociology",slug:"sociology",abbreviation:"fsoc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:R,name:"Frontiers in Society Journal Archive",slug:"society-journal-archive",abbreviation:S,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2690,name:"Frontiers in Social Psychology",slug:"social-psychology",abbreviation:"frsps",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2819,name:"Frontiers in Smart Grids",slug:"smart-grids",abbreviation:"frsgr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2288,name:"Frontiers in Sleep",slug:"sleep",abbreviation:"frsle",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2552,name:"Frontiers in Skin Cancer",slug:bl,abbreviation:"fskcr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1786,name:"Frontiers in Signal Processing",slug:"signal-processing",abbreviation:"frsip",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1704,name:"Frontiers in Sensors",slug:"sensors",abbreviation:"fsens",space:{id:c,domainName:d,__typename:b},__typename:a},{id:v,name:"Frontiers in Science archive",slug:"science-archive",abbreviation:G,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3737,name:"Frontiers in Science Diplomacy",slug:"science-diplomacy",abbreviation:"fsdip",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2766,name:"Frontiers in Science",slug:"science",abbreviation:"fsci",space:{id:c,domainName:d,__typename:b},__typename:a},{id:657,name:"Frontiers in Robotics and AI",slug:"robotics-and-ai",abbreviation:"frobt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1606,name:"Frontiers in Research Metrics and Analytics",slug:"research-metrics-and-analytics",abbreviation:"frma",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1479,name:"Frontiers in Reproductive Health",slug:"reproductive-health",abbreviation:"frph",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1830,name:"Frontiers in Remote Sensing",slug:"remote-sensing",abbreviation:"frsen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:659,name:"Frontiers in Rehabilitation Sciences",slug:"rehabilitation-sciences",abbreviation:"fresc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3550,name:"Frontiers in Regenerative Medicine",slug:"regenerative-medicine",abbreviation:"fregm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1949,name:"Frontiers in Radiology",slug:"radiology",abbreviation:"fradi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3189,name:"Frontiers in RNA Research",slug:"rna-research",abbreviation:"frnar",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2306,name:"Frontiers in Quantum Science and Technology",slug:"quantum-science-and-technology",abbreviation:"frqst",space:{id:c,domainName:d,__typename:b},__typename:a},{id:R,name:"Frontiers in Public Health Archive",slug:"public-health-archive",abbreviation:S,space:{id:v,domainName:F,__typename:b},__typename:a},{id:609,name:"Frontiers in Public Health",slug:"public-health",abbreviation:"fpubh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:36,name:"Frontiers in Psychology",slug:"psychology",abbreviation:"fpsyg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:71,name:"Frontiers in Psychiatry",slug:"psychiatry",abbreviation:"fpsyt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3267,name:"Frontiers in Protistology",slug:"protistology",abbreviation:"frpro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2452,name:"Frontiers in Proteomics",slug:"proteomics",abbreviation:"fprot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3171,name:"Frontiers in Prosthetics and Orthotics",slug:"prosthetics-and-orthotics",abbreviation:"fpror ",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3643,name:"Frontiers in Polymer Science",slug:"polymer-science",abbreviation:"fplms",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1558,name:"Frontiers in Political Science",slug:"political-science",abbreviation:"fpos",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3615,name:"Frontiers in Polar Science",slug:"polar-science",abbreviation:"fposc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:373,name:"Frontiers in Plant Science",slug:"plant-science",abbreviation:"fpls",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3477,name:"Frontiers in Plant Physiology",slug:"plant-physiology",abbreviation:"fphgy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3589,name:"Frontiers in Plant Genomics",slug:"plant-genomics",abbreviation:"fpgen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3579,name:"Frontiers in Plant Ecology",slug:"plant-ecology",abbreviation:"fpley",space:{id:c,domainName:d,__typename:b},__typename:a},{id:210,name:"Frontiers in Physiology",slug:"physiology",abbreviation:"fphys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:616,name:"Frontiers in Physics",slug:"physics",abbreviation:"fphy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1803,name:"Frontiers in Photonics",slug:"photonics",abbreviation:"fphot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3604,name:"Frontiers in Photobiology",slug:"photobiology",abbreviation:"fphbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:176,name:"Frontiers in Pharmacology",slug:"pharmacology",abbreviation:"fphar",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3388,name:"Frontiers in Personality Disorders",slug:"personality-disorders",abbreviation:"fprsd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:606,name:"Frontiers in Pediatrics",slug:"pediatrics",abbreviation:"fped",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2554,name:"Frontiers in Pediatric Dermatology",slug:"pediatric-dermatology",abbreviation:"fpdm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:R,name:"Frontiers in Pathology and Oncology Archive",slug:"pathology-and-oncology-archive",abbreviation:S,space:{id:y,domainName:O,__typename:b},__typename:a},{id:610,name:cc,slug:cd,abbreviation:ce,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3351,name:cc,slug:cd,abbreviation:ce,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2705,name:"Frontiers in Parasitology",slug:"parasitology",abbreviation:"fpara",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1727,name:"Frontiers in Pain Research",slug:"pain-research",abbreviation:"fpain",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2679,name:"Frontiers in Organizational Psychology",slug:"organizational-psychology",abbreviation:"forgp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1702,name:"Frontiers in Oral Health",slug:"oral-health",abbreviation:"froh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2232,name:"Frontiers in Ophthalmology",slug:"ophthalmology",abbreviation:"fopht",space:{id:c,domainName:d,__typename:b},__typename:a},{id:w,name:r,slug:x,abbreviation:W,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3123,name:"Frontiers in Ocean Sustainability",slug:"ocean-sustainability",abbreviation:"focsu",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2612,name:"Frontiers in Occupational Therapy",slug:"occupational-therapy",abbreviation:"froct",space:{id:c,domainName:d,__typename:b},__typename:a},{id:628,name:"Frontiers in Nutrition",slug:"nutrition",abbreviation:"fnut",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2062,name:"Frontiers in Nuclear Medicine",slug:"nuclear-medicine",abbreviation:"fnume",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2172,name:"Frontiers in Nuclear Engineering",slug:"nuclear-engineering",abbreviation:"fnuen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Frontiers in Neuroscience",slug:"neuroscience",abbreviation:"fnins",space:{id:c,domainName:d,__typename:b},__typename:a},{id:L,name:"Frontiers in Neurorobotics",slug:"neurorobotics",abbreviation:"fnbot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3056,name:"Frontiers in Neuropsychiatry",slug:"neuropsychiatry",abbreviation:"fnpsy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:141,name:"Frontiers in Neurology",slug:"neurology",abbreviation:"fneur",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cf,name:"Frontiers in Neuroinformatics",slug:"neuroinformatics",abbreviation:"fninf",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3283,name:"Frontiers in Neuroinflammation",slug:"neuroinflammation",abbreviation:"fnein",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1973,name:"Frontiers in Neuroimaging",slug:"neuroimaging",abbreviation:"fnimg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1833,name:"Frontiers in Neuroergonomics",slug:"neuroergonomics",abbreviation:"fnrgo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:K,name:"Frontiers in Neuroengineering",slug:"neuroengineering",abbreviation:"fneng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cg,name:"Frontiers in Neuroenergetics",slug:"neuroenergetics",abbreviation:"fnene",space:{id:c,domainName:d,__typename:b},__typename:a},{id:y,name:"Frontiers in Neuroanatomy",slug:"neuroanatomy",abbreviation:"fnana",space:{id:c,domainName:d,__typename:b},__typename:a},{id:bN,name:"Frontiers in Neural Circuits",slug:"neural-circuits",abbreviation:"fncir",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2021,name:"Frontiers in Network Physiology",slug:"network-physiology",abbreviation:"fnetp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3130,name:"Frontiers in Network Neuroscience",slug:"network-neuroscience",abbreviation:"fnnsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2357,name:"Frontiers in Nephrology",slug:"nephrology",abbreviation:"fneph",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2320,name:"Frontiers in Natural Products",slug:"natural-products",abbreviation:"fntpr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1528,name:"Frontiers in Nanotechnology",slug:"nanotechnology",abbreviation:"fnano",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2882,name:"Frontiers in Musculoskeletal Disorders",slug:"musculoskeletal-disorders",abbreviation:"fmscd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3275,name:"Frontiers in Multiple Sclerosis",slug:"multiple-sclerosis",abbreviation:"fmscr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3152,name:"Frontiers in Mollusk Science",slug:"mollusk-science",abbreviation:"fmlsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2031,name:"Frontiers in Molecular Neuroscience",slug:"molecular-neuroscience",abbreviation:"fnmol",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2086,name:"Frontiers in Molecular Medicine",slug:"molecular-medicine",abbreviation:"fmmed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:698,name:"Frontiers in Molecular Biosciences",slug:"molecular-biosciences",abbreviation:"fmolb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2807,name:"Frontiers in Microbiomes",slug:"microbiomes",abbreviation:"frmbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:310,name:"Frontiers in Microbiology",slug:"microbiology",abbreviation:"fmicb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2327,name:"Frontiers in Metals and Alloys",slug:"metals-and-alloys",abbreviation:"ftmal",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2307,name:"Frontiers in Membrane Science and Technology",slug:"membrane-science-and-technology",abbreviation:"frmst",space:{id:c,domainName:d,__typename:b},__typename:a},{id:602,name:"Frontiers in Medicine",slug:"medicine",abbreviation:"fmed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1573,name:"Frontiers in Medical Technology",slug:"medical-technology",abbreviation:"fmedt",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3135,name:"Frontiers in Medical Engineering",slug:"medical-engineering",abbreviation:"fmede",space:{id:c,domainName:d,__typename:b},__typename:a},{id:950,name:"Frontiers in Mechanical Engineering",slug:"mechanical-engineering",abbreviation:"fmech",space:{id:c,domainName:d,__typename:b},__typename:a},{id:608,name:"Frontiers in Materials",slug:"materials",abbreviation:"fmats",space:{id:c,domainName:d,__typename:b},__typename:a},{id:655,name:"Frontiers in Marine Science",slug:"marine-science",abbreviation:"fmars",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2100,name:"Frontiers in Manufacturing Technology",slug:"manufacturing-technology",abbreviation:"fmtec",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2931,name:"Frontiers in Mammal Science",slug:"mammal-science",abbreviation:"fmamm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2896,name:"Frontiers in Malaria",slug:"malaria",abbreviation:"fmala",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3107,name:"Frontiers in Lupus",slug:"lupus",abbreviation:"flupu",space:{id:c,domainName:d,__typename:b},__typename:a},{id:435,name:"Frontiers in Linguistics",slug:"linguistics",abbreviation:"fling",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2636,name:"Frontiers in Language Sciences",slug:"language-sciences",abbreviation:"flang",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2670,name:"Frontiers in Lab on a Chip Technologies",slug:"lab-on-a-chip-technologies",abbreviation:"frlct",space:{id:c,domainName:d,__typename:b},__typename:a},{id:ch,name:"Frontiers in Integrative Neuroscience",slug:"integrative-neuroscience",abbreviation:"fnint",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1723,name:"Frontiers in Insect Science",slug:"insect-science",abbreviation:"finsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3093,name:"Frontiers in Influenza",slug:"influenza",abbreviation:"finfl",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3073,name:"Frontiers in Inflammation",slug:"inflammation",abbreviation:"finmn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3200,name:"Frontiers in Industrial Microbiology",slug:"industrial-microbiology",abbreviation:"finmi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3291,name:"Frontiers in Industrial Engineering",slug:"industrial-engineering",abbreviation:"fieng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2765,name:"Frontiers in Impact Journals",slug:"impact-journals",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3078,name:"Frontiers in Immunotherapeutics",slug:"immunotherapeutics",abbreviation:"fimms",space:{id:c,domainName:d,__typename:b},__typename:a},{id:276,name:"Frontiers in Immunology",slug:"immunology",abbreviation:"fimmu",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2379,name:"Frontiers in Imaging",slug:"imaging",abbreviation:"fimag",space:{id:c,domainName:d,__typename:b},__typename:a},{id:629,name:"Frontiers in ICT",slug:"ict",abbreviation:"fict",space:{id:c,domainName:d,__typename:b},__typename:a},{id:16,name:"Frontiers in Humanities and Social Sciences Archive",slug:"humanities-and-social-sciences-archive",abbreviation:G,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3759,name:"Frontiers in Human Rights",slug:"human-rights",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:1588,name:"Frontiers in Human Neuroscience",slug:"human-neuroscience",abbreviation:"fnhum",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1533,name:"Frontiers in Human Dynamics",slug:"human-dynamics",abbreviation:"fhumd",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2733,name:"Frontiers in Horticulture",slug:"horticulture",abbreviation:"fhort",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3316,name:"Frontiers in Histology",slug:"histology",abbreviation:"frhis",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2378,name:"Frontiers in High Performance Computing",slug:"high-performance-computing",abbreviation:"fhpcp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2456,name:"Frontiers in Hematology",slug:"hematology",abbreviation:"frhem",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2063,name:"Frontiers in Health Services",slug:"health-services",abbreviation:"frhs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:y,name:"Frontiers in Health Archive",slug:"health-archive",abbreviation:G,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3508,name:"Frontiers in Green Chemistry",slug:"green-chemistry",abbreviation:"fgrch",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1728,name:"Frontiers in Global Women's Health",slug:"global-womens-health",abbreviation:"fgwh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2918,name:"Frontiers in Geochemistry",slug:"geochemistry",abbreviation:"fgeoc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1540,name:"Frontiers in Genome Editing",slug:"genome-editing",abbreviation:"fgeed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:240,name:"Frontiers in Genetics",slug:"genetics",abbreviation:"fgene",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3496,name:"Frontiers in Genetic Microbiology",slug:"genetic-microbiology",abbreviation:"fgemi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3227,name:"Frontiers in Genetic Disorders",slug:"genetic-disorders",abbreviation:"frged",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2333,name:"Frontiers in Gastroenterology",slug:"gastroenterology",abbreviation:"fgstr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1529,name:"Frontiers in Future Transportation",slug:"future-transportation",abbreviation:"ffutr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1725,name:"Frontiers in Fungal Biology",slug:"fungal-biology",abbreviation:"ffunb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2826,name:"Frontiers in Fuels",slug:"fuels",abbreviation:"ffuel",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3207,name:"Frontiers in Freshwater Science",slug:"freshwater-science",abbreviation:"ffwsc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1366,name:"Frontiers in Forests and Global Change",slug:"forests-and-global-change",abbreviation:"ffgc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2689,name:"Frontiers in Forensic Science",slug:"forensic-science",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2289,name:"Frontiers in Food Science and Technology",slug:"food-science-and-technology",abbreviation:"frfst",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3559,name:"Frontiers in Fluorescence",slug:"fluorescence",abbreviation:"fflur",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2987,name:"Frontiers in Fish Science",slug:"fish-science",abbreviation:"frish",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3489,name:"Frontiers in Fire Science and Technology",slug:"fire-science-and-technology",abbreviation:"firtc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2749,name:"Frontiers in Financial Economics",slug:"financial-economics",abbreviation:"ffecn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Frontiers in FSHIP Test Journal",slug:"fship-test-journal",abbreviation:"ftest",space:{id:i,domainName:j,__typename:b},__typename:a},{id:bJ,name:"Frontiers in Evolutionary Neuroscience",slug:"evolutionary-neuroscience",abbreviation:"fnevo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2955,name:"Frontiers in Ethology",slug:"ethology",abbreviation:"fetho",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3032,name:"Frontiers in Epigenetics and Epigenomics",slug:"epigenetics-and-epigenomics",abbreviation:"freae",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2394,name:"Frontiers in Epidemiology",slug:"epidemiology",abbreviation:"fepid",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3450,name:"Frontiers in Environmental Toxicology",slug:"environmental-toxicology",abbreviation:"fentx",space:{id:c,domainName:d,__typename:b},__typename:a},{id:627,name:"Frontiers in Environmental Science",slug:"environmental-science",abbreviation:"fenvs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2888,name:"Frontiers in Environmental Health",slug:"environmental-health",abbreviation:"fenvh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2851,name:"Frontiers in Environmental Engineering",slug:"environmental-engineering",abbreviation:"fenve",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2547,name:"Frontiers in Environmental Economics",slug:"environmental-economics",abbreviation:"frevc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1697,name:"Frontiers in Environmental Chemistry",slug:"environmental-chemistry",abbreviation:"fenvc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2756,name:"Frontiers in Environmental Archaeology",slug:"environmental-archaeology",abbreviation:"fearc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:15,name:"Frontiers in Engineering archive",slug:"engineering-archive",abbreviation:G,space:{id:i,domainName:j,__typename:b},__typename:a},{id:626,name:"Frontiers in Energy Research",slug:"energy-research",abbreviation:"fenrg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3115,name:"Frontiers in Energy Efficiency",slug:"energy-efficiency",abbreviation:"fenef",space:{id:c,domainName:d,__typename:b},__typename:a},{id:106,name:"Frontiers in Endocrinology",slug:"endocrinology",abbreviation:"fendo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1696,name:"Frontiers in Electronics",slug:"electronics",abbreviation:"felec",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1800,name:"Frontiers in Electronic Materials",slug:"electronic-materials",abbreviation:"femat",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2998,name:"Frontiers in Educational Psychology",slug:"educational-psychology",abbreviation:"fepys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1239,name:"Frontiers in Education",slug:"education",abbreviation:"feduc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:625,name:"Frontiers in Economics",slug:"economics",abbreviation:"fecon",space:{id:c,domainName:d,__typename:b},__typename:a},{id:471,name:"Frontiers in Ecology and Evolution",slug:"ecology-and-evolution",abbreviation:"fevo",space:{id:c,domainName:d,__typename:b},__typename:a},{id:c,name:"Frontiers in Earth Science Archive",slug:"earth-science-archive",abbreviation:"gslfj",space:{id:n,domainName:Q,__typename:b},__typename:a},{id:654,name:"Frontiers in Earth Science",slug:"earth-science",abbreviation:"feart",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3309,name:"Frontiers in Earth Observation and Land Monitoring",slug:"earth-observation-and-land-monitoring",abbreviation:"feolm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2161,name:"Frontiers in Drug Safety and Regulation",slug:"drug-safety-and-regulation",abbreviation:"fdsfr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2137,name:"Frontiers in Drug Discovery",slug:"drug-discovery",abbreviation:"fddsv",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2136,name:"Frontiers in Drug Delivery",slug:"drug-delivery",abbreviation:"fddev",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2775,name:"Frontiers in Disaster and Emergency Medicine",slug:"disaster-and-emergency-medicine",abbreviation:"femer",space:{id:c,domainName:d,__typename:b},__typename:a},{id:788,name:"Frontiers in Digital Humanities",slug:"digital-humanities",abbreviation:"fdigh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1534,name:"Frontiers in Digital Health",slug:"digital-health",abbreviation:"fdgth",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2999,name:"Frontiers in Developmental Psychology",slug:"developmental-psychology",abbreviation:"fdpys",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2873,name:"Frontiers in Detector Science and Technology",slug:"detector-science-and-technology",abbreviation:"fdest",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3611,name:"Frontiers in Design Engineering",slug:"design-engineering",abbreviation:"fdese",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2550,name:"Frontiers in Dermatological Research",slug:"dermatological-research",abbreviation:"fdmre",space:{id:c,domainName:d,__typename:b},__typename:a},{id:607,name:"Frontiers in Dental Medicine",slug:"dental-medicine",abbreviation:"fdmed",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2597,name:"Frontiers in Dementia",slug:"dementia",abbreviation:"frdem",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1785,name:"Frontiers in Control Engineering",slug:"control-engineering",abbreviation:"fcteg",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1724,name:"Frontiers in Conservation Science",slug:"conservation-science",abbreviation:"fcosc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3454,name:"Frontiers in Condensed Matter",slug:"condensed-matter",abbreviation:"fconm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1511,name:"Frontiers in Computer Science",slug:"computer-science",abbreviation:"fcomp",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3566,name:"Frontiers in Computational Physiology",slug:"computational-physiology",abbreviation:"fcphy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:bu,name:"Frontiers in Computational Neuroscience",slug:"computational-neuroscience",abbreviation:"fncom",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3234,name:"Frontiers in Complex Systems",slug:"complex-systems",abbreviation:"fcpxs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1787,name:"Frontiers in Communications and Networks",slug:"communications-and-networks",abbreviation:"frcmn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1238,name:"Frontiers in Communication",slug:"communication",abbreviation:"fcomm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2535,name:"Frontiers in Cognition",slug:"cognition",abbreviation:"fcogn",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2857,name:"Frontiers in Coatings, Dyes and Interface Engineering",slug:"coatings-dyes-and-interface-engineering",abbreviation:"frcdi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3222,name:"Frontiers in Clinical Microbiology",slug:"clinical-microbiology",abbreviation:"fclmi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1729,name:"Frontiers in Clinical Diabetes and Healthcare",slug:"clinical-diabetes-and-healthcare",abbreviation:"fcdhc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2551,name:"Frontiers in Clinical Dermatology",slug:"clinical-dermatology",abbreviation:"fcldm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1490,name:"Frontiers in Climate",slug:"climate",abbreviation:"fclim",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3338,name:"Frontiers in Chromosome Research",slug:"chromosome-research",abbreviation:f,space:{id:c,domainName:d,__typename:b},__typename:a},{id:2587,name:"Frontiers in Child and Adolescent Psychiatry",slug:"child-and-adolescent-psychiatry",abbreviation:"frcha",space:{id:c,domainName:d,__typename:b},__typename:a},{id:601,name:"Frontiers in Chemistry",slug:"chemistry",abbreviation:"fchem",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1532,name:"Frontiers in Chemical Engineering",slug:"chemical-engineering",abbreviation:"fceng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3038,name:"Frontiers in Chemical Biology",slug:"chemical-biology",abbreviation:"fchbi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3322,name:"Frontiers in Ceramics",slug:"ceramics",abbreviation:"fceic",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1440,name:"Frontiers in Cellular and Infection Microbiology",slug:"cellular-and-infection-microbiology",abbreviation:"fcimb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1523,name:"Frontiers in Cellular Neuroscience",slug:"cellular-neuroscience",abbreviation:"fncel",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3084,name:"Frontiers in Cellular Immunology",slug:"cellular-immunology",abbreviation:"fcimy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:403,name:"Frontiers in Cell and Developmental Biology",slug:"cell-and-developmental-biology",abbreviation:"fcell",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3178,name:"Frontiers in Cell Signaling",slug:"cell-signaling",abbreviation:"fcsig",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2655,name:"Frontiers in Cell Death",slug:"cell-death",abbreviation:"fceld",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1901,name:"Frontiers in Catalysis",slug:"catalysis",abbreviation:"fctls",space:{id:c,domainName:d,__typename:b},__typename:a},{id:755,name:"Frontiers in Cardiovascular Medicine",slug:"cardiovascular-medicine",abbreviation:"fcvm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2662,name:"Frontiers in Carbon",slug:"carbon",abbreviation:"frcrb",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3513,name:"Frontiers in Cancer Interception",slug:"cancer-interception",abbreviation:"fcint",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3433,name:"Frontiers in Cancer Control and Society",slug:"cancer-control-and-society",abbreviation:"fcacs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:921,name:"Frontiers in Built Environment",slug:"built-environment",abbreviation:"fbuil",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1418,name:"Frontiers in Blockchain",slug:"blockchain",abbreviation:"fbloc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2971,name:"Frontiers in Bird Science",slug:"bird-science",abbreviation:"fbirs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3300,name:"Frontiers in Biophysics",slug:"biophysics",abbreviation:"frbis",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2222,name:"Frontiers in Biomaterials Science",slug:"biomaterials-science",abbreviation:"fbiom",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1722,name:"Frontiers in Bioinformatics",slug:"bioinformatics",abbreviation:"fbinf",space:{id:c,domainName:d,__typename:b},__typename:a},{id:452,name:"Frontiers in Bioengineering and Biotechnology",slug:"bioengineering-and-biotechnology",abbreviation:"fbioe",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1380,name:"Frontiers in Big Data",slug:"big-data",abbreviation:"fdata",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1589,name:"Frontiers in Behavioral Neuroscience",slug:"behavioral-neuroscience",abbreviation:"fnbeh",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2432,name:"Frontiers in Behavioral Economics",slug:"behavioral-economics",abbreviation:"frbhe",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2796,name:"Frontiers in Bee Science",slug:"bee-science",abbreviation:"frbee",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3214,name:"Frontiers in Batteries and Electrochemistry",slug:"batteries-and-electrochemistry",abbreviation:"fbael",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3011,name:"Frontiers in Bacteriology",slug:"bacteriology",abbreviation:"fbrio",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3040,name:"Frontiers in Audiology and Otology",slug:"audiology-and-otology",abbreviation:"fauot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:603,name:"Frontiers in Astronomy and Space Sciences",slug:"astronomy-and-space-sciences",abbreviation:"fspas",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1437,name:"Frontiers in Artificial Intelligence",slug:"artificial-intelligence",abbreviation:"frai",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2940,name:"Frontiers in Arachnid Science",slug:"arachnid-science",abbreviation:"frchs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2834,name:"Frontiers in Aquaculture",slug:"aquaculture",abbreviation:"faquc",space:{id:c,domainName:d,__typename:b},__typename:a},{id:981,name:"Frontiers in Applied Mathematics and Statistics",slug:"applied-mathematics-and-statistics",abbreviation:"fams",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3417,name:"Frontiers in Applied Environmental Microbiology",slug:"applied-environmental-microbiology",abbreviation:"faemi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2714,name:"Frontiers in Antibiotics",slug:"antibiotics",abbreviation:"frabi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3443,name:"Frontiers in Anti-Cancer Therapies",slug:"anti-cancer-therapies",abbreviation:"facth",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3253,name:"Frontiers in Antennas and Propagation",slug:"antennas-and-propagation",abbreviation:"fanpr",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1719,name:"Frontiers in Animal Science",slug:"animal-science",abbreviation:"fanim",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2513,name:"Frontiers in Anesthesiology",slug:"anesthesiology",abbreviation:"fanes",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1989,name:"Frontiers in Analytical Science",slug:"analytical-science",abbreviation:"frans",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2909,name:"Frontiers in Amphibian and Reptile Science",slug:"amphibian-and-reptile-science",abbreviation:"famrs",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1705,name:"Frontiers in Allergy",slug:"allergy",abbreviation:"falgy",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1541,name:"Frontiers in Agronomy",slug:"agronomy",abbreviation:"fagro",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3631,name:"Frontiers in Agricultural Engineering",slug:"agricultural-engineering",abbreviation:"faeng",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2477,name:"Frontiers in Aging Neuroscience",slug:"aging-neuroscience",abbreviation:"fnagi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:1566,name:"Frontiers in Aging",slug:"aging",abbreviation:"fragi",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2449,name:"Frontiers in Aerospace Engineering",slug:"aerospace-engineering",abbreviation:"fpace",space:{id:c,domainName:d,__typename:b},__typename:a},{id:2195,name:"Frontiers in Adolescent Medicine",slug:"adolescent-medicine",abbreviation:"fradm",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3426,name:"Frontiers in Acoustics",slug:"acoustics",abbreviation:"facou",space:{id:c,domainName:d,__typename:b},__typename:a},{id:979,name:bs,slug:"frontiers-for-young-minds",abbreviation:"frym",space:{id:c,domainName:d,__typename:b},__typename:a},{id:3260,name:"Frontiers In Ocean Engineering",slug:"frontiers-in-ocean-engineering",abbreviation:"focen",space:{id:c,domainName:d,__typename:b},__typename:a},{id:L,name:"FSHIP Test Journal 2",slug:"fship-test-journal-2",abbreviation:"FTJ2",space:{id:i,domainName:j,__typename:b},__typename:a},{id:i,name:ci,slug:cj,abbreviation:ck,space:{id:P,domainName:bC,__typename:b},__typename:a},{id:3746,name:ci,slug:cj,abbreviation:ck,space:{id:c,domainName:d,__typename:b},__typename:a},{id:cf,name:cl,slug:cm,abbreviation:cn,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3231,name:cl,slug:cm,abbreviation:cn,space:{id:c,domainName:d,__typename:b},__typename:a},{id:n,name:co,slug:cp,abbreviation:cq,space:{id:n,domainName:Q,__typename:b},__typename:a},{id:2078,name:co,slug:cp,abbreviation:cq,space:{id:c,domainName:d,__typename:b},__typename:a},{id:ch,name:cr,slug:cs,abbreviation:ct,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2359,name:cr,slug:cs,abbreviation:ct,space:{id:c,domainName:d,__typename:b},__typename:a},{id:8,name:cu,slug:cv,abbreviation:cw,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2446,name:cu,slug:cv,abbreviation:cw,space:{id:c,domainName:d,__typename:b},__typename:a},{id:10,name:cx,slug:cy,abbreviation:cz,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3230,name:cx,slug:cy,abbreviation:cz,space:{id:c,domainName:d,__typename:b},__typename:a},{id:n,name:cA,slug:cB,abbreviation:cC,space:{id:i,domainName:j,__typename:b},__typename:a},{id:2358,name:cA,slug:cB,abbreviation:cC,space:{id:c,domainName:d,__typename:b},__typename:a},{id:3660,name:"Advanced Optical Technologies",slug:"advanced-optical-technologies",abbreviation:"aot",space:{id:c,domainName:d,__typename:b},__typename:a},{id:cg,name:cD,slug:cE,abbreviation:cF,space:{id:i,domainName:j,__typename:b},__typename:a},{id:3659,name:cD,slug:cE,abbreviation:cF,space:{id:c,domainName:d,__typename:b},__typename:a},{id:K,name:cG,slug:cH,abbreviation:"abp",space:{id:i,domainName:j,__typename:b},__typename:a},{id:3695,name:cG,slug:cH,abbreviation:"ABP",space:{id:c,domainName:d,__typename:b},__typename:a}]},serverRendered:h,routePath:"\u002Fjournals\u002Foncology\u002Farticles\u002F10.3389\u002Ffonc.2023.1043244\u002Ffull",config:{baseUrl:"https:\u002F\u002Fwww.frontiersin.org",appName:"article-pages-2022",spaceId:c,spaceName:A,domain:d,loopUrl:"https:\u002F\u002Floop.frontiersin.org",ssMainDomain:d,googleRecaptchaKeyName:"FrontiersRecaptchaV2",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase\u003E\u003E article",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Review Editor\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country\u002Fregion\",\"frontiersDefaultTerm\":\"country\u002Fregion\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries\u002Fregions\",\"frontiersDefaultTerm\":\"countries\u002Fregions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Review Editors\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Content Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Content Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"}]}'\n",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmServerUrl:"https:\u002F\u002Ftag-manager.frontiersin.org",gtmPreview:"env-1",faviconSize512:"https:\u002F\u002Fbrand.frontiersin.org\u002Fm\u002Fed3f9ce840a03d7\u002Ffavicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https:\u002F\u002Fbrand.frontiersin.org\u002Fm\u002F1c8bcb536c789e11\u002FGuidelines-Frontiers_Logo_1200x628_1-91to1.png",_app:{basePath:"\u002F",assetsPath:"\u002Farticle-pages\u002F_nuxt\u002F",cdnURL:e}},apollo:{contentfulJournalsDelivery:Object.create(null),contentfulJournalsPreview:Object.create(null),contentfulHomeDelivery:Object.create(null),contentfulHomePreview:Object.create(null),frontiersGraph:Object.create(null)}}}("journal_journal","public_space",1,"frontiersin.org",null,"","_self",true,3,"frontierspartnerships.org","_blank",false,0,2,"China","citation_author","citation_author_institution","Frontiers in Oncology","Department of Oncology, Bishan Hospital of Chongqing Medical University","PDF","Department of Oncology, Bishan Hospital of Chongqing Medical University, China",5,451,"oncology",4,"description","Frontiers","Help center","Link","Grey","Medium","ssph-journal.org","fship","Front. Oncol.","2234-943X",void 0,18,13,"fonc-13-1043244.pdf",1920,"por-journal.com",7,"escubed.org",1918,"fipp","https:\u002F\u002Fd2csxpduxe849s.cloudfront.net\u002Fmedia\u002FE32629C6-9347-4F84-81FEAEF7BFA342B3\u002FA08FCA58-05EE-4283-A13E51F93BB73C97\u002Fwebimage-6A59331A-8816-4B2C-BC3F6EF168F6183E.jpg","image","2022-06-27T10:00:39Z","fonc",57,"journal_field","10.3389\u002Ffonc.2023.1043244","Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report","\u003Csec\u003E\u003Ctitle\u003EBackground\u003C\u002Ftitle\u003E\u003Cp\u003EHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approved for the standard third-line treatment for NSCLC in China. Herein we report an elderly NSCLC patient without any driver gene mutations who was undergoing anlotinib as a front-line treatment and who achieved long-term survival.\u003C\u002Fp\u003E\u003C\u002Fsec\u003E\u003Csec\u003E\u003Ctitle\u003ECase summary\u003C\u002Ftitle\u003E\u003Cp\u003EThe 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1).\u003C\u002Fp\u003E\u003C\u002Fsec\u003E\u003Csec\u003E\u003Ctitle\u003EConclusion\u003C\u002Ftitle\u003E\u003Cp\u003EThis patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy.\u003C\u002Fp\u003E\u003C\u002Fsec\u003E",1995236,"Jingyi","Xiaoqing","Li","Juan","Dan","Mengyao",2043266,"Lan",993634,"Shengwen Calvin","United States",1003220,"Kohei",970570,"Xiaobo",1116571,"TAO",{},502,"Thoracic Oncology","thoracic-oncology","EPUB","fonc-13-1043244.xml","Frontiers | Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report","https:\u002F\u002Fwww.frontiersin.org\u002Fjournals\u002Foncology\u002Farticles\u002F10.3389\u002Ffonc.2023.1043244\u002Ffull","BackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tole...","og:title","og:description","keywords","og:site_name","og:image","og:type","og:url","twitter:card","citation_volume","citation_journal_title","citation_publisher","citation_journal_abbrev","citation_issn","citation_doi","citation_firstpage","citation_language","citation_title","citation_keywords","citation_abstract","citation_pdf_url","citation_online_date","citation_publication_date","dc.identifier","articles","editors","research-topics","How we publish","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fhow-we-publish","Fee policy","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Ffee-policy","Research Topics","https:\u002F\u002Fforum.frontiersin.org\u002F","Frontiers Planet Prize","https:\u002F\u002Fwww.frontiersplanetprize.org\u002F","this link will take you to the Frontiers Planet Prize website","Career opportunities","https:\u002F\u002Fcareers.frontiersin.org\u002F","https:\u002F\u002Fwww.frontiersin.org\u002Fabout\u002Fcontact","skin-cancer","Author guidelines","Editor guidelines","https:\u002F\u002Fwww.frontiersin.org\u002Fjournals","https:\u002F\u002Fwww.frontiersin.org\u002Farticles","Articles","https:\u002F\u002Fhelpcenter.frontiersin.org","Frontiers for Young Minds","Frontiers Facebook",9,"Transplant International","transplant-international","ti",1921,"Spanish Journal of Soil Science","spanish-journal-of-soil-science","sjss","ebm-journal.org","Public Health Reviews","public-health-reviews","phrs","Pathology and Oncology Research","pathology-and-oncology-research","pore",21,"Pastoralism: Research, Policy and Practice","pastoralism-research-policy-and-practice","past",11,"Oncology Reviews","oncology-reviews","or","Journal of Pharmacy & Pharmaceutical Sciences","journal-of-pharmacy-pharmaceutical-sciences","jpps","Journal of Cutaneous Immunology and Allergy","journal-of-cutaneous-immunology-and-allergy","JCIA","Journal of Abdominal Wall Surgery","journal-of-abdominal-wall-surgery","jaws",1919,"International Journal of Public Health","international-journal-of-public-health","ijph","Frontiers in Pathology","pathology","fpath",12,17,6,"Experimental Biology and Medicine","experimental-biology-and-medicine","EBM","European Journal of Cultural Management and Policy","european-journal-of-cultural-management-and-policy","ejcmp","Earth Science, Systems and Society","earth-science-systems-and-society","esss","Dystonia","dystonia","dyst","British Journal of Biomedical Science","british-journal-of-biomedical-science","bjbs","Aerospace Research Communications","aerospace-research-communications","arc","Advances in Drug and Alcohol Research","advances-in-drug-and-alcohol-research","adar","Acta Virologica","acta-virologica","av","Acta Biochimica Polonica","acta-biochimica-polonica"));</script><script src="/article-pages/_nuxt/9cc2c68.js" defer></script><script src="/article-pages/_nuxt/51ff06b.js" defer></script><script src="/article-pages/_nuxt/e16d0bc.js" defer></script><script src="/article-pages/_nuxt/5f5c456.js" defer></script><script src="/article-pages/_nuxt/e261291.js" defer></script><script src="/article-pages/_nuxt/8eb37ac.js" defer></script><script src="/article-pages/_nuxt/ca2a6ed.js" defer></script><script src="/article-pages/_nuxt/9b8d23d.js" defer></script><script src="/article-pages/_nuxt/92bc9eb.js" defer></script><script data-n-head="ssr" src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" data-body="true" async></script><script data-n-head="ssr" src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" data-body="true" async></script><script data-n-head="ssr" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" data-body="true" async></script><script data-n-head="ssr" src="https://api.altmetric.com/v1/doi/10.3389/fonc.2023.1043244?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" data-body="true" async></script><script data-n-head="ssr" src="https://widgets.figshare.com/static/figshare.js" data-body="true" async></script><script data-n-head="ssr" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" data-body="true" async></script> </body> </html>